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Abbreviations: 
AA amino acid (for amino acid abbreviations see Table A below) 
Ac(M)NPV Autographa californica (Multinucleocapsid) Nuclear Polyhedrosis Virus 
Bm(M)NPV Bombyx mori (Multinucleocapsid) Nuclear Polyhedrosis Virus 
bp base pair 
BSA bovine serum albumin 
BV Budding virus 
ConA ConcanavalinA 
DMF dimethylformamide 
DoM ß-1-o-dodecylmaltoside 
dpi days post infection 
DTE 1,4-dithioerythritol 
dufung" inactivated dUTPase and Uracil-N-glycosidase 
ELISA Enzym-linked immunosorbent assay 
EDTA (ethylene-l,2-diamino)N-tetra-acetic acid 
FTIR Fourier Transform Infra Red 
GAM-FITC goat anti-mouse conjugated to fluoresceine 
G-protein GTP-binding protein (e.g. transducin) 
GST glutathione-S-transferase 
HPO horseradish peroxidase 
IFA Immunofluorescent assay 
kb kilobasepair 
lys T4 lysozyme 
Mb Mamestra brassica cell line 
MOI Multiplicity Of Infection 
PAPm/r HPO and mouse/rabbit anti-HPO 
PBS Phosphate Buffered Saline 
PC phosphatidyl choline 
PDE Phosphodiesterase 
PDV Polyhedra derived virus 
PF68 Pluronic F-68 
pfu plaque forming unit 
polh polyhedrine 
R(h)* light activated rhodopsin 
RAM(PO) rabbit anti-mouse Ig (conjugated to HPO) 
ROS Rod Outer Segment 
RT Room Temperature 
SAR(PO) Swine anti-rabbit Ig (conjugated to HPO) 
SAR-TRITC Swine anti-rabbit conjugated to rhodamine 
SDS-PAGE SDS Polyacrylamide gel electroforesis 
Sf9 Spodoptera frugiperda cell line 
v-ops opsin produced in insect cells by recombinant virus 
v-rho rhodopsin generated from v-ops by incubation with 1 l-cis retinal. 
wt wildtype 
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Table A One- and three letter code abbreviations of amino acids. 
amino acid 
Alanine 
Arginine 
Asparagine 
Aspartic acid 
Cysteine 
Glutamine 
Glutamic acid 
Glycine 
Histidine 
Isoleucine 
Leucine 
Lysine 
Methionine 
Phenylalanine 
Proline 
Serine 
Threonine 
Tryptophane 
Tyrosine 
Valine 
three letter code 
Ala 
Arg 
Asn 
Asp 
Cys 
Gin 
Glu 
Gly 
His 
He 
Lea 
Lys 
Met 
Phe 
Pro 
Ser 
Thr 
Trp 
Tyr 
Val 
one letter code 
A 
R 
N 
D 
С 
Q 
E 
G 
H 
I 
L 
К 
M 
F 
Ρ f 
s 
τ 1 
w 
Y ï 
V 
Table В List ofprimairy antisera 
antigen 
bovine rhodopsin 
glutathione-S-transferase from 
Schistosoma juponicum exressed 
in E. coli 
AcNPV expressed membrane-
bound proteins in Sf9 cells 
T4 lysozyme expressed in E. 
coli 
antibody 
CERNJS858 
R-6-5 
R2-12N 
K16-193L 
T13-34L 
K42-41L 
1D4 
CERNLC909 
CERNLC9010 
CERNLC914 
CERNLC915 
CERNLC916 
CERNLC941 
CERNLC942 
CERNLC943 
epitope 
N-term. 3-14 
N-term. 3-8 
loopi2 
loope2 
loop ІЗ 230-252 
C-term. 340-348 
-
. 
Ig type 
rabbit polyclonal 
mouse monoclonal IgG 
mouse monoclonal IgG2b 
mouse monoclonal IgM 
mouse monoclonal IgGl 
mouse monoclonal IgGl 
mouse monoclonal IgGl 
rabbit polyclonal 
rabbit polyclonal 
rabbit polyclonal 
rabbit polyclonal | 
rabbit polyclonal 1 
rabbit polyclonal 
rabbit polyclonal ¡| 
rabbit polyclonal 1 
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CHAPTER 1 
GENERAL INTRODUCTION 

1.1 The rod visual pigment rhodopsin 
Rhodopsin is the visual pigment of the rod photoreceptor cells in the retina of the vertebrate 
eye (Fig 1.1, panel A). The outer segment of the rod cell contains stacks of disk-shaped 
membranes packed with the photoreceptor rhodopsin (Fig 1.1, panel C). Rhodopsin consists of 
an integral membrane protein, opsin, containing a covalently bound chromophore, li-си reti­
nal. Upon absorption of light the chromophore isomerizes to all-trans and the resulting confor­
mational changes (photolytic cascade) lead to signal site exposure, G-protein (transducin) 
binding, and subsequent desensitization by a specific rhodopsin kinase and a 45 kDa protein 
(arrestin or S-antigen). In turn, transducin activates a phosphodiesterase which hydrolyses 
cGMP, the second messenger. The decrease in cGMP concentration in the outer segment 
effectuates closure of a Na+, K+, Ca 2 + channel in the plasma membrane (Fig 1.2). The resul­
ting hyperpolarization modulates transmitter release at the synapse of the rod cell, and this 
signal is then processed through a series of neurons and via the optic nerve transmitted to the 
brain (Fig 1.1, panel B). 
Rhodopsin and the process of phototransduction have been extensively studied during the last 
40 years and have evolved as a model system for G-protein coupled receptors. Over the last 
years a new approach has been developed: in vitro expression. This allows exploration of the 
functional properties of rhodopsin on a molecular level trough (site-directed) mutagenesis and 
labeling. A wide variaty of expression systems have been described for the in vitro expression 
of bovine rhodopsin: monkey kidney cells [1], insect cells in combination with recombinant 
baculovirus [2], Xenopus oocytes [3], human kidney cells [4], Chinese hamster ovary cells [5] 
and a cell-free expression system [6]. Information gained in this way about the structure and 
function of rhodopsin will be discussed here. 
1.1.1 The structure of rhodopsin 
Rhodopsin belongs to the large family of G-protein coupled receptors, currently comprising at 
least 300 members. The primary structure of 32 visual pigments is now known and apart from 
some variation in amino acid sequence and overall length, the structural features are essentially 
similar. 
Rhodopsin's primary structure (Fig 1.3 [7]) reveals regions of hydrophilic amino acids in the 
polypeptide chain separated by seven hydrophobic regions of 21-28 amino acids. Topographi­
cal studies have shown that it is a transmembrane protein with the carboxyl terminus facing the 
cytoplasma (intracellular) and the amino terminus located intra-discally (extracellularly) (Fig 
1.4a [8]). The chromophore 11-си retinal is covalently linked to Lys296 via a protonated 
Schiff base [9]. 
The intradiscal/extracellular domain: This is formed by the amino terminus and the three 
extracellular membrane domains connecting loops. Two residues (positions 2 and 15) of the 
amino terminus are N-glycosylated [10] and four different oligosaccharides have been 
identified [11]. Recent findings suggest that in general N-linked oligosaccharides may play 
multiple roles during the conformational maturation of glycoproteins [12]. This is supported 
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Figure 1.1 Overall topography of the vertebrate eye (A), the retina (B) and the rod cell (Q. Panel B: the 
photoinduced membrane hyperpolarization modulates the synaptic activity at the base of the rod and cone photore-
ceptor cells. The signals are then processed by the series of cells shown in the middle. Ultimately, the signals are 
sent out to the brain via the optic nerve. Panel C: the outer segments of rod cells contain stacks of disk membranes 
that contain the photoreceptor protein rhodopsin. The expanded cross-section representation of the disk shows the 
membrane lipid bilayer of both surfaces of the disk. Densely packed rhodopsin molecules traverse the lipid bilayer, 
as shown by the oval shapes. The expanded view at the right of the figure is a conception of how the polypeptide 
chain of rhodopsin may exist in three dimensions. The N-terminal region with two attached carbohydrate chains is 
exposed at the intradiskal surface. The polypeptide chain traverses the membrane as seven packed helical regions 
and terminates at the carboxyl end on the cytoplasmic surface. The cutaway view shows retinal linked to the 
seventh helix, nested in a pocket formed by the inside surface of the helical bundle. 
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Figure 1.2 A model for rhodopsin activation and termination. Activation, light (or ligand in other G-protein 
coupled receptors) drives a conformational change in the receptor (R*), enabling it to catalyse G-protein 
(transducin) GDP-GTP exchange. GTP-binding G-proteins dissociate into a andßy components and the a-subunit 
of transducin activates a cGMP phosphodiesterase (PDE). In the dark, cation channels are opened by bound 
cGMP. The light activated hydrolysis ofcGMP depletes this intracellular second messenger and the cation channel 
is closed resulting in plasma membrane hyperpolarization (panel B). Termination ofR*. in the continued presence 
of stimuli, is initiated by receptor specific kinases (RK), which phosphorylate serine and threonine residues in the 
carboxyl termini of activated receptors. Phosphorylation reduces, but does not inactivate, the receptor's ability to 
drive G-protein nucleotide exchange. Receptor phosphorylation also enables arrestin to bind the receptor, 
preventing receptor interaction with G-protein and inactivating the transduction cascade. 
by the findings that several amino acid substitution, deletion and insertion mutations in bovine 
rhodopsin affect glycosylation, targeting and binding of ll-cis retinal (Table 1.1). Some of 
these mutations are related to the disease autosomal dominant retinitis pigmentosa (ADRP). 
Another structural feature of the intradiscal domain is a buried disulfide bridge between the 
cysteine residues 110 and 187 [13,14]. Substitution of either of these residues affect expression 
levels, glycosylation, and the ability to bind ll-cis retinal (Table 1.1). However, substitution 
of any other cysteine residue shows little or no effect [25]. 
It is striking that structural effects (abnormal glycosylation, targeting and no/reduced ability to 
bind 11-си retinal) are especially seen when changes are made in the extracellular domain of 
opsin. Hence, it appears that this domain is of particular structural importance. 
The cytoplasmic/intracellular domain: In general, amino acid substitution [14-25], deletion 
[26-28] or insertion [29] mutants in this domain do not have structural effects and these mu­
tants form a normal photopigment. Some structural effects are only seen at positions in the 
interface region (Table 1.1). 
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A fourth additional loop is generally assumed to be formed by the anchorage of two palmitoyl 
chains, covalently attached as thioester to the adjacent cysteine residues 322 and 323 [30-32]. 
The cysteine residue at position 322 is essential for palmitoylation. Substitution of this residue 
also prevents palmitoylation of Cys323, whereas substitution of Cys323 still allows palmitoyla­
tion of Cys322. Opsin mutants, which do not contain a Cysll0/Cysl87 disulfide bridge, are 
not palmitoylated, and substitution of Cysl40 or Cysl85 reduces the extent of palmitoylation 
(Table 1.1). However, the palmitoyl groups are not necessary for the formation of a photopig-
ment (=80% regeneration of WT) [25], and also chemical removal of the palmitoyl chains 
from native rat rhodopsin only slightly affected its regeneration capacity [33]. 
The carboxy terminus contains seven putative phosphorylation sites for rhodopsin kinase, 
located in the region 330-348. Recent findings identify serines 338 and 343 as the major sites 
of phosphorylation (mono- and di-phosphorylated Rh*). Triphosphorylation appears to occur 
on one or more of the four threonine residues at positions 335, 336, 340 and 342 [34-37]. 
The transmembrane domain: The seven transmembrane helices provide a binding pocket for 
the chromophore 11-си retinal (Fig 1.1c). Rhodopsin binds its ligand, Π-cis retinal, via a 
protonated Schiff base between the carboxyl group of retinal and the e-amino group of lysine 
296 [9]. Several amino acid residues in the transmembrane domains are highly conserved 
among visual pigments or even the entire family of G-proteins [38-40]. Interesting is the 
mechanism by which different visual pigments tune the absorbance spectrum of the 
chromophore (440 nm in model compounds), facilitating vision from the ultraviolet to the far 
red (range 360-600 nm). An important element in this spectral tuning is the counterion for the 
protonated Schiff base. This amino acid has now been identified as Glull3 in bovine 
rhodopsin [16,23,24]. Only carboxyl residues at this position [23,41] or position 117 [42] can 
sustain a pigment with normal spectral properties. In other Glull3 mutants a dramatic spectral 
shift from 498 to 380 nm is observed, but their absorbance bands are pH- and anion-dependent 
(lower pH and higher anion concentration stabilizing the protonated rhodopsin-like state 
[17,23,41]). (Table 1.2). Several other residues in the transmembrane domains have also been 
identified to interact with the chromophore in bovine rhodopsin [43,44] or play a role in 
spectral tuning of visual pigments [45-48]. (Table 1.2) 
3D-structure: Two recent papers provide a framework for the transmembrane structure of the 
G-protein coupled receptor family. A probable arrangement of the transmembrane helices, that 
is compatible with a low-resolution projection density map [49], has been proposed [50] (Fig 
1.4b). The map of bovine rhodopsin, which was determined by two-dimensional electron 
crystallography to a resolution of 9À, confirmed the alleged presence of seven transmembrane 
domains. Four of the helices appear to be positioned almost perpendicularly to the membrane 
and the other three are tilted so that they overlap in projection. However, the ultimate goal is 
to resolve a three-dimensional structure by x-ray diffraction analysis of 3D-crystals. A light-
stable rhodopsin analog would offer important advantages in such studies. Several retinal 
analogs that cannot undergo 11-ей to ail-trans isomerization have been developed for 
generating rhodopsin-like pigments but none of them were totally light-stable [51,52]. 
However, it was reported, that an opsin mutant (Trp265-Phe) in combination with a 
nonisomerizable retinal analog resulted in a light-stable rhodopsin analog ( λ „ 493 nm)[53]. 
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Figure 1.4 Model for rhodopsin topography (panel A, adapted front [8]) and arrangement of the helices (panel B, 
adapted from [50]). A, The 348-amino acid sequence of bovine rhodopsin is shown in the lipid bilayer. Its 
aminoterminal sequence, bearing oligosaccharide chains on Asn 2 and 15, is exposed to the intradiskal or 
extracellular surface. The polypeptide chain traverses the lipid bilayer 7 times (helices I-VII), exposing loop el-еЗ 
to the inside surface of the disk membrane (extracellular) and loops И-І4 and the carboxyl terminus to the 
intracellular (cytoplasmic) surface. The putative loop І4 would be formed by the insertion of thiopalmitoyl chains 
into the lipid bilayer. Loops i2, іЗ and i4 are shown as sites of interaction with transducin. The carboxyl terminus 
contains several serine and threonine residues as putative phosphorylation sites for rhodopsin kinase. B, Projec­
tion model for the arrangement and orientation of the seven helices in G-protein coupled receptors. The view is 
from the intracellular side of the membrane. The positions of the the highly conserved residues are labeled with the 
amino acid and important residues in rhodopsin are indicated. 
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1.1.2 Rhodopsin function 
All members of the receptor family to which rhodopsin belongs effectuate their intracellular 
response through the intermediary action of a GTP-binding regulatory protein or G-protein. 
The visual pigments are distinguished as a group from all other receptors because they 
covalently bind the chromophore 11-ds retinal, whereas all of the other receptors bind their 
ligands noncovalently. Absorbance of visible light near 500 nm triggers isomerization of this 
chromophore to all-trans. The resulting fast conformational changes (photolytic cascade) lead 
to signal site exposure, G protein (transducin) binding, and subsequent desensitization by the 
specific rhodopsin kinase and arrestin. Finally the chromophore is released from the apopro­
tein opsin. 
The photolytic cascade: The primary step in vision is the photo-isomerization of the retinal 
chromophore, occurring within 200 femtoseconds [54,55], which induces a series of spectral 
transitions, Batho - Lumi - Meta I - Meta II - Meta Ш, and finally the chromophore is 
released (Fig 1.5). 
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Figure 1.5 The photolytic reaction cascade of rhodopsin. The successive formation of photointermediates 
following light-induced 11-cis - all-trans retinal isomerization is given, together with the reaction kinetics and 
absorbance maximum. 
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Within 1 ms, photoactivated rhodopsin (Rh*) arrives at an equilibrium between two 
conformations, Metarhodopsin I and Metarhodopsin II. This equilibrium mixture is pH-
dependent, favoring Meta II at acidic pH [56], and is stable for several seconds at room 
temperature and even for minutes at 0°C. Meta Π is the active form which triggers signal 
transduction. An event that is likely to be important is the Schiffs base deprotonation occuring 
in the Meta I - Meta II transition [57]. The protonation change at the Schiff base is accompa­
nied by uptake of a proton from solution [58]. However, Schiff base deprotonation probably 
precedes proton uptake and formation of the signaling state [59-61]. This indicates that there 
maybe two different forms of metarhodopsin Π which must be successively formed to generate 
full activity to bind and catalyze nucleotide exchange in the G protein. In bovine rhodopsin, 
the Meta I - Meta Π equilibrium is sensitive to amino acid substitutions: the mutations His21-
1-Phe/Cys [62,63], Ala292-Glu and Glul22~Ile [63] shift the equilibrium to Meta I, whereas 
the mutations His65-Phe, Hisl52~Phe [62], Asp83-Asn, Glul34-Gln/Leu, Argl35-Leu [63] 
shift it to Meta II. It should be noted however that the effects of these mutations were only 
analyzed in detergent solution. Solubilization in detergent has dramatic effects on the pKa of 
the Meta I - Meta II equilibrium, shifting it from 7.3 in membrane suspension upwards to 
>8.5 (nonylglucoside, dodecylmaltoside [64]) or down to 6.4 (digitonin [58]). 
To date, FTIR difference spectroscopy has provided the most detailed information on the 
conformational transitions in the photocascade (Fig 1.6 [65]). Minor alterations in protein 
structure involving the peptide backbone (amide I around 1650 cm"1 and amide II around 1550 
cm"
1) and aspartic and/or glutamic carboxyl groups were already detected at the Batho stage. 
The former increase upon going to Meta Π and involve larger changes in protein carboxyl 
groups (region 1700-1800 cm"1). In this area some bands have already been assigned to 
specific residues through site-specific mutagenesis [66,67]. This will be discussed in detail in 
chapter 6. 
wavenumbers (cm1) 
Figure 1.6 FUR difference spectra of the photolytic transitions in the photoreceptor membrane [65]. Rho-Batho 
presents the difference spectrum obtained by subtraction the rhodopsin spectrum from the batho spectrum. The 
other spectra are obtained in a similar way. Negative peaks thus represent structural elements in the dark state 
(rhodopsin) which are altered upon formation of the photointermediate. Positive peaks represent new structural 
elements in the photointermediate. 
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Transducin binding and activation: Transducin, a member of the heterotrimeric GTP-binding 
protein family, is composed of the GTP-binding o-subunit, which interacts with a β- and γ« 
subunit, with Rh* and with PDE. Early studies of the binding of transducin to proteolytically 
digested rhodopsin indicated that the third cytoplasmatic loop (i3) was implicated in the 
binding but that the carboxy terminus was not involved [68]. In a further study, based upon 
the competition of free synthetic peptides from the surface sequences of rhodopsin with Meta 
II for binding to transducin, it was demonstrated that loops i2, i3 and i4 contained binding 
sites for transducin and that loop il and the C-terminal were not involved [69]. Some specific 
requirements for transducin binding have been determined by mutagenesis of rhodopsin (Table 
1.3). The binding and activation of transducin are separate processes. Replacement or deletion 
studies revealed that loop i2 and i3 are required for the activation of bound transducin [19]. 
Substitution or reversal of the highly conserved charge pair Glul34/Argl35 abolished the 
ability to bind transducin [19]. Substitution of amino acids that interact with the chromophore 
also may affect transducin activation (Table 1.3), which might be the result of an altered 
structure of Meta II. Mutation of either Lys296, the attachment site for the chromophore, or 
Glull3, the Schiff base counterion, results in a mutant with constitutive activity of opsin. That 
is, these mutants can activate transducin in the absence of chromophore and without require­
ment of light. These data have led to the suggestion that a salt bridge between Lys296 and 
Glull3 helps to constrain opsin to an inactive conformation [70-72]. The E113Q mutant 
containing an unprotonated Schiff base chromophore linkage (380 nm form) can also be 
activated directly by UV light to catalyze nucleotide exchange by transducin [73]. The negative 
charge at position 134 also seems to be necessary to maintain opsin in an inactive confor­
mation [72]. These findings suggest that the active state of rhodopsin can be reached via a 
number of pathways. 
Desensitization: Intracellular signalling is arrested by the light-dependent phosphorylation of 
rhodopsin and subsequent binding of arrestin. Phosphorylation of photoactivated rhodopsin 
occurs at the carboxy terminal tail by rhodopsin kinase, a member of the G protein-coupled 
receptor kinases. A enzymatically truncated form of rhodopsin, lacking the C-terminal 
sequence 329-348, still could bind rhodopsin kinase but was not phosphorylated. However, 
binding of rhodopsin kinase to Rh* was inhibited when loop ІЗ was cleaved (similar to the 
binding of transducin) [74]. As mentioned above, the major phosphorylation sites have 
recently been identified [34-37]. Once Rh* is phosphorylated, a unique mechanism appears to 
regulate dissociation of the kinase. The autophosphorylated form of rhodopsin kinase has a 
significantly lowered affinity for phosphorylated Rh* compared with unphosphorylated Rh* 
[75], suggesting that rhodopsin kinase autophosphorylation may be a mechanism to regulate 
the extent of rhodopsin phosphorylation. 
Although phosphorylation is an important element in inhibiting continued transducin activation 
by Rh*, binding of arrestin to phosphorylated Rh* completes this inhibition. Synthetic peptides 
of rhodopsin's loop i3 and to a lower extent of loop il inhibit arrestin binding to phosphoryla­
ted Rh* [76], suggesting that these loops may play an important role in arrestin binding. 
Evidently and remarkably the third cytoplasmatic loop of rhodopsin is important for activation 
(transducin binding) as well as desensitization (rhodopsin kinase and arrestin binding). 
After termination is completed, a phosphatase is able to dephosphorylate the receptor. 
Subsequent rebinding of 11-cfs retinal enables the resulting rhodopsin molecule to participate 
again in the phototransduction process. 
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Table 1.1 Survey of amino acid Subsumtion, deletion (del) and insertion (ins) in bovine rhodopsin, 
that effect biosynthesis, structure and/or regeneration. 
mutation 
del 101-108 
del 171-172 
del 173-174 
del 175-176 
del 177-178 
del 177-182 
del 179-180 
del 181-182 
del 181-197 
del 189-190 
del 189-198 
del 191-192 
del 203-204 
del 205-206 
del 207-208 
del 290-293 
del 7-10 
del 11-14 
del 18-20 
del 21-29 
del 183-184 
D190A 
del 234-250 
A26G 
ins 26,27-myc* 
A32G.E33S 
ins 32,33-myc 
Q64G.H65S 
ins 64,65-myc 
R69T.T70S 
ins 69,70-myc 
T97G 
ins 97,98-myc 
P107S 
ins 106,107-myc 
ins 194,195-myc 
ins 197,198-myc 
ins 280,281-myc 
F283G.G284S 
ins 283,284-myc 
ins 318,319-myc 
domain* 
el 
TMIV 
TMIV 
e2 
e2 
e2 
e2 
e2 
e2 
e2 
e2 
e2 
TMV 
TMV 
TMV 
TM VII 
N 
N 
N 
N 
e2 
e2 
ІЗ 
N 
N 
N 
N 
il 
il 
il 
il 
ТМИ 
TM II 
el 
el 
e2 
e2 
e3 
еЗ 
еЗ 
І4 
observations 
non-, mono- and completely glycosylated forms 
(the smear bands between 41 and 68 kD, charac­
teristic for wild-type (WT) expression in COS 
cells, are absent) 
no regeneration with the chromophore 
mainly non- and completely glycosylated forms 
poor regeneration (10-20% of WT) 
poor regeneration 
no or poor regeneration 
ref 
[26] 
[20] 
[29] 
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mutation 
N2Q 
G3C/P 
T4K 
N15Q/A/C/E/K/R 
N2.15Q 
K16C/R 
T17M/V 
T58R 
V87D 
G89D 
G106W 
R135L/W 
T17M 
P23H 
Y178C 
D190G 
Cl IOS 
C187S 
C110,185,187S 
E113K 
E113K,K296E 
E122K 
E134D/R 
! E134R.R135E 
с nos 
C140S/A/H/Y 
C185S 
C187S 
C322S 
У C323S 
C322.323S 
domain* 
N 
N 
N 
N 
N 
N 
N 
TMI 
TMII 
TMII 
el 
І2 
N 
N 
e2 
e2 
ТМШ 
e2 
TM III,e2 
TMIII 
TM III.VII 
І2 
І2 
TMIII 
І2 
e2 
e2 
С 
С 
С 
observations 
mono-glycosylation; normal regeneration 
non- (N2.15Q) or mono-glycosylated forms; no 
(K16), reduced and pH-dependent (N15), or nor­
mal (T17) regeneration 
ER localization (N15Q; N2.15Q) 
non-, mono- and completely glycosylated forms; 
ER and plasma membrane localization; no re­
generation; ADRP related 
non-, mono- and completely glycosylated (not in 
T17M) forms; ER localization; no regeneration; 
ADRP related 
reduced expression levels; glycosylation 
pattern as del 101-108; no regeneration 
glycosylation pattern as del 101-108; 
no regeneration 
non- and completely glycosylated forms 
no (C322 mutants) or reduced palmitoylation 
no (CIIOS, C187S) or normal regeneration 
ref I 
[78] H 
[81] 
[79] 
[24] 
[80] 
[25] 
* localization of the residues in the topographical model (Fig. 1.4) is indicated by N, N-terminal; 
el , loop el; e2, loop e2; e3, loop e3; il, loop il; i2, loop І2; ІЗ, loop іЗ; І4, loop І4; С, C-terminal. 
* insertion of a 12-amino acid epitope derived from the c-Myc protein flanked by penta-glycine linkers 
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Table 1.2 
Mutations that affect the spectral properties of bovine rhodopsin. (wildtype: ímax => 498 nm) 
mutation 
D83G 
D83N 
E113A 
E113D 
E113N 
E113Q 
E113Q.A117D 
FU5A 
A117D 
A117F 
E122A 
E122D 
E122Q 
E122I 
W126L 
W126A 
F261Y 
F261Y.A269T 
W265A 
W265F 
W265Y 
Y268F 
A269T 
1 A292D 
domain 
TMII 
ТМШ 
TMVI 
ТМ П 
λ
™*χ («m) 
501 
492 
496 
506 
510 
507 
520 
496 
500 
495 
493 
495 
475 
490 
476 
476 
475 
479 
482 
480 
480 
497 
490 
486 
510 
520 
470 
480 
483 
493 
514 
488 
observations 
pKa 5.7; anion-dependent 
pKa > 8.5 
pKa 6.7 
pKa 6; anion-dependent 
рКаб 
anion-dependent 
poor regeneration 
44% regeneration 
22% regeneration 
58% regeneration 
68% regeneration 
52% regeneration 
ref 
[16] 
[16] 
[21] 
[41] 
[41] 
[23] 
[41] 
[41] 
[23] 
[17] И 
[42] N 
[43] 
[42] 
[43] 
[43] 
[43] 
[24] 
[17] 
[43] 
[23] 
[24] 
[17] 
[43] 
[43] 
[47] 
[47] 
[43] 
[43] 
[43] 
[43] 
[47] 
[43] 
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Table 1.3 Mutations that affect binding and/or activation of transducin. 
j mutation 
N-terminus 
del 7-10* 
del 11-14* 
del 18-20* 
del 21-29* 
TMII 
D83N$ 
mm 
E113Q$ 
E113Q,K296G$ 
E122Q/A* 
E122D$ 
W126F/L/A$ 
loop І2 
E134D* 
E134Q 
E134R.R135E* 
E134A.R135E 
Е134АД135А 
R135Q 
loop e2 
Y191L 
Y192L 
del 193-194 
loop ІЗ 
del 234-250* 
del 236-239 
del 236-243 
del 237-249 
S240A 
T243V 
del 244-249 
K248L 
TMVI 
W265Y/F/A* 
P267G/A/S/N 
Y268F$ 
ТМ П 
A292D$ 
K296G/A/E/H/ 
T/C/Q/V/L/F 
loop І4 
C316S 
observations 
all transducin activation ι (10-20%) 
transducin activation ι (66%), PDE activation blocked 
constitutively active * 
constitutively active * 
transducin activation ι (85/65%) 
transducin activation t (150%) 
transducin activation l (87%) 
transducin activation J (82/62/69%) 
transducin activation ι (56%) 
transducin activation t (145%) 
transducin activation^ (74%), PDE activation blocked 
constitutively active * 
no transducin activation 
no transducin activation 
no transducin activation 
transducin activation i (8%) 
transducin activation i (55%) 
transducin activation ι (75%) 
transducin activation J (27%) 
poor regeneration, no transducin activation 
transducin activation ι (54%) 
transducin activation ι (3%) 
binding of transducin but no activation 
transducin activation t (60%) 
transducin activation l (40%) 
no transducin activation 
transducin activation i 
transducin activation l (69/54/4%) 
transducin activation l (79/54/59/51%) 
transducin activation ι (62%) 
transducin activation ι (46%) 
constitutively active * 
1 transducin activation ι (40%) 
rcf 1 
[78] 
[76] 
[70,71] 
[70,71] 
[24,44] 
[24] 
[44] 
[44] 
[20,24] 
[20,24] 
[76] 
[22] 
[19,20,24] 
[19] 
[24] 
[20,24] 
[78] 
[78] 
[78] 
[20] 
[20] 
[20] 
[19] 
[20] 
[20] 
[20] 
[18,20] 
[44] 
[44] 
[44] 
[44] 
[70,71] 
[22] 
[25] 
* constitutively active: activation of transducin already by the apoprotein (i.e. in the absence of chromophore 
and in the absence of light) 
* these mutations are also listed in Table 1.1 
* these mutations are also listed in Table 1.2 
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Figure 1.7 Cellular infection cycle of a nuclear polyhedrosis virus (panel A). Panel В shows the structural 
components of the two phenotypes, BV (budded virus) and PDV (polyhedra derived virus). 
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1.2 Baculovirus mediated expression 
The use of the insect cell/recombinant baculovirus expression system (for review see [83-86]) 
has become widespread since its development in the early 1980's. There are several reasons 
why this eukaryotic expression system has become so popular, including (1) potentially high 
protein expression levels, (2) ability to accomodate large DNA inserts, (3) protein processing 
similar to higher eukaryotic cells and (5) ease of insect cell culture. The most commonly used 
member of the family of Baculoviridae is Autographa californica multiple nuclear polyhedrosis 
virus (Ac(M)NPV), although other members like Bombyx mori (Bm) MNPV have also been 
exploited as expression vectors. 
Life cycle: The life cycle of AcMNPV (Fig 1.7, panel A) starts by entering the cell (primary 
infection) and subsequent replication in the nucleus. Progeny virions are transported into the 
cytoplasm, where they bud from the cell and are then free to infect other cells (Fig 1.7, panel 
B; secondary infection). Later in the infection cycle progeny viruses are surrounded by 
polyhedrin, forming the characteristic intranuclear inclusion bodies, polyhedra (Fig 1.7, panel 
B). Upon cell lysis and death of the host these polyhedra are released into the environment, 
waiting to be ingested by other feeding insects. In the new host the polyhedra dissolve in the 
alkaline conditions in the midgut and the virion particles are released (Fig 1.7, panel A). 
Baculoviruses are rather host-specific insect viruses [87], although recently a limited host 
range expansion by recombinant BmMNPV and AcMNPV has been reported [88]. 
Regulation of gene transcription: There are currently three generally accepted categories of 
baculovirus genes: early, late and very late hyperexpressed genes (for review see [89]). Early 
gene promoters are recognized by host cell RNA polymerase II [90]. Genes which are 
transcribed, only after viral DNA replication has been initiated, are classified as late genes. In 
contrast to late genes, which are transcribed over a defined temporal window (e.g. [91]), the 
very late genes (e.g. polyhedrin and plO) begin to be transcribed well after the initiation of 
late gene transcription and their transcription continues very late into the infection after late 
gene transcription ceases [92]. Although the nature of late gene transcription and the differenti-
al regulation of late and very late genes is not yet understood, recent evidence indicates that 
AcMNPV induces the production of an RNA polymerase unrelated to host RNA polymerases 
[93]. Splicing does not play a major role in the regulation of most baculovirus genes; however 
it occurs for at least one gene, which may lead to differentially expressed forms [94]. 
Recombinant virus: Recombinant virus is obtained by homologous recombination after 
cotransfection of host cells with viral DNA (133.894 bp circular genome for AcNPV [95]) and 
a transfervector, which contains a plasmid for bacterial replication, a viral promoter and 
flanking sequences, and the cDNA insert (Fig 1.8). The strong very late promoter of the 
abundantly expressed polyhedrin is generally used for the expression of heterologous protein. 
However, other promoters like the very late plO promoter [96] and the late basic protein 
promoter, which have been duplicated in place of the polyhedrin gene [91], have also been 
exploited. 
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Figure 1.8 Strategy for the construction of baculovirus expression vectors (i.e. recombinant bactdovirus). 
Replacement of the polyhedrin gene by "your favorite gene" (YFG). kbp - kilobasepairs; wt = wildtype; ree = 
recombinant. 
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In addition, stably transformed insect cells have been produced for heterologous gene expressi-
on under control of the early IE1 gene promoter [97]. 
For rapid identification of recombinant virus, transfer vectors containing an additional reporter 
gene, such as LacZ [98], luciferase [99], alkaline phosphatase [100], have been constructed. In 
addition, modifications of the transfecting DNA have increased the efficiency of recombination 
like the use of linearized AcMNPV DNA (reviewed in [101]) and the use of conditionally 
lethal genomes [102-104]. A comparison between cell lines originating from Spodoptera 
frugiperda and Trichoplusia ni resulted in a higher number and faster appearance of (recombi-
nant) virus plaques for the latter [105]. 
Transfer vectors: Several transfer vectors have been developed for expression of heterologous 
protein (reviewed in [106]). Requirements for high level expression under control of the 
polyhedrin promoter have been investigated thoroughly [83,107,108]. The majority of high-
level expression vectors contain the entire polyhedrin leader sequence intact, upto and inclu-
ding the "A" of the polyhedrin ATG translation start codon. Expression levels under control of 
the very late polyhedrin and plO promoter, and the late basic protein promoter are quite 
comparable [109-111]. However, the latter may be advantageous when producing proteins 
requiring extensive post-translational modifications (e.g glycosylation and proteolytic cleava-
ge), since the cell may be better equipped to carry out such processes earlier in infection. 
Multiple expression vectors have also been constructed which can be used to produce two to 
four different proteins [112-114]. 
Cell lines: The most commonly used host cell lines for production of heterologous proteins are 
Sf9 and Sf21, which originate from the oviduct of Spodoptera frugiperda, the fall army worm. 
However, recently alternative lepidopteran insect cell lines originating from e.g. Trichoplusia 
ni, Mamestra brassicae, Estigmene acrae and Lymantria dispar have been investigated [115-
119]. Although no single cell line produced the highest yield for every recombinant protein 
investigated [115], expression of secreted proteins semed to be higher in cell lines originating 
from Trichoplusia ni [118,119]. 
Post-translational modifications: Although the insect cell is capable of complex site-specific 
glycosylation [120], baculovirus infection reduces the production of complex processed 
carbohydrate patterns resulting in partially processed high-mannose forms. Studies on 
glycosylation of heterologous proteins in insect cells during baculovirus infection [121-124] 
showed that the nature of N-glycosylation was dependent on the time period post infection: 
complex oligosaccharides are still generated early in the infection, but only trimmed high-
mannose residues remain late in the infection. However, despite this change in glycosylation 
pattern, the majority of proteins expressed in the baculovirus system show identical biological 
activity to their fully processed "native' counterparts. 
Other posttranslational modifications, such as phosphorylation [125-129], palmitoylation [127-
130] and isoprenylation [129] can be correctly performed in the insect cells during baculovirus 
infection. 
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Large scale production of heterologous protein; Along with the development of the baculovi-
rus expression system the need has come up for production of heterologous protein on a large 
scale and consequently for scale-up of the insect cell culture. In general, the most efficient and 
convenient scale-up methodology involves suspension culture (for review see [131-132]). 
Several bioprocessing areas have been investigated including the effects of media [133-139], 
cell density [139-142] and multiplicity of infection (MOI) [141,143]. However, one of the 
major concerns in suspension culture is providing sufficient oxygen without damaging the 
insect cells, since they are quite sensitive to shear effects. In bioreactors, surface aeration is 
usually not sufficient, even at high stirring rates, and sparging of oxygen is required. The 
resulting generation of foam and formation and/or breakage of gas bubbles, increases cell 
death. Addition of surfactant polymers like Pluronic F-68 reduces foam formation and 
stabilizes gas bubbles and helps to protect the insect cells from the adverse effects of sparging 
[144,145]. 
Expression of G-protein coupled receptors: Rhodopsin was the first G-protein coupled receptor 
to be expressed in the baculovirus expression system [2]. Since then several other members of 
this family were succesfully expressed in this system, e.g. adrenergic receptors [99,146,147], 
muscarinic cholinergic receptors [146,148,149], dopamine receptors [128,150] and serotonin 
receptors [127]. All of these were processed correctly (glycosylation, palmitoylation, 
phosphorylation), and expression levels varied between 1-30 pmol/mg protein. However, as 
far as investigated only part (average of 50%) of these expressed G-protein coupled receptors 
was biologically active [146,151]. Nevertheless, these results demonstrate the general utility of 
the baculovirus system for production of relatively large quantities of functional G-protein 
coupled receptors. 
Although the expression level of functional rhodopsin in Xenopus oocytes is reasonably high 
(0.25 pmol/cell), only a limited amount of oocytes can be injected [3]. Expression levels of 
functional rhodopsin in human embryonic [4] or COS-1 monkey kidney cells [1] varies 
between 2-10 pmol/106 cells. This is 5-10 times less the amount of functional rhodopsin 
obtained through recombinant baculovirus. It should be noted, that also in these expression 
systems a small amount of non-glycosylated protein is produced and that ca 50% of the produ-
ced protein is not biologically active. Attempts to achieve an acceptable level of opsin 
expression in E. coli or yeast cells were unsuccessful [1; S.A. Zozulya, unpublished results]. 
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1.3 Aims and outline of this thesis 
Rhodopsin is a complex integral membrane protein which requires intermittent membrane 
translocation and several posttranslational modifications in order to fullfill all its structural and 
functional properties. In vitro expression allows exploration of properties like wavelength 
regulation, receptor mechanism, biosynthesis and lipid-protein interactions in much detail. 
From this point of view, we have selected the recombinant baculovirus expression system for 
the expression of wild-type, mutant and fusion proteins of bovine rhodopsin. For functional 
analysis recombination with the chromophore 11-ds retinal, purification and reconstitution in 
proper lipids is essential. The aim of this investigation was to optimize the expression system 
and exploit this to study structure-function relationships in bovine rhodopsin on a molecular 
level using a selection of point mutations. 
Materials and methods used throughout this thesis are collected in chapter 2. Chapter 3 
describes the search for optimal conditions of expression, regeneration, purification, recon-
stitution and labeling of bovine rhodopsin. 
Rhodopsin belongs to the large family of G-protein coupled receptors. A wealth of knowledge 
has accumulated on the excitation and desensitization pathways of this important mode of 
signal transduction, but molecular details on the structure of and signal generation by the 
various receptor proteins are nearly completely lacking. Chapter 4 describes a novel approach 
for structural studies: expression of rhodopsin fusion proteins ultimately to be used for 
crystallization purposes. 
Site-specific mutagenesis is a powerful tool to probe structural and/or functional roles of 
protein residues. Chapter 5 describes the effect of selected single amino acid substitutions on 
opsin biosynthesis. In chapter 6 the effect of selected mutations on the functional properties of 
bovine rhodopsin is described. In combination with FTIR difference spectroscopy this 
approach is able to provide very detailed and hitherto unaccessible molecular information 
about the structure and photo-induced conformational changes in rhodopsin. 
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CHAPTER 2 
MATERIALS AND METHODS 

2.1 Materials 
Restriction enzymes, T4 DNA kinase and ligase were purchased from Gibco BRL (Gaithers-
burg, USA). Opsin c-DNA was a gift from D. Hogness [25]. Monoclonal antibodies against 
rhodopsin were kindly provided by G. Adamus and P. Hargrave [19], and the hybridoma cell 
line 1D4 by R. Molday [20]. Immunoglobulins were obtained from Dako (Glostrup, Den-
mark). Tissue culture materials were purchased as described [1] with the exception of FCS 
(Hyclone, Utah, USA) and the antibiotics penicillin and streptomycin (Gibco BRL). 
2.2 Site-directed mutagenesis, transfervectors and recombinant virus. 
In general, the procedures suggested by Maniatis et al [2] were followed for construction of 
Plasmids and (bacterio)phages, and preparation of plasmid and phage DNA (plasmids: pUc, 
pAc; phages: M13; hosts: JM109, MV1190 and CJ236 for plasmids and phages; HB101 and 
DH5o for plasmids). Site-directed mutagenesis was performed using the approach developed 
by Kunkel [3] incorporated into the Biorad Mutagene kit (Biorad, Hercules, CA USA). This is 
based on growing M13-phage, containing the bovine opsin cDNA obtained from the plasmid 
bd20 [4,5], in a dut'ung" E. coli strain (CJ236), followed by isolation and mutagenesis of 
uracil containing ss-DNA using oligonucleotides with the desired mutation for strand duplica-
tion. Upon subsequent transformation in a wildtype E. coli strain (MV1190), the original 
uracil containing strand will be destroyed and the mutant will predominantly replicate. Table 
2.2 lists the oligonucleotides (column 1) used to introduce the desired point mutations (column 
2) on the uracil containing ss-DNA template (column 3) in Table 2.2. In most of the cases the 
mutation not only changed the codon sequence of the bovine opsin cDNA but also created or 
removed an endonuclease recognition sequence. Therefore mutations were rapidly identified 
by restriction analysis and/or by sequence analysis using the chain termination method des-
cribed by Sanger [6], as listed in Table 2.1 (column 4). 
(Mutant) opsin cDNA was isolated and transferred to transfervector pAc373 [7], pAcRP23 [8] 
or pAcDZl [9]. The resulting clone (Table 2.1, column 5) was then co-transfected with 
wildtype AcNPV DNA into cultured Sf9 cells as described [1,10] in order to produce 
recombinant baculovirus expressing, wildtype or mutant opsin, by homologous recombination. 
Recombinant virus was isolated either by immunohistochemical screening (transfer vectors 
pAc373 and pAcRP23 [1,11]) or by chromogenic screening (transfer vector pAcDZl [1,12]). 
Relevant recombinant baculoviruses are listed in Table 2.1 (column 6). 
2.3 Cell culture 
Baculovirus propagation, transfection, isolation of recombinant virus, culture media preparati-
on and insect cell culture were principally performed as described [1,10]. The Spodoptera 
frugiperda cell line IPLB-SÍ9 was maintained at 27 °C, either in TNM-FH medium plus 10% 
fetal calf serum (FCS), 50 μg/ml streptomycin and 50 U/ml penicillin, or in the serum-free 
medium Ex-Cell400 (Seralab, Sussex, England). Cells were cultured in monolayers using 
culture dishes or flasks (Costar, Badhoevedorp, The Netherlands) up to lxlO6 cells/ml. Large-
scale production was achieved in suspension culture (0.1-10 1) using spinner flasks (Bélico, 
Vineland, USA) or a 15 liter bioreactorsystem (Applikon, Illinois, USA). Cells were grown up 
to 2xl06 cells/ml, while stirring at 100-200 rpm with overlay aeration and with addition of 
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Pluronic-F68 (Sigma, Bornem, Belgium) to a final concentration of 0.1% during cell 
growth and 0.3% during viral infection. Viability and quality of cells were assessed by 
their morphology, their extent of attachment in monolayers and by trypan blue exclusion. 
A Mamestra brassicae derived cell line, kindly provided by L. King [13], was maintained 
at 27 °C in TNM-FH medium as above but with 5% FCS when cultured in monolayers up 
to 5xl05 cells/ml, and 10% FCS when cultured in suspension up to lxlO6 cells/ml. 
Viral infections (МОЫ0) were performed in one third of the final volume during 1-2 hr, 
and then supplemented with medium without FCS to a final cell density of 2xl06 cells/ml 
in suspension or lxlO6 cells/ml in monolayer culture. Virus titers were determined by 
plaque-assay [10]. 
2.4. Enzyme-linked immunosorbent assay (ELISA) 
For quantitive determination of opsin the ELISA-assay described before [14] was slightly 
adapted. The polystyrene wells were coated with 150 μΐ of a suspension of bovine rod 
outer segments (ROS) containing 20 picomoles of rhodopsin per ml of PBS (pH 7.4). For 
calibration bovine rhodopsin was used in the concentration range 0.02-10 picomoles/well. 
Unknown samples were diluted to a range between 4ХІ02 and 2xl05 infected cells/well. 
The primary antiserum CERNJS858 [15] was used in a final dilution of 1:4000. Reaction 
with secondary antibody, HPO-assay and computation were performed as described [14]. 
Total protein was determined in parallel samples using BioRad and/or Pierce (Rockford, 
Illinois, USA) protein assay kits with BSA as a standard. 
2.5. SDS-PolyAcrylamide Gel Electroforesis 
Total protein extracts were prepared by freeze-thawing the sedimented cells twice in 
destilled water (50 μ1/106 cells) with addition of leupeptin (10 ¿tg/ml) and EDTA (10 mM), 
followed by a DNAse treatment (2 ^g/106 cells, 15 min, RT). Samples were solubilized by 
addition of 4% SDS, 15 mM Tris-HCl buffer (pH 6.8), 10% glycerol, 0.006% bromophe-
nol blue and 20 mM DTE (final concentrations and added in the listed sequel). SDS-
polyacrylamide gel electrophoresis was performed as described [16] in 12,5% (w/v) slab 
gels (0.7 mm thickness) using the (mini)Protean II equipment (BioRad). Gels were stained 
in Coomassie blue R-250 (0.2 g in 50 ml methanol/40 ml bidest/10 ml acetic acid) for 10-
60 min at RT and destained in bidest/acetic acid/methanol (875/75/50 (v/v)) at RT or 60 
°C. If necessary a more sensitive silver staining [17] was subsequently performed. For 
molecular weight calibration the following standards were used: Phosphorylase A (94 kD), 
bovine serum albumin (67 kD), ovalbumin (43 kD), carbonic anhydrase (30 kD), trypsin 
inhibitor (20 kD) and o-lactalbumin (14 kD) (Pharmacia, Uppsala, Sweden). 
2.6 Electro-Immunoblotting 
After separation by gel electrophoresis the proteins were electrophoretically transferred 
[18] to nitrocellulose paper (Schleicher and Schuil BA 85, pore size 0.45 μπι) in blotting 
buffer (25 mM Tris, 200 mM glycine, 20% methanol) using the (mini)Trans-blot (Biorad). 
Subsequently the blots were soaked in 5% BS A/PBS for 1-2 h at RT in order to block free 
protein binding sites on the nitrocellulose filter, followed by the first antibody incubation 
(16 h at RT). The antisera used for opsin identification on blots and their dilutions are 
listed in Table 2.2. After rinsing in an excess of PBS detection was accomplished via 
incubation with a second or third antibody conjugated to peroxidase (RAMPO or SARPO 
(1:500) in PBS; RAM or SAR Ig (1:300) followed by PAPm or PAPr Ig (1:500) in PBS), 
another rinse, and, finally, incubation with the peroxidase substrate 4-chloro-l-naphtol 
41 
(0.3% w/v in PBS containing 16.5% v/v methanol and 0.02% v/v H 20 2). Depending on 
staining intensity, incubation was continued for up to 20 min, after which the blots were 
rinsed in destilled water and dried for storage. 
Table 2.2 
List of opsin antisera used for immunoblot and immunofluorescence assay [15,19,20]. 
antibody 
CERNJS858 
R2-12N 
K16-193L 
T13-34L 
K42-41L 
1D4 
epitope 
_ 
N-term. 3-8 
loop i2 
loop e2 
loop ІЗ 230-252 
C-term. 340-348 
Ig type 
polyclonal 
monoclonal IgG2b 
monoclonal IgM 
monoclonal IgGl 
monoclonal IgGl 
monoclonal IgGl 
Dilution 
blot 
1000 
500 
200 
200 
500 
1000 
IFA 
1000 
200 
100 
100 
200 
500 
Antisera were diluted in PBS or, for IFA on intact cells, in culture medium. 
2.7 ImmunoFIuorescence Assay (IFA) 
Single- and double-label indirect immunofluorescence staining of cultured cells was 
performed as follows: Sf9 cells were grown on cover slips or 8-well slides (Cel-line 
associates Inc., Newfield, NJ USA) up to a density of 1.106 cells/ml and subsequently 
infected with recombinant virus. In order to determine the reactivity of intact cells with 
selected opsin antisera, the latter were added at 1 dpi to the culture medium. At 2 dpi the 
cells were fixed on their carrier (1 min at RT in ethanol/aceton 1:1 v/v) and rinsed in PBS. 
At this stage both extracellular and intracellular epitopes are accessible and if required a 
first or second antibody incubation can be performed (1 h, RT). The antisera used for opsin 
identification and their dilutions are listed in Table 2.2. After rinsing twice in an excess of 
PBS staining was accomplished by incubation with a second/third antibody conjugated to 
fluoresceine (GAM-FITC (1:50) in PBS) or rhodamine (SAR-TRITC (1:100) in PBS) for 
30 min at RT. Following another rinse and mounting with Aquamount (BDH, Poole, 
Dorset, England), the samples were examined using a Olympus BH2 microscope with 
camera set-up. For pictures a Fuji P1600D film was used. 
2.8 Regeneration 
All manipulations involving rhodopsin were performed in dim red light (Schott-Jena 
RG645 cut-off filter). Regeneration of v-ops with ll-cis retinal into rhodopsin could be 
accomplished in either total cellular membrane preparations, a purified membrane fraction 
(see below) or a detergent extract using 5 mM dodecylmaltoside (DoM) [21]. Sf9 cells are 
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harvested at 3 dpi, and lysed and homogenized in a narrow-fitting Potter-Elvehjem tube in 
1 ml buffer A/108 cells (buffer A: 5 mM PIPES; 10 mM EDTA pH 6.5) with addition of 
leupeptin (200 μΜ) and DTE (5 mM). For a purified membrane fraction the homogenate is 
layered on a 50% sucrose cushion (w/v) in buffer A and centrifuged for 1.5 h at 70.000xg 
and 9°C. The band at the interface is collected and resuspended in buffer A. For rege­
neration the total or a purified membrane fraction is collected by centrifugation (30 min. ; 
9°C; lOO.OOOxg), and the precipitate is resuspended in 0.5 ml buffer B/108 cells (buffer B: 
20 mM PIPES; 130 mM NaCl; 5 mM KCl; 2 mM MgCl2; 2 mM CaCl2; 0.1 mM EDTA; 5 
mM DTE; pH 6.5) with addition of leupeptin (200 μΜ) and DoM (0.5 mM or 5 mM). The 
suspension is incubated for 2-4 h at RT under Argon on a rotating wheel with 1 l-cis retinal 
(added as a DMF-solution; 10-fold molar excess over v-ops; final DMF concentration 
<2%). After regeneration is completed (2-4 h) a 200 mM DoM-solution is added to a final 
DoM concentration of 20 mM, DTE is added to a final concentration of 5 mM, and the 
suspension is rotated overnight at 4"C under Argon in order to solubilize the v-rho [22]. In 
some cases the regeneration level could be enhanced by preincubating the suspension with 
retina lipids (added as a solution in methanol at 100-fold molar excess over recombinant 
opsin; final methanol concentration <2%) by rotating for 0.5 h at RT under Argon, prior 
to addition of ll-cur-retinal. For extraction of retina lipids the lipid extraction method 
described before [23] was slightly adapted. Light adapted bovine retinas were homogenized 
and filtered as described [24]. The filtrate was centrifuged (50.000xg, 30 min, 4°C) and the 
pellet was resuspended in destilled water (100 μΐ/retina) under Argon. Subsequently metha­
nol and dichloromethane were added (ratio 4:10:5 v/v) and the resulting suspension was 
thoroughly mixed by vortexing under Argon. Then another 5 volumes of destilled water 
and dichloromethane were added (final ratio 9:10:10). Thorough vortex-mixing under 
Argon followed by centrifugation (lOOOxg, 10 min, RT), resulted in two liquid phases. The 
bottom dichloromethane phase, containing the retina lipids, was blown to dryness with 
nitrogen and the lipids were resuspended in dichloromethane/methanol (ratio 4:1 v/v, 200 
μΐ/retina) and stored (-20 °C) Lipid concentration in the extract was determined by a 
modified Fiske-Subbarow phosphate assay [25]. 
2.9 Purification 
A first purification step was performed either by affinity-chromatography over ConA-
Sepharose or immuno-affinitychromatography on immobilized 1D4 [22]. For that purpose, 
the DoM-extract was freed from unsoluble material by centrifugation (20 min.; 4°C; 
lOO.OOOxg), and applied to a column of ConA-Sepharose (Pharmacia) (1 ml gel/108 cells) 
at a flow rate of 1 ml/h. Unbound material is eluted with ten volumes of buffer С (buffer 
C: buffer В with addition of 20 mM nonylglucose) followed by five volumes of buffer С 
containing 50 mM glucose. During the washing steps the detergent is exchanged for 20 
mM nonylglucose [21]. V-rho is then eluted with buffer С containing 200 mM e-methyl-
mannose. This procedure effectuates fifty to hundred fold purification. 
For immunoaffinity-chromatography the DoM-extract is applied to a column of the 
monoclonal antibody 1D4 immobilized onto Affigel Hz (BioRad) according to the 
manufacturer's instructions. 1D4 was obtained by NaS04 precipitated from ascites, 
produced in nude mice by i.p. injection of the corresponding hybridoma [20]. The final gel 
contained ca 3 mg antibody /ml gel and 0.1 ml gel is used per initial 108 cells. Unbound 
material is eluted with 10 volumes of buffer C, and bound v-rho subsequently eluted with 
buffer С containing 100 μΜ of peptide 338-348. This procedure allows at least two 
hundred-fold purification resulting in quite pure preparations. Its capacity/cost ratio is quite 
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poor, however, (Mab and peptide are quite expensive) and therefore routinely purification 
is accomplished by ConA-Sepharose chromatography in combination with reconstitution 
over a sucrose gradient (see next section). 
2.10 Reconstitution 
Reconstitution of the purified v-rho into a lipid envirionment was achieved in two different 
ways. First by addition of a 150-molar excess of phospholipid (egg PC or retina extract), 
dissolved in 20 mM nonylglucose, followed by dialysis against 3 χ 50 volumes of buffer В 
(24-48 h; 4°C). The resulting proteoliposomes are collected by centrifugation (16 h; 4°C; 
lOO.OOOxg) [22]. This approach only works with easily dialysible detergents like nonylglu­
cose. A more general applicable approach, also suitable for dodecylmaltose, was developed 
taking use of the capacity of inclusion compounds like cyclodextrins to form inclusion 
complexes with detergents (DeGrip et al, in preparation). Hereto the purified v-rho was 
mixed again with a 100-fold molar excess of retina lipids and the mixture was concentrated 
on a Filtran Omega 30K filter to a volume of ca 2 ml. Solid ß-cyclodextrin (Aldrich, 
Bornem, Belgium) was added until the solution becomes clearly turbid (final concentration 
varies between 80-120 mM, depending on detergent concentration). The resulting suspensi-
on was layered on top of a sucrose step gradient (10% containing 10 mM ß-cyclodextrin, 
10%, 20% and 45% (w/v) in 3x diluted buffer B) followed by centrifugation (24h; 4 °C; 
lOO.OOOxg). The resulting proteoliposomes were collected from the 20%/45% interface, 
washed twice with destilled water, and stored at -80 °C until further use. The gradient 
procedure effectuates another three to four-fold purification, resulting, in combination with 
ConA-Sepharose chromatography, in v-rho preparations of at least 75% purity, which are 
suitable for all functional analyses. 
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CHAPTER 3 
OPTIMIZATION OF VARIOUS FACETS OF RHODOPSIN 
EXPRESSION USING RECOMBINANT BACULOVIRUS.* 
Adapted from: G.L.Í. DeCaluwé, I. VanOostrum, J.J.M. Janssen and W.J. DeGrip 
(1993) In vitro synthesis of bovine rhodopsin using recombinant viras, Methods in 
Neurosciences 15, 307-321. 

3.1 Introduction 
Rhodopsin is a complex integral membrane protein which requires intermittent membrane 
translocation and several posttranslational modifications (glycosylation, palmitoylation, 
disulfide bridge formation, recombination with ll-cis retinal) in order to fulfill all its 
structural and functional properties. In vitro expression allows exploration of properties 
like wavelength regulation, receptor mechanism, biosynthesis and lipid-protein interactions 
in much detail through labeling and (site-specific) mutagenesis. For this purpose we have 
selected the recombinant AcNPV baculovirus system, as this is a eukaryotic expression 
system, which performs all common eukaryotic posttranslational modifications and has 
been used successfully for the high level expression of foreign genes (for review see 
[1,20]). Baculoviruses are rather host-specific insect viruses [3], although recently a host 
range expansion by recombinant viruses of BmNPV and AcNPV has been reported [4]. 
Still, the most commonly used host cell lines are Sf21 and Sf9 which originate from the 
oviduct of Spodoptera frugiperda, the fall army worm. 
Nuclear polyhedrosis baculoviruses like AcNPV have the unique property of producing a 
protein matrix in which progeny virions are embedded at a late stage of infection (nuclear 
occlusion bodies) to protect virions upon subsequent cell lysis. The strong promoter of the 
abundantly expressed matrix protein (polyhedrin) is generally used for the expression of 
heterologous protein [1,2]. Recombinant virus is obtained by homologous recombination 
after co-transfection of host cells with viral DNA (133.894 bp circular genome [5]) and a 
transfer vector, which contains ca 3 kb viral sequences flanking the polyhedrin promoter 
and the c-DNA insert. Several transfer vectors have been developed, which differ in the 5' 
and 3' region of the polyhedrin gene. For rapid identification of recombinant virus, transfer 
vectors containing an additional reporter gene, such as LacZ, have been constructed. 
Depending on the transfer vector used, recombinant virus can be isolated either via 
immunohistœhemical/morphological screening [6,7] or by chromogenic/morphological 
screening using constitutively expressed ß-galactosidase [8]. 
In this chapter we will elaborate on in vitro synthesis of bovine rhodopsin using recombi-
nant AcNPV baculovirus. 
3.2 Materials and methods 
Baculovirus manipulations, Sf9 cell culture, inhibition ELISA assay, regeneration and 
purification were principally performed as described in chapter 2. 
For large scale-up a 15 1 stirred vessel (Applikon, Illinois) was used. Conditions for cell 
growth and viral infection were: TNM-FH medium supplemented with 10% FCS, antibio-
tics (50 f*g/ml streptomycin and 50 U/ml penicillin) and 0,3% Pluronic F-68 (Sigma), 
surface aeration with air (= 1 atm) and stirred at 100-200 rpm. Dissolved oxygen (D02) 
was measured using a 02-sensor (Ingold, Urdorf, Switzerland). Samples were taken for 
determination of the cell density and the pH of the culture medium. Cell viability was 
determined by trypan blue exclusion. Cells were infected with recombinant opsin virus 
(AcNPVDZl/1-ops; MOI=5) for 1 h without stirring and then stirred at 200 rpm with 
surface aeration. After 1 h infection in the vessel a 100 ml sample was transferred to a 
spinnerbottle and stirred at 100 rpm. 
In preparation for studies using protein labeling, amino acid concentrations in Grace's 
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Figure 3.1 Optimization of opsin expression. Expression levels are given in μ# opsin per mg protein (n=3). 
Opsin levels were assayed by inhibition ELISA at 3 dpi (panel A,B,D), or at 1, 2 and 3 dpi (panel C). 
Suspension culture was performed in spinner bottles (Bélico 1967-00250). In panel А, В and С 100 ml 
suspension cultures of Sf9 cells (ca 2 χ 10* cells/ml) or Mb cells (ca Ι χ 1& cells/ml; panel B, bar 2) were 
infected with recombinant virus AcNPVRP23.ops (MOI=10). 
(A) Effect of medium and Pluronic F-68 (0,1% during cellgrowth and 0,3% during infection): 1, TNM-FH (TF 
- PF68); 2, TNM-FH plus Pluronic F-68 (TF + PF68); 3, Ex-Cell400plus Pluronic F-68 (EC + PF68). 
(B) Effect of cell type: Sfl (1) vs Mb (2) cells. 
(C) Rate of opsin production at 1,2 and 3 dpi, and effect ofMOI=10 vs MOI=2. 
(D) Variation in 5' leader sequence: monolayer cultures of Sß cells in 6-well petridishes were infected with 
recombinant viruses (MOI =10) obtained from the corresponding transfer vectors (shown between parenthesis) 
containing the opsin c-DNA (ops; 45 bp leader sequence) or the 5' truncated opsin c-DNA (l-ops; 5 bp leader 
sequence): 1, AcNPV373.eps (pAc373/45bp); 2, AcNPVRP23.eps (pAcRP23/45bp); 3, AcNPVDZl.ops 
(pAcDZl/45bp); 4, AcNPVDZl.l-ops (pAcDZl/Sbp). 
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medium were varied (see table 3.3) and their concentration before and after infection was 
determined by acid hydrolysis and analysis on a 4151 Alpha Plus Amino Acid Analyser 
(LKB, Uppsala, Sweden) with ninhydrine post-column derivation. Sf9 cells were grown in 
TNM-FH medium supplemented with 10% FCS, antibiotics (50 μg/ml streptomycin and 50 
U/ml penicillin) and 0,1% Pluronic F-68 (suspension culture). After infection with 
recombinant virus medium was replaced by either TNM-FH or Grace's medium, supple­
mented with antibiotics (50 Mg/ml streptomycin and 50 U/ml penicillin) and 0,3% Pluronic 
F-68 (suspension culture). 
3.3 Results 
Expression level 
Baculovirus-based expression systems produce very high levels of soluble proteins (5-10% 
of total cell protein [1,2]), but generally much lower yields of membrane proteins (0.1-1 % 
of total protein [9]). Since a higher yield is much more efficient productionwise and 
reduces relative cost and purification losses, we have evaluated several factors in order to 
achieve maximal production of functional opsin. 
Medium: Large-scale production of recombinant protein can be achieved in suspension 
culture [10] but insect cells are very sensitive to mechanical shear. Addition of a cell-
protective agent like Pluronic F-68 was reported to improve cell viability [11]. Inclusion of 
0.3% Pluronic F-68 (Fluka) in a suspension culture of Sf9 cells increased the opsin 
production after 3 days by about 50% (Fig. ЗЛА, bar 1 vs 2). Hence, 0.3% Pluronic F-68 
was used in all subsequent experiments employing suspension culture. The additional 
increase in production by ca 30% upon culturing the cells in the serum-free medium Ex-
Cell400 (Fig. 3.1 A, bar 3) is only marginal as compared to the ca fivefold higher levels 
reported for soluble proteins under the same conditions [13]. 
Rate of production: Since the polyhedrin promoter is activated late in the infection cycle, 
we followed the opsin production in Sf9 cells at 1, 2 and 3 days post infection (dpi) (Fig. 
3.1C). Later stages are not appropiate since cell lysis starts as of 4 dpi and results in 
variable losses in yield of cellular membranes (not shown). As expected, peak levels were 
obtained after 3 dpi, but were somewhat dependent on the infection conditions. At 
MOI=2, lower levels were usually obtained than at MOI=10 (Fig. 3.1C, bar 3 versus 4). 
Consequently, subsequent results are all based on infection at MOI=10 and cell harvest at 
3 dpi. 
Variation in 5' noncoding region of the c-DNA insert: Bovine opsin c-DNA [13] was 
cloned in three different transfer vectors [14]: pAc373 [15], pAcRP23 [16] and pAcDZl 
[8]. Only upon reduction of the opsin 5' leader from 45 to 5 bases a significant increase in 
opsin production was observed (Fig. 3.1D). This may be due to the fact that the opsin 
leader is GC-rich, while an AT-rich 5'-leader sequence, like that of polyhedrin [17] will 
enhance transcription levels [18], although other factors have to be involved as well. 
Cell-type: A Mamestra brassicae derived cell line (Mb) was reported to produce 2-3 fold 
higher levels of recombinant protein than Sf21 cells because of its larger biomass [19]. 
However, we find similar yields of total protein for Mb and Sf9 cells (454 ± 6 VJ 499 ± 6 
Hg/106 cells) and similar expression levels for opsin (Fig. 3.1B). 
Large scale-up: Sf9 cell growth (A) and viral infection (B) in a 15 liter stirred vessel was 
studied and compared to a 100 ml suspension culture (Fig 3.2). In the reactor, surface 
51 
aeration with stirring rates of 100-200 rpm were used resulting in a D 0 2 of 26-35%; the 
suspension in the spinnerbottle was stirred at 100 rpm. Nevertheless, cell growth and 
viability were comparable in both the reactor and the spinnerbottle (Fig 3.2, panel A), also 
when the experiment was started with a cell viability of 80% (panel B). During cell 
growth, the pH of the culture medium was reasonably stable (panel A and B). However, 
after viral infection the pH dramatically increased in both the reactor and the spinnerbottle 
(panel B). In order to compare opsin production in either system, the cells in the reactor (4 
liter culture) were infected after 92 h culture with recombinant opsin virus and subse­
quently a 100 ml sample was transferred to a spinnerbottle. Opsin production according to 
ELISA amounted to 22 pmol/ml at 3 dpi and to 30 pmol/ml at 4 dpi for both the reactor 
(200 rpm) and spinnerbottle (100 rpm), and hence is not significantly different in these sys­
tems. Further optimization should lead to even higher production levels (e.g. grow cells at 
higher densities (4-5.106 cells/ml), infect at MOI=10, and then dilute with fresh medium 
to a cell density of 2.106 cells/ml). 
A В 
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- - + - - tota l cel ls 
—e~- pH 
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time (h) 
Figure 3.2 Large scale-up of the expression system lo a bioreactor. Sß cell growth (panel A) and infection 
(panel B) with recombinant opsin virus AcNPVDZl/l-ops (MOU5) were compared in a 4 I stirred vessel 
bioreactor (10 I total volume) and in a 100 ml spinnerbottle (250 ml total volume) with surface aeration and 
addition of 0.3% Pluronic-F68 to the medium. Viability was determined by trypan blue exclusion. 
The spinnerbottle was stirred at 100 rpm. Stirring rate in the bioreactor was increased (panel A) from 100 rpm 
(D02 ca 26%) via 150 rpm (D02 ca 27%) up to 200 rpm (D02 ca 35%) (panel B). 
Regeneration 
For functional analysis it is essential that the produced opsin can be regenerated with the 
chromophore 11-си retinal into a photosensitive pigment. Regeneration could be accom­
plished in total cellular membrane preparations or a purified membrane fraction. After 
extensive investigation, the scheme described in Fig. 3.3A proved to give reliable results. 
A density separation was required to separate membrane fractions of higher density, 
containing v-ops with low regeneration capacity, from a lower density fraction with high 
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regeneration capacity. The latter fraction, which represents 40-50% of the total opsin 
produced, shows a comfortable 70-80% regeneration, compared to only 20-30% in the 
initial total cellular membrane preparation. Some further enrichment in v-rho is achieved 
upon subsequent detergent-solubilization using 10 mM DoM. The resulting supernatant 
contains 8-10 ^g v-ops/mg protein, 70-80% of which is present as v-rho. Several conditi­
ons were tested to improve regeneration of total cellular membrane preparations and 
purified membranes (Table 3.1). Varation in ll-cis retinal excess (10-40x), temperature 
and time, or addition of lipids (0-400x), dodecylmaltoside (0.5-5mM), polyethyleenglycol 
(0,3%), oA-crystallin (100mg/ml) and glycerol (10-20%) did not strongly influence the 
regeneration capacity of v-ops. Addition of retina lipids gave no significant improvement 
upon regeneration of v-ops in total membranes. However, the regeneration capacity of v-
ops in purified membranes or sucrose pellets (not shown) was enhanced by additition of 
100 fold molar excess of retina lipids (Table 3.2). 
In order to avoid the laborious and time-consuming centrifugation step, we selected 
regeneration in total cellular membrane preparations, with a 10 fold molar excess of ll-cis 
retinal and a 100 fold molar excess of retina lipids over v-ops, as standard conditions. This 
now reproducibly yields regeneration percentages between 40-60%. The resulting photo-
pigment v-rho is fully light-sensitive and the corresponding difference spectrum with ^щ^ 
at 498 nm is identical to that of native bovine rhodopsin (see chapter 6). 
Table 3.1 
List of conditions tested in order to improve regeneration of v-ops in total or purified membranes. 
condition/addition 
time 
temperature 
11-СІ5 retinal 
dodecylmaltoside 
lipids 
polyethyleneglycol 4000 
¡1 glycerol . 
¡ aA-crystallin 
total membranes 
1 h - 16 h 
_ 
10-40-3x5 fold1 
0 .5 -5 mM 
retina lipids 0-200 fold1 
ROS PC 50 fold1 
egg PC 50 fold1 
-
10-20% 
2 - 10 fold1 
purified membranes 
3h 
4 - RT - 37 "C 
10 fold1 
_ 
retina lipids 0-400 fold1 
egg PC 50 fold1 
0,3% 
_ 
fold: molar excess over v-ops 
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Table 3.2 Influence of retina lipids on production ofrhodopsin in total and purified membranes. 
retina lipids 
molar excess2 
Ox 
50x 
lOOx 
200x 
400x 
relative amount of v-rho produced1 
total 
membranes3 
45 
41 
45 
45 
-
purified 
membranes3 
23 
22 
30 
28 
27 
% v-rho relative to total amount of v-ops expressed 
molar excess over v-ops 
regeneration capacities in total membranes varied between 40-60%, 
in purified membranes between 60-80%. 
Purification. 
In order to study the functional and structural properties of the pigment obtained through in 
vitro expression it is essential to purify the protein and reconstitute it into proper lipids. 
Exploiting the fact that v-rho is manno-glycosylated, 20-30 fold purification could be 
accomplished by the simple and inexpensive technique of affinity-chromatography over 
ConA-Sepharose. The resulting preparations (Fig. 3.3B, spectrum 1) contain 10-15% v-rho 
on a protein weight basis. Immunoblots probed with antibodies against opsin (A), viral pro­
teins (B; for preparation of these antibodies see chapter 4) and digoxigenin-labeled ConA 
(C; kit from Boehringer) show major contaminants originating from viral glycoproteins 
near 37 and 64 kDa [3,7] in the eluted v-rho fraction (Fig 3.4). Elution conditions have 
been optimized to reduce contamination by viral glycoproteins in the v-rho fractions as 
much as possible (Fig. 3.5). A continuous (panel A) or step gradient (panel B) of o-
methylmannose had no significant effect: v-rho already starts to elute at 50 mM together 
with viral glycoproteins. Rinsing the column with 50 mM solutions of glucose and o-
methylglucose before elution of v-rho improves the purification factor, since viral 
glycoproteins already partly elute under these conditions. In panel С v-rho also already 
eluted with 50 mM o-methylglucose but this is due to column overload and does not occur 
when 1 ml column per 108 cells is used (not shown). Also the excess retinal (additional 
absorbance peak around 360 nm, in Fig. 3.3B spectrum 1, indicates that this not complete­
ly removed in the original procedure) can be effectively removed by rinsing the column 
with 50 mM glucose before elution of v-rho. Hence, for the purification of v-rho using 
ConA-Sepharose a rinse with 50 mM glucose and 50 mM a-methylglucose, respectively 
before eluting v-rho with 200 mM α-methyl mannose has been adapted as standard 
procedure. In order to avoid overloading of the column, a bed volume of at least 1 ml is 
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Figure 3.3 Purification of v-rho. (A) Scheme for purification of v-rho. Recovery is based on v-ops content. 
The percentage v-ops present as v-rho is given as % v-rho. (B) Absorbance spectra of v-rho after purification 
over ConA-Sepharose (spectrum 1) and immunoaffinity chromatography over immobilized 1D4 (spectrum 2). 
In the finally adapted procedure the retinal-contamination (360 nm peak in curve 1) could be nearly 
completely removed by the preceding (methyl)glucose rinse. 
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Contamination in v-rho purified over ConA-Sepharose. Immunoblot analysis of eluted v-rho fractions (lanes 1, 
1 pmol; lanes 2, 0.5 pmol) and ROS (lanes 3, 1 pmol; lanes 4, 0.5 pmol). Immunoblots were probed with: A, 
CERNJS858 (dilution 1:1000) for identification of opsin; B, CERNLC914 (dilution 1:1000) for identification of 
viral proteins; C, D,gConA (kit from Boehringer, Mannheim, Germany) for identification of ConA-binding 
glycoproteins. 
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used per extract of 108 cells. Under these conditions 50-60 fold purification is achieved 
with a recovery of at least 80% and the purity of the resulting v-rho preparations varies 
between 15-25 % on a protein base. 
Additional 3-4 fold purification can be achieved by immunoaffinity chromatography over 
the immobilized monoclonal antibody 1D4 [20] using the corresponding epitope-peptide 
338-348 for elution of bound v-rho. This selective, but rather expensive procedure yields 
preparations, which contain at least 50% v-rho on a protein weight basis (Fig. 3.3B, 
spectrum 2) and are suitable for most functional analyses. Since reconstitution into proteoli-
posomes (next section) by itself affords at least 3-fold purification, we usually compromise 
between yield and purity by using ConA-Sepharose purified preparations directly for 
reconstitution. 
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Reconstitution 
In order to create a more native environment the purified v-rho was reconstituted into 
suitable lipids (egg PC or retina extract). Lipids were added in a molar ratio to v-ops of 
150:1 and proteoliposomes generated by removal of detergent through dialysis or a sucrose 
stepgradient (see chapter 2). This accomplished at least three-fold further purification, but 
simultaneously resulted in 25-50% loss of v-ops. Hence, 15-30% of the initial v-ops is 
recovered in proteoliposomes, of which at least 80% is v-rho in a purity of 60-80%. 
Hence, the v-rho finally obtained in this way is of sufficient purity and has the proper 
membrane environment to allow all functional analysis. 
Amino acid requirement 
Non-radioactive isotope labeling is a powerful approach to assign bands in FTIR difference 
spectra to certain protein residues (see chapter 6). For this purpose we examined whether 
opsin production was affected by culture in Grace's medium, which only contains free 
amino acids, during infection with recombinant virus and how far we could reduce amino 
acid concentrations. The use of Grace's medium is important in this respect, in that no 
other amino acid source (like lactalbumin hydrolysate, yeastolate or BSA in TNM-FH) can 
be used for protein synthesis. The production of v-ops was not significantly affected when 
Grace's medium was used (Fig 3.6), and a two-fold reduction in the amino acid levels 
(except cysteine) was very well tolerated. The consumption of amino acids during infection 
was estimated by analysis of the culture medium at 3 dpi. The cysteine concentration 
strongly decreased, and this amino acid might become a limiting factor. In general agree­
ment with Vaughn et al [21] and Bedard et al [22] at large consumption was observed of 
serine/threonine, valine, isoleucine, leucine, tyrosine and cystein decreased, whereas the 
alanine concentration strongly increased. The latter probably represents one of the 
metabolic end-products and an energy source [39]. 
6
 I I Ш TNM-FH 
Figure 3.6 Opsin expression in Grace's medium in dependence of the amino acid concentration. Opsin levels 
were assayed by inhibition ELISA al 3 dpi and are given in micrograms opsin per milligram protein (n=3). 
S/9 cells in suspension cultures (left two bars) or in monolayer cultures (right three bars) were infected with 
recombinant virus AcNPVDZlll-ops (MOI=I0). Amino acid concentrations in Grace's medium (1*AA) are 
reduced two- (112*AA) and four- (1/4*AA) fold, respectively, except for cysteine. Free amino acid concen­
tration in TNM-FH is the same as in Grace's medium. 
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3.4 Discussion 
Under the various conditions described above, the functionality of the opsin produced 
(glycosylation, targeting, capacity to regenerate into rhodopsin upon addition of 11-cis-
retinal) did not vary significantly. Hence, the highest expression level of functional opsin 
was achieved upon using recombinant virus with 5' truncated opsin c-DNA, a high 
infection density (MOI =10), addition of 0.3% Pluronic F-68 to stabilize the cells and a 
production time of 3 days. Under these conditions levels of 50 picomoles opsin/106 cells 
(ca 4 μg opsin/mg protein; ca 4 mg opsin/liter culture) are reproducibly achieved. This is a 
reasonably high level for a complex transmembrane protein [9], and in fact comparable to 
the production rate of a bovine rod photoreceptor cell (15-25 picomoles/day)! ! 
Hence, the recombinant baculovirus system affords relatively high yields of in vitro 
expressed opsin with correct folding, posttranslational modification and targeting (see 
chapter 5). The relatively low overall regeneration capacity (40-60%) remains presently 
unexplained, but may be related to "structural stress" due to a relative high packing density 
of this heterologous membrane protein in an unusual lipid environment. Relatively low 
ligand-binding capacity has also been reported for other membrane receptors expressed in 
this system [9]. By the same reasoning the relatively low yield as compared to soluble 
proteins can be explained as well as the low response to changes in the 5' noncoding 
region, which strongly effect expression levels of soluble proteins. Although several factors 
which can be of influence on the regeneration capacity were examined (Table 3.1 and 3.2), 
other factors still could be investigated. In vitro, the use of cosolvents (Polyethyleneglycol 
[23], glycerol [24]) in aqueous systems has been shown to enhance protein refolding and 
decrease aggregation. In vivo, expression in the early stage of infection (e.g. under control 
of the basic protein promotor [22,26,27]), where the cellular metabolic integrity has not yet 
suffered too seriously from the viral infection, and folding/stabilization of the protein 
during synthesis in the cell for example by co-expression of a chaperone [28], disulfide 
isomerase [29] or cyclophilin [30] are options that need to be considered. 
Regeneration in total membranes, purification over ConA-Sepharose and subsequent 
reconstition in retina lipids yields at least 150-fold purification of v-rho with 20-30% 
overall recovery of v-ops. Our purification scheme leads to preparations of at least 80% 
purity suitable for most functional analysis. The overall yield still compares favorably with 
those obtained in mammalian expression systems [31,32]. In addition, bioreactors are being 
developed for insect cell culture, which will allow suspension cultures of 10-30 liters in the 
near future [10]. A pilot experiment with a 15 liter stirred vessel bioreactor with regard to 
insect cell culture and recombinant viral infection gave promising results. However, 
conditions such as aeration (surface and/or sparging [33]), stirring rates and viral infection 
(MOI [34] and cell density) nead to be further optimized. In such a bioreactor sufficient 
material can be produced to permit studies by powerful but rather insensitive biophysical 
techniques like solid-state NMR. 
NMR-analysis requires isotope-labeling of the protein and also for FTIR difference 
spectroscopy isotope labeling of protein residues is generally required in order to identify 
their vibrational bands and to investigate their role in the structural changes during 
phototransduction [35]. Because labeled amino acids are very expensive minimal concentra­
tions in the medium need to be determined. A 4 fold reduction in the concentration of quite 
a few amino acids can easily be tolerated without a change in opsin production, while the 
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other ones (except cysteine) allow a 2 fold reduction. For labeling purposes the best 
strategy would be to examine and adapt the concentration of each amino acid individually. 
Finally, scrambling of amino acids in the insect cell during infection needs to be examined 
in more detail, in order to assess which isotopically labeled amino acids can be added 
during infection without metabolic transfer of label to other amino acids. 
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CHAPTER 4 
EXPRESSION OF (RHOD)OPSIN FUSION PROTEINS 

4.1 Introduction 
Rhodopsin, the visual pigment of the rod photoreceptor cell in the vertebrate retina, is 
composed of an integral membrane proteinmoiety, opsin, harbouring a chromophore, l i­
d i retinal, covalently linked in a protonated Schiff base to Lys296 [1]. The sequence 
suggests the characteristic schematic model for its three-dimensional arrangement of seven 
helical membrane domains nested around the chromophore [2,3,4,5]. The seven trans­
membrane arrangement has recently been confirmed by electron imaging studies on 2D-
crystals [6]. 
Rhodopsin "translates" the photon signal into protein conformational changes (for 
review see [7]). Visual pigments represent a subfamily of the large protein family of G-
protein coupled receptors, which all use GTP-binding proteins as signal mediators and 
share the structural motif of seven helical membrane domains [8]. 
A wealth of knowledge has accumulated on the excitation and desensitization pathways of 
this important mode of signal transduction, but details on the molecular structure of/and 
signal generation by the various receptor proteins are nearly completely lacking. Neither a 
crystal structure nor a suitable crystallization protocol of any member of this protein family 
has yet been reported. These proteins are completely insoluble in aqueous environment 
unless detergents are added, which seriously complicates crystallization studies (additional 
components, phase separation, protein destabilization). Earlier, we already described our 
studies to optimize crystallization conditions for rhodopsin [9], but in spite of many efforts 
crystals of rhodopsin with high-resolution diffraction quality could not yet be produced. 
Here we describe a novel approach, expression of rhodopsin fusion proteins with a 
soluble protein, which is interesting for several reasons. First of all, such a combination 
might have a better crystallization behaviour. Furthermore, it would be interesting to study 
the effect of the fused protein on functional properties of rhodopsin like membrane inserti­
on, glycosylation, targeting, photocascade and signal transduction. 
In first instance, the fusion partner we selected was gluthatione-S-transferase (GST), 
a dimeric cytosolic enzyme that is involved in the detoxification of endogenous and 
xenobiotic electrophilic substances. Four isoenzymic species (ο, μ, π and θ) can be 
distinguished in mammals, and crystal structures for three gene classes (α, μ and π) have 
been reported [10-13] which reveal a similar folding pattern of the secondary structural 
elements of the subunits. Another major advantage of glutathione-S-transferase as a fusion 
partner is that it allows one-step purification over immobilized glutathione. Here we use the 
c-DNA of the GST of Schistosoma japonicum (Sj26 [14]), which is available in the bacte­
rial expression vector pGEX [15] and has an overall homology of 42% with class μ 
isoenzymes [14]. 
Our second, and evident, choise was T4 lysozyme. This enzyme of bacteriophage 
T4 hydrolyses the N-acetylmuramic acid-peptide side chain linkages in the bacterial cell 
wall [16,17]. The X-ray crystal structure of T4 lysozyme has already been reported in 1978 
[18] and later refined at 1.7 Á resolution [19]. Since then T4 lysozyme serves as a model 
for studying the structural basis of protein folding and stability using side directed mutage-
nesis and a variety of crystallization conditions have been reported [20-22]. T4 lysozyme as 
a fusion partner also allows one-step affinity purification [23,24]. 
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Figure 4.1 Construction of the GST-opsin fusion transfer vector. Details are described in the materials and 
methods section. Black boxes indicate promoter regions: taq promoter in pGEX-2T; pob/hedrin promoter in 
pAcRP23. Abbrevations for restriction sites: B, BamHI; Bg, Bglll. 
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4.2 Materials and methods 
Baculovirus manipulation, Sf9 cell culture, site directed mutagenesis, SDS-PAGE, 
immunoblotting, ELISA assay, immunofluorescence assay and opsin regeneration were 
performed as described in chapter 2. 
Construction of an gst-opsin fusion transfer vector: From the bacterial expression vector 
pGEX-2T [15] a 1.5 kb Hindll fragment was isolated, containing the cDNA coding for 
gluthatione-S-transferase of Schistosoma japonicum. After ligation with BglII-linker DNA 
and digestion with Bglll and BamHI, the resulting 0.9 kb fragment, without a stop-codon at 
the 3' end, was cloned into the BamHI cloning site of transfer vector pAcRP23 [25]. 
Subsequently, opsin cDNA with truncated leader (1-ops, cf. chapter 2 and 3) could be 
cloned in the BamHI site of this vector, pAcRP23/GST, at the 3' end of GST, resulting in 
a open reading frame ending at the opsin stop codon (Fig 4.1). 
Construction of an opsin-T4 fysozyme fusion transfer vector: First, the transfer vector 
pAcRP23/GST (see above) could be cut with BamHI and, because of a remaining additio­
nal Bglll linker with Bglll, and the =10 kb vector, pAcRP23.BglII, could be isolated. A 
BamHI site in the opsin cDNA, just before the TAA termination codon, was created via 
site directed mutagenesis with the oligonucleotide 5'cgttcatggatccggcccttg3' and M13/l-ops 
as template (chapter 2). From the resulting mutant (BB-ops) a 1.1 kb BamHI fragment, 
containing the opsin cDNA, was isolated and cloned into transfer vector pAcRP23.Bglll , 
to yield fusion transfer vector pAcRP23/BB-ops. A 3.1 kb Sphl/BamHI fragment from 
pAcRP23/BB-ops, containing the opsin sequence, was then ligated with a 10.5 kb 
Sphl/BamHI fragment from transfer vector pAcDZl [26], resulting in the fusion transfer 
vector pAcDZl/BB-ops, which contains the lacZ reporter gene (Fig 4.2). For convenient 
cloning of the T4 lysozyme gene, a pUc plasmid with an additional Bglll site (pUcl9poly-
II) was created by ligation of a hybrid of the oligonucleotides 5'gatcccgagatctgt3' and 
5'gatcacagatctcgg3' in the BamHI cloning site of pUcl9. A 0.6 kb BamHI/Hindlll 
fragment from M13mpl8-T4 lysozyme (kindly provided by B.W. Matthews, Howard 
Hughes Medical Institute, Oregon, USA) was cloned into the Bglll/Hindlll cloning sites of 
pUcl9polyII. Subsequently a PCR-reaction was performed with the pUc sequencing primer 
5'gttgtaaaacgacggccagt3' as forward primer and the mutation primer 5'gttttcatatggatccttt-
aaata3'as reverse primer, in order to create a BamHI site ca 70 bp behind the TAA stop 
codon of the T4 lysozyme cDNA. The resulting 0.6 kb product was isolated, digested with 
BamHI and cloned into the BamHI cloning site of fusion transfer vector pAcDZl /BB-ops, 
resulting in an open reading frame ending in the T4 lysozyme stop-codon (pAcDZl/ops-
lys; Fig 4.2). 
Preparation of immunogens for antibody production: In order to selectively detect the 
fusion partners and to identify viral membrane-bound proteins, antisera were developed 
using T4 lysozyme, GST and a crude membrane fraction of wt-virus infected cells as 
immunogen, respectively (Table 4.1). Purified T4 lysozyme was kindly provided by B.W. 
Matthews. GST from Schistosoma japonicum was expressed in E. coli and purified essen­
tially as described [15] with some minor adjustments: Triton X-100 was replaced by 
dodecylmaltoside (DoM) and gluthatione-agarose was replaced by glutathione-Sepharose 
4B, prepared by coupling of glutathione (GSH reduced, Boehringer, Mannheim, Germany) 
to tresyl-Sepharose 4B (Pharmacia, Brussels, Belgium) according to the manufacturer's 
instructions, resulting in 6-7 μπιοί GSH/ml gel. A purified membrane fraction of Sf9 cells 
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Figure 4.2 Construction of the opsìn-T4 lysozyme fusion transfer vector. Details are described in the 
materials and methods section. Black boxes indicate promoter regions: heatshock promoter for LacZ 
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infected with AcNPV was prepared as described (chapter 2, section 2.8) and subsequently 
extracted under rotation in buffer В (see below; 16 h, 4°C). The resulting DoM-extract was 
freed from unsoluble material by centrifugation (Eppendorf, 14 krpm, 15 min, 4°C) and 
used for immunization. 
Preparation of polyclonal antibodies: For the immunization the following protocol was 
used: albino female adults of New Zealand white rabbits were injected intracutaneously at 
multiple sites on the back with an emulsion prepared from 1 ml of immunogen solution and 
1 ml of Freund's complete adjuvant. After 4-5 weeks booster injections were given in arm­
pits and groins with Freund's incomplete adjuvant with two weeks interval. Test bleedings 
to determine antibody titers were taken before each injection, and finally the rabbits were 
exsanguinated by cardiac puncture. The blood was allowed to clot overnight at 4°C and 
subsequently the serum was collected after centrifugation (lO.OOOxg, 20 min., 4<>C) and 
stored at -20°C. 
Antibody titration by ELISA: Immunogens suspended in PBS were coated onto polystyrene 
wells by incubation for 16 h at 4°C (150 μί, 0.1-1 μg protein). The wells were washed 
twice with assay buffer (PBS containing 0.1% bovine serum albumin and 0.01% Ammonyx 
LO). A serial dilution of antiserum in assay buffer (100 μί) was added to the wells and 
incubated for 1 h at RT. The wells were washed again (3 times), followed by an 1 h 
incubation at RT with 100 μί of 1:2000 diluted swine-anti rabbit immunoglobulins 
conjugated to horseradish peroxidase (SARPO; Dako, Glostrup, Denmark). After another 
washing routine (5 times) bound peroxidase was assayed enzymatically with o-phenylene-
diamine (100 μί per well of a solution containing 40 mg o-phenylenediamine and 40 μί 
30% H 2 0 2 per 100 ml 0.1 M citrate-phosphate buffer, pH 5.0). The reaction was perfor­
med for 10-20 min at RT until sufficient colour development, and then stopped by addition 
of 100 μί 2 M H 2S0 4 per well and the absorbance was measured at 492 nm with a Titertek 
Multiscan photometer. Titration curves were constructed by a semilog plot of the absorban­
ce versus the corresponding dilution of antiserum. Titers were determined graphically as 
the reciprocal of the dilution required to give 50% of the maximal absorbance, obtained at 
low dilution (1:100 or 1:200). 
Purification of GST-opsin fusion protein: Sf9 cells were infected with recombinant GST-
opsin virus (МОЫ0) and harvested at 3 dpi. Cells were then resuspended in buffer A (20 
mM PIPES; 130 mM NaCl; 5 mM KCl; 2 mM MgCl2; 2 mM CaCl2; 0.1 mM EDTA) and 
DoM was added to a final concentration of 20 mM (buffer B). After lh extraction under 
rotation (RT), the DoM-extract was freed from insoluble material by centrifugation 
(Eppendorf, 14 krpm, 15 min, RT), applied to GSH-Tresyl Sepharose 4B and rotated for 
30 min at RT. Unbound material was removed by centrifugation (Eppendorf, 2 krpm), the 
gel then washed three times with buffer В and subsequently bound material was eluted with 
5 mM GSH in buffer B. 
GST enzyme activity assay: GST and GST-opsin enzyme activity was assayed by thiolysis 
as described [27]. The assay solution includes 1 ml 0.1M potassium phosphate buffer (pH 
7) containing 0.2 mM />-nitrophenyl acetate and 0.5 mM GSH, and enzyme. The increase 
in absorbance at 400 nm in time is recorded. The absorbance coefficient for p-nitropheno-
late at pH 7 is taken as 8.79 mM"1 cm"1 at 400 nm [27]. 
67 
Table 4.1 
Antisera directed against glutathione-S-transferase, T4 lysozyme and AcNPV membrane-bound proteins. 
serum 
CERNLC909 
CERNLC9010 
CERNLC914 
CERNLC915 
CERNLC916 
CERNLC941 
CERNLC942 
CERNLC943 
immunogen 
GST 
GST 
AcNPV 
AcNPV 
AcNPV 
T4 lysozyme 
T4 lysozyme 
T4 lysozyme 
amount 
(Mg) 
150 
150 
300 
300 
300 
100 
200 
150 
booster 
injections 
3 $ 
2 
5 
5 
7* 
4* 
3 
3 
titer 
final bleeding 
20.000 
40.000 
20.000 
20.000 
10.000 
30.000 
70.000 
40.000 
$
 second booster injection was performed with 300 pg. 
* rabbit got ill after third booster injection. 
* last booster injection was performed with 200 pg. 
100 
i_ с 
Figure 4.3 Titer development in rabbits immunized with AcNPV membrane-bound proteins (914, 915, 916), 
GST (909, 9010) or T4 Lysozyme (941, 942, 943). The amount of immunogen used is given in Table 4.1. First 
booster injections are given after 5 weeks, followed by several booster injections at 2 weeks intervals. The last 
data point of each curve shows the titer of the final bleeding (cf. also Table 4.1). 
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4.3 Results 
Musea* 
Antibody titers generally depend on the immunogenicity of the antigen and may depend on 
the amount of immunogen used for immunization. After several booster injections 
relatively high titer antisera were obtained for all immunogens (Table 4.1; Fig 4.3). The 
antisera raised against viral membrane-bound proteins react on immunoblot with quite a 
number of proteins from Sf9 cells infected with AcNPV (Fig 4.4, lane 1). The antibodies 
raised against GST and T4 lysozyme nicely recognize these proteins (Fig 4.4, lanes 2 and 3 
respectively). Also they are quite specific as they show very little cross-reactivity with 
proteins from Sf9 cells infected with wild-type virus (e.g. Fig 4.9). 
' 1 ' 2 3 
• • • • ' • • ' . ' • " : • • ' . 
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Figure 4.4 Immunoreactivity of antisera. Proteins are separated on a 12% SDS-PACE gel and electroblotted 
to nitrocellulose paper. Lanes: 1, 1.5 μ£ of AcNPV membrane-bound proteins incubated with CERNLC914 
(dilution 1:1000); 2, 0.1 μg purified GST incubated with CERNLC909 (dilution 1:1000); 3, 0.1 pg purified T4 
lysozyme incubated with CERNLC942 (dilution 1:3000). Detection is accomplished by standard incubation 
with HPO-labeled second antibodies and assay for HPO activity (cf. chapter 2). 
GST-opsin fusion protein. 
Immunofluorescent analysis of infected Sf9 cells shows that GST-opsin fusion proteins are 
targeted to the plasma membrane (Fig 4.5). Both components of the GST-opsin fusion 
protein can be identified in the membrane using antibodies raised against rhodopsin (Fig 
4.5A) and GST (Fig 4.5B). 
The GST-opsin fusion protein can be purified over immobilized glutathione (Fig 4.6). 
There is no detectable impurity in the purified fraction according to Coomassie Brilliant 
Blue and subsequent silver staining of the SDS-PAGE gel (Fig 4.6, lane 5). Immunoblot 
analysis shows that the GST-opsin fusion protein reacts with polyclonal antibodies raised 
against rhodopsin (Fig 4.7, CERNJS858 [28]). A positive reaction with monoclonal 
antibodies against the N-terminus (Fig 4.7, R6-5 [29]) and the C-terminus (Fig 4.7, 1D4 
[30]) indicates that the opsin part of the GST-opsin fusion protein is full-length. Further­
more, the GST-opsin fusion protein is glycosylated, as inferred from its binding to labeled 
ConcavalinA (Fig 4.7, 14C-ConA). The fusion protein runs at a molecular weight of 67±3 
kD, which is expected for a combination of a 26 and a 40 kD protein. Expression levels 
are in the same range as those of wild-type opsin (Fig 4.8, panel A). The enzymatic 
activity of purified GST and purified fusion protein GST-opsin was measured by thiolysis 
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Figure 4.5 Immunohistochemical analysis of GST-opsin biosynthesis in infected Sf9 celL·. The GST-opsin 
fusion protein is localized in pcrmeabilized cells with: A, the monoclonal antibody 1D4 (dilution 1:500) 
reactive with the C-terminus of bovine rhodopsin [29]: B, the polyclonal antiserum CERNLC909 (dilution 
1:1000) elicited against GST. Immunoreactivity is detected by reaction with fluorescein conjugated goat anti-
mouse immunoglobulin G (IgG; dilution 1:25) and rhodamin conjugated swine anti-rabbit IgG (dilution 1:50) 
(DAKO, Glostrup, Denmark). The relative staining intensity and distribution over the cell population is 
identical for both antibodies. 
Mr 1 
(kD) 
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Figure 4.6 Purification of GST-opsin fusion proteins over immobilized GSH. Proteins are separated on a 
10% SDS-PAGE gel and stained with Coomassie Brilliant Blue followed by silver staining. Lanes: Mr, 
molecular weight markers: 1, total cellular extract of Sf9 cells infected with recombinant GST-opsin virus 
(AcNPVRP23/GST-ops) at 3 dpi; 2, DoM-extract; 3, DoM-pellet; 4, non-binding fraction after application to 
GSH-Tresyl Sepharose; 5, bound fraction after elution from GSH-Tresyl Sepharose with 5 mM GSH; 6, rod 
outer segment (ROS) membranes. The positions of the GST-opsin fusion protein (<) and of opsin (<) are indi­
cated. 
(Fig 4.8, panel B) [27]. The specific activity (23.7 μπιοΐ/min/mg for GST and 7.6 
μπιοΐ/min/mg for GST-opsin) is comparable when the difference in molecular weight is 
taken into account. Hence, all these signs are quite promising, but the crucial test would be 
whether the fusion protein would recombine with ll-ris-retinal into a functional photopig-
ment. Unfortunately, although a variety of incubation conditions with 11-di-retinal has 
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been investigated, under none of them we could find a trace of formation of a light-
sensitive pigment. 
1 2 3 1 2 3 1 2 3 1 2 3 
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Figure 4.7 Immunoblot analysis of the immunoreactivity profile of the GST-opsin fusion protein. Proteins are 
separated on a 10% SDS-PAGE gel and electroblotted onto nitrocellulose. Lanes; 1, total cellular extract of 
Sf9 cells infected with recombinant GST-opsin virus (AcNPVRP23/GST-ops) at 3 dpi; 2, purified GST-opsin 
fusion protein; 3, ROS membranes. Opsin and the GST-opsin fusion protein are recognized by the polyclonal 
antiserum CERNJS858 [26](dilution 1:1000); the C-terminal directed monoclonal antibody 1D4 [29] (dilution 
1:500); the N-terminal directed monoclonal antibody R6-5 [28] (dilution 1:200), (all elicited against bovine 
rhodopsin) and ,4C-labeled ConA. Detection is accomplished by standard incubation with HPO-labeled second 
antibodies and assay for HPO activity (antibodies), or by autoradiography (l4C-ConA). The positions of the 
GST-opsin fusion protein (•<), opsin monomer (<) and opsin dimers (ξ) are indicated. 
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Figure 4.8 
Expression level and enzymatic activity of the GST-opsin fusion protein. A, Expression levels are given in 
picomol per million cells (n=3). Monolayers of Sf9 cells were infected with recombinant virus 
AcNPVRP23/ops (ops), AcNPVDZl/l-ops (l-ops) and AcNPVRP23/GST-ops (gst-ops) respectively (MOhlO). 
GST-opsin and opsin levels were assayed by inhibition ELISA at 3 dpi. B, Activity of purified GST and GST-
opsin fusion protein was determined by thiolysis [27]. The increase in absorbance at 400 nm was recorded in 
time. The extinction coefficient for p-nitrophenolate is taken as 8.79 тМ'ст'1 at 400 nm. Calculated specific 
activities are 23.7 ¡imollminlmg for GST and 7.6 μmol/min/mg for GST-opsin. 
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Opsin-T4 lysozvme fiision protein. 
Infection of Sf9 cells with recombinant virus AcNPVDZl/ops-lys leads to expression of 
protein of ca 54 kD which reacts with both anti-opsin and anti-T4 lysozyme antibodies (Fig 
4.9 A and B, lanes 3 and 5). Hence this satisfies the criteria of an opsin-T4 lysozyme 
fusion protein. Aspects like expression level, glycosylation, targeting and purification have 
not yet been addressed. After incubation of recombinant ops-lys virus infected cells, 
harvested at 3 dpi, with 11-dj-retinal the opsin-T4 lysozyme fusion protein was nearly 
completely solubilized by dodecylmaltose (Fig 4.9, lanes 4 vs 5). Most importantly, this 
extract showed the presence of a light sensitive pigment with a λ,^ close to that of wild-
type rhodopsin (Fig 4.10). 
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Figure 4.9 Expression of the opsin-T4 lysozyme fusion protein analyzed by immunoblot. Monolyers of Sf9 
cells were infected with recombinant virus (MOfcIO) and collected at 3 dpi. Lanes: 1, wild-type 
(AcNPV/DZl); 2, l-ops (AcNPVDZl/l-ops); 3, opsin-T4 lysozyme (AcNPVDZl/ops-lys); 4, DoM-pellet of 
opsin-T4 lysozyme after regeneration; 5, DoM-extract of opsin-T4 lysozyme after regeneration; 6, ROS 
membranes (1 pmol rhodopsin); 7, T4 lysozyme (0.1 pg). Lanes 1,2 and 3 contain total cellular extracts of 
1.10s cells; lanes 4 and 5 represent an equivalent number of cells. Opsin and opsin-T4 lysozyme fusion protein 
are identified by CERNJS858 [26] (A. dilution 1:1000), opsin-T4 lysozyme fiision protein and T4 lysozyme are 
identified by CERNLC942 (B, dilution 1:3000). Detection is accomplished by standard incubation with HPO-
labeled second antibodies and assay for HPO activity. The positions of T4-lysozyme (-), opsin (<) and the 
opsin-T4 lysozyme fusion protein (<i are indicated. 
fho—lys 
400 500 
wavelength (nm) 
Figure 4.10 Spectral properties of the rhodopsin-T4 lysozyme fusion protein. Difference spectra of wild-type 
rhodopsin (v-rho) and the rhodopsin-T4 lysozyme fusion protein (rho-lys) in the presence of 50 mM hydroxyla-
mine (unbleached minus bleached). k
max
: v-rho. 498 nm; rho-lys, =500 nm. 
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4.4 Discussion 
Expression of the GST-opsin fusion protein followed a normal biosynthesic pattern as 
evident from its apparent molecular weight, the reactivity with a variety of antibodies, its 
glycosylation and correct targeting. In this respect, it is interesting to note that all these 
parameters indicate that correct translocation of the opsin transmembrane domains was 
accomplished in spite of the long N-terminal presequence with the entire, soluble GST-
domain. Hence, the first signal sequence (start-transfer) in opsin is still correctly recogni­
zed and the preceding GST-sequence is transferred in full and (re)folded in the E.R.-lumen 
into a functional enzyme. However, the GST-opsin fusion protein did not recombine with 
11-е« retinal into a photosensitive pigment. It has been demonstrated, that small perturbati­
ons in the extracellular (intradiscal) domains of rhodopsin easily lead to incorrect folding 
and loss of regeneration capacity [31,32]. Although N-terminal addition of small peptides 
do not seem to affect the opsin structure [33,34], fusion with a large, soluble domain appa­
rently impairs correct folding of opsin to such an extent, that the capacity to recombine 
with 11-a's-retinal is completely lost. Nevertheless the very simple purification scheme for 
this fusion-protein again demonstrates the powerful potential of GST-fusion proteins for 
purification purposes. 
Modifications at the C-terminal of rhodopsin do not seem to have such a detrimental effect 
on opsin regeneration [35-37]. Hence, we changed our strategy and aimed at C-terminally 
connected fusion partners. Our first target, an opsin-T4 lysozyme fusion protein, could be 
correctly expressed using recombinant baculovirus. Although several aspects still need to 
be examined, the most important observation is that this fusion protein does recombine 
with H-e« retinal into a photosensitive pigment. At this stage, we could not yet definitely 
establish whether the spectral properties of this fusion protein are identical to wild-type 
rhodopsin, or whether the fusion partner induces a small shift in Л
т а х
, as e.g. has been 
observed upon C-terminal his-tagging (Janssen et al, unpublished). 
An one-step purification procedure based on the affinity of T4 lysozyme for muramyl 
moieties is now being investigated. Substrates like muropeptide C6 of E. coli В murein 
[23] and chitin [24] have already been used for affinity purification of T4 lysozyme. 
However, we need to establish whether the fusion protein is sufficiently stable under the 
elution conditions described (IM NaCl in 50 mM Tris buffer pH 7.3 [23] and 0.25M KCl 
in 50 mM sodium acetate buffer pH 4.6 [24]). Also the presence of detergent may 
influence the binding conditions of T4 lysozyme to the substrates. Hence, several parame­
ters will have to be analyzed to optimize binding and elution conditions for affinity 
purification of the rhodopsin-T4 lysozyme fusion protein. 
Expression of the C-terminally connected fusion proteins opsin-GST and opsin-polyhedrin 
is now in progress. Although polyhedrin (a baculovirus structural protein, for review see 
[38]) is not a soluble protein, it already under physiological conditions forms crystalline 
arrays [39] and might therefore enhance rhodopsin crystallization. 
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CHAPTER 5 
EFFECT OF SELECTED MUTATIONS ON OPSIN BIOSYNTHESIS, 
EXAMINED BY USING RECOMBINANT BACULOVIRUS 
MEDIATED EXPRESSION.* 
* G.L.J. DeCaluwé and W.J. DeGrip, in preparation. 

5.1 Introduction 
Rhodopsin is a complex integral membrane protein containing seven transmembrane 
domains, which harbor th chromophore 11 -cis retinal covalently linked to Lys296 via a 
protonated Schiff base [1]. The N-terminal region is glycosylated [2] and is of structural 
importance, together with the three intradiscal loops and the disulfide bridge between 
CysllO and Cysl87 [3,4]. Two cytoplasmic loops are supposed to play a role in signal 
transduction [5] together with an additional surface loop generated by palmitoylation and 
membrane-anchoring at Cys322 and Cys323 [6] (Fig. 5.1). Evidently, rhodopsin requires 
intermittent membrane translocation and several posttranslational modifications (glycosyla-
tion, palmitoylation, disulfide bridge formation, recombination with 11-ris retinal) in order 
to fulfill all its structural and functional properties. In vitro expression allows exploration 
of properties like wavelength regulation, receptor mechanism, biosynthesis and lipid-
protein interactions in much detail through (site-specific) mutagnesis. For this purpose we 
have selected the recombinant AcNPV baculovirus system, as this is an eukaryotic 
expression system, which performs all common eukaryotic posttranslational modifications 
and has been successfully employed for the high level expression of foreign genes (for 
review see [7,8]). 
Bovine rhodopsin and mutant species have been expressed in vitro in many different 
systems: COS cells [9], insect cells using recombinant baculovirus [10], Xenopus oocytes 
[11], kidney cells [12], Chinese hamster ovary cells [13] and a cell-free expression system 
[14]. However, not much is known about the structural requirements for a proper 
biosynthesis of rhodopsin. In this chapter the biosynthesis of opsin in insect cells under 
control of che baculovirus polyhedrin promoter is examined in more detail [15], and tht 
influence of selected mutations (indicated in Fig. 5.1) on the opsin biosynthesis is investi­
gated. We have chosen for substitution о highly conserved amino acid residues which are 
located in the transmembrane or interface regions, where effects on functional properties 
have been described and effects on biosynthesis are indicated or may be expected. 
The picture emerges, that the rhodopsin sequence is delicately tuned to correct membrane 
translocation and folding. A variety of substitutions affect this process to a variable extent, 
while some mutations even have an effect at an earlier stage and seem to abort the 
translational process. 
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Figure 5.1 Mode! for the topography of Rhodopsin [47]. The amino acids substituted in the present work are 
indicated in black. Th. ¡hemolysin proteolytic recognition sites. 
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5.2 Materials and methods. 
Baculovirus expression, site directed mutagenesis, SDS-PAGE, immunoblotting, Elisa and 
immunofluorescence assay were performed as described in chapter 2. 
Palmitoylation: Sf9 cells were incubated with 14C-palmitic acid (1 μΠ/106 cells; spec.act. 
50-60 mCi/mmol; Amersham) during infection with recombinant virus. Cells were 
harvested at 3 dpi, lysed by freeze-thawing twice in destilled water with addition of 
leupeptin (200 μΜ) and EDTA (10 mM), sedimented (Eppendorf, 14 krpm, 5 min., RT), 
and the precipitate was resuspended in buffer A (20 mM PIPES; 130 mM NaCl; 5 mM 
KCl; 2 mM MgCl2; 2 mM CaCl2; 0.1 mM EDTA; 5 mM DTE; pH 6.5). Then DoM was 
added to a final concentration of 20 mM and the suspension rotated overnight at 4°C. The 
resulting DoM-extract was used for immunoprecipitation of v-ops. 
Immunoprecipitation: ProteinA-agarose (10 μΐ; Pierce) was loaded with CERNJS858 (10 μΐ 
[16]) by overnight rotation at 4°C in 0.5 ml of buffer A containing 20 mM DoM. Unbound 
material was removed by several centrifugation (Eppendorf, 2 krpm) and washing (buffer 
A/20 mM DoM) steps. The DoM-extract (previous paragraph) was freed from unsoluble 
material by centrifugation (Eppendorf, 14 krpm, 15 min., 4°C), applied to ProteinA-
agarose loaded with CERNJS858 (100 μ1/10 μΐ gel) and rotated overnight at 4°C. Unbound 
material was removed by centrifugation (Eppendorf, 2 krpm), followed by washing twice 
(0.5 ml buffer A/20 mM DoM) and elution of bound material in SDS-PAGE sample-buffer 
(4% SDS, 15 mM Tris-HCl pH 6.8, 10% glycerol, 0.006% bromophenol blue and 20 mM 
DTE; 100 μ1/10 μΐ gel). 
Thermolysin digestion: Sf9 cells were infected with recombinant virus and collected at 3 
dpi by centrifugation (lOOOxg, 5 min., RT). Lysed cells (prepared as above) and intact 
cells were gently resuspended in thermolysin digestion buffer (10 mM Tris-Acetate pH 7.2; 
4 mM CaCl2; 10% thermolysin w/w on protein basis; 50 μ1/10
6
 cells) and incubated for 5 
min at RT. Subsequently the reaction was stopped by addition of EDTA-solution (0.5M pH 
8) to a final EDTA concentration of 0.2 M. Intact cells were then lysed and SDS-PAGE 
samples (150 μ1/106 cells) were prepared by addition of SDS-PAGE sample buffer (final 
concentrations see above). 
5.3 Results 
Glycosylate 
As presented before, immunoblot analysis shows that v-ops (opsin produced in insect cells 
by recombinant virus) migrates with about the same apparent molecular weight as fully 
processed native bovine rod opsin (Fig. 5.2, lanes 1 and 5). A positive immunoreaction 
with monoclonal antibodies against the N-terminus (R2-12N), loop e2 (T13-34L) [17] and 
the C-terminus (1D4)[18] indicates that the full-length protein is produced (see below and 
[19]). Such data suggest that v-ops is glycosylated as well. This is confirmed by adding the 
N-glycosylation inhibitor tunicamycin upon infection of Sf9 cells with recombinant virus. 
The resulting immunopositive product now still contains the complete opsin sequence [19], 
but migrates with lower apparent molecular weigth (Fig. 5.2, lanes 2-4), which in fact 
corresponds to that of non-glycosylated bovine opsin. Under high-resolution conditions the 
glycosylated v-ops seems to consist of two species (Fig. 5.3). Reduction of the opsin 5' 
leader from 45 to 5 bases (1-ops; cf. chapter 3) increases the opsin production but also the 
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Figure 5.2 Inhibition ofv-ops glycosylation by 
tunicamycin. Immunoblot analysis ofSß cells infec-
ted with recombinant opsin virus (AcNPVRP23/ops) 
in the absence (lane 1) or presence of increasing 
concentrations of tunicamycin (5 pg/ml) (lane 2), 10 
fig/mi (lane 3), 25 μg/ml (lane 4). Lane 5 presents 
bovine ROS membranes as a control. Opsin was 
identified by incubation with antiserum CERNJS858 
[16]. Per lane the extract of '5.104 cells was ap­
plied. 
Figure 5.3 V-ops production by different recombi­
nant viruses. Immunoblot analysis ofSf9 cells infec­
ted with: wild-type baculovirus AcNPV (lane 1); 
recombinant baculoviruses, produced using different 
transfer vectors (cf. chapter 3): AcNPV373/ops 
(lane 2), AcNPVRP23/ops (lane 3), AcNPVDZl/ops 
(lane 4) and AcNPVDZl/l-ops (lane 5). Opsin was 
identified by incubation with antiserum CERNJS85S 
[16]. Per Urne the extract of4.104 cells was ap­
plied. Position of glycosylated (arrow) andnon-
glycosylated (arrowhead) opsin is indicated. 
relative amount of non-glycosylated species (Fig. 5.3, lane 5). 
Several of the selected amino acid substitutions affect opsin glycosylation to a variable 
extent (Fig 5.4). First of all, the ratio of the upper and lower glycosylated bands (arrow) 
shows quit some variation. However this partly depends on cellular factors, since some 
variation is also observed within different batches of one species. Hence it is presently not 
clear whether a mutation-dependent effect also operates here. Secondly a number of 
mutations clearly enhance the relative amount of non-glycosylated product (arrowhead, 
E113C/Y; E122L; E134D/R; K248L). This pattern has been reproduced in several 
experiments. These non-glycosylated products do contain the full protein sequence, as they 
all react with the C-terminal monoclonal antibody 1D4 (Fig 5.4B). The strongest effects 
are seen for E122L, K248L and E134D. For E134 mutants this effect on opsin glycosyla­
tion has already been reported before [19]. Remarkably the production of non-glycosylated 
species varies for different mutations on one site (E113C>E113Y»E113Q=E113D; 
E134D>E134R). No interference with glycosylation was observed with the other mutants 
tested: D83N (lane 2), E113Q (lane 3), E113D (lane 4), W265F (lane 12), Y268S (lane 
13), P291A (lane 14) and A299C/V300A/P303G (lane, 16) (Fig. 5.4). Expression levels 
and apparent molecular weights of the synthesized v-ops and mutant products are listed in 
Table 1. Although at high expression levels of opsin (opsDZl and in particular 1-opsDZl) 
also variable amounts of intact non-glycosylated proteins are produced (Table 1, Fig. 5.3) 
this is less consistently observed than with the mutants. In addition, the mutants are not 
generally expressed at high but rather normal or even somewhat lower levels (Table 1). 
Since the pattern of Fig 5.3 has been consistently obtained, we conclude that the interfe­
rence with glycosylation is due to the mutation, as already previously inferred for E134 
mutants [19]. The mutations E113Q/D, E134R,R135E and W265F significantly reduced 
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Table 5.1 Biosynthesis of opsin and selected mutant species in Sf9 cells, infected with 
corresponding recombinant virus. 
species1 
ops (373) 
ops (RP23) 
ops (DZ1) 
1-ops (DZ1) 
R69H (DZ1) 
D83N (RP23) 
E113Q(DZ1) 
E113D(DZ1) 
E113Y(DZ1) 
E113C(DZ1) 
E122L(l-opsDZl) 
E134D (RP23) 
E134R (DZ1) 
E134R/R135E (DZ1) 
K248L (RP23) 
W265F(DZ1) 
Y268S (DZ1) 
P291A (RP23) 
Y301F (DZ1) 
A299C/V300A/P303G (RP23) 
expression level2 
(pmol/106 cells) 
20-25 
20-25 
30-35 
40-50 
25-30 
25-35 
10-15 
10-15 
15-25 
15-25 
25-35 
30-40 
20-30 
10-20 
35-45 
10-15 
15-20 
15-20 
5-10 
15-20 
MWofproduct(s)3 
38 kD 
38 kD 
38 kD; 31 kD 
38 kD; 31 kD 
22 kD 
38 kD 
38 kD 
38 kD 
38 kD; 31 kD 
38 kD; 31 kD 
38 kD; 31 kD 
38 kD; 31 kD 
38 kD; 31 kD 
38 kD; 31 kD 
38kD;31 kD 
38 kD 
38 kD 
38 kD 
30 kD 
38 kD 
1
 in parenthesis the usedpAc transfervector 
2
 measured by inhibition-ELISA and/or by immunoblot analysis 
3
 apparent MW on SDS-PAGE gels: 38 kD represents the glycosylated 
and 31 kD the поп-glycosylated intact protein; 30 kD and 22 kD 
represent a glycosylated but truncated protein. 
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the expression level, indicating that these amino acid substitutions do affect the translation 
efficiency in this system. 
Our conclusion that the non-glycosylated product contains fully intact opsin is further 
substantiated by a positive immunoreaction with monoclonal antibodies against the N-
terminus (Fig 5.5; panel B), and the extracellular loop e2 (panel C). 
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Figure 5.4 Effect of selected mutations on v-ops glycosylation. ¡mmunoblot analysis of opsin mutants. Sf9 
cells were infected with corresponding recombinant mutant opsin virus. Opsin was identified by incubation 
with antiserum CERNJS858 (A) or 1D4 (B). Lanes: 1, R69H; 2, D83N; 3, E113Q; 4, E113D; 5, E113Y; 6, 
E113C; 7, E122L; 8, E134D; 9, E134R; 10, E134R/R135E; 11, K248L; 12, W265F; 13, Y268S; 14, P291A; 
15, Y301F; 16, A299C/V300A/P303G. Per lane was applied the extract of 2.104 cells (lane 7); 4.104 cells 
(lanes 2,5,6,8 and 11); LIO5 cells (lanes 1,9,12,13,14 and 16); 2.105 cells (lanes 3,4,10and 15). Position of 
glycosylated (arrow) and поп-glycosylated (arrowhead) opsin is indicated. 
Incomplete translation 
Two of the mutations investigated, R69H and Y301F, lead to a truncated product of ca 22 
and 30 kD respectively (Fig 5.4, lanes 1 and 15; Table 1). Both products contain the N-
terminus and the extracellular loop e2 still but lack the C-terminus (Fig 5.4; Fig 5.5). 
These mutants also do not produce discrete bands, but a broad band or a band pattern, 
indicating that these two mutations induce aberrant interruption and abortion of the 
translational process. The truncated products have a strong tendency to aggregate (Fig 5.4, 
lanes 1,15; Fig 5.5, lane 5). Remarkably, the truncated products are at least partially 
glycosylated, as inferred from their binding to labeled ConcavalinA (not shown). 
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Figure 5.5 Product analysis of selected v-ops mutants with a panel of antibodies. Immunoblot analysis ofSß 
cells infected with wild-type (AcNPVDZl/ops) and recombinant mutant opsin virus. Lanes: 1, v-ops; 2, 
E134D; 3, E134R; 4, E134R/R135E; 5, R69H; 6, K248L; R, bovine ROS membranes. Opsin was identified by 
incubation with: A, polyclonal antiserum CERNJS858; B, monoclonal antiserum R2-12N against the amino-
terminus; C, monoclonal antiserum T13-34L against loop e2; D, monoclonal antiserum 1D4 against the 
carboxy-terminus. Per Urne the extract of 5.1(f cells was applied. Position of glycosylated (arrow) and non-
glycosylated (arrowhead) opsin is indicated. 
Palmitoylation 
Because insect cells are able to sustain thiopalmitoylation [20], we also examined whether 
v-ops and selected mutants are palmitoylated. Hereto Sf9 cells were incubated with 
[14C]palmitic acid during infection with recombinant virus. Opsin was then solubilized with 
dodecylmaltose, immunoprecipitated and, following SDS-PAGE, opsin was identified by 
immunoblot (Fig 5.6, panel A) and palmitoylation by autoradiography (Fig 5.6, panel B). 
A large number of proteins in infected cells are palmitoylated (Fig 5.6, panel B, lane 1). 
Opsin could be isolated by immunoprecipitation and clearly displayed label incorporation 
(Fig. 5.6, panel B, lane 4; Fig. 5.7, lane 1; the higher molecular weigth bands in the 
immunoblot (Fig 5.6, panel A, lanes 3 and 4) are immunoglobulins which were eluted from 
the Protein Α-agarose). So, indeed opsin is also palmitoylated in this system. When opsin 
was overexpressed, the then produced non-glycosylated product (arrowhead) appears not to 
be very soluble in detergent solution, but did incorporate label (Fig 5.6, lanes 2). If, on the 
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other hand, at normal expression levels glycosylation is partly inhibited by addition of 
tunicamycin during infection, the resulting non-glycosylated product is also palmitoylated 
and can be extracted in detergent solution (Fig. 5.7, lane 2). This indicates a difference in 
conformation between non-glycosylated v-ops, resulting from overexpression, and non-
glycosylated v-ops, due to inhibition of glycosylation. 
For all mutants investigated the intact glycosylated form behaves comparable to its wild-
type equivalent: it is palmitoylated and is easily solubilized in detergent solution (Fig 5.7). 
This is not the case for the non-glycosylated forms. Although the mutants are expressed at 
low or average levels, the non-glycosylated species behave as the wild-type equivalent 
obtained upon "overexpression", i.e. they are palmitoylated but do not dissolve upon 
detergent treatment (not shown). 
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Figure 5.6 V-ops is palmitoylated. Immunoblot (A) 
and autoradiographic (B) analysis ofSf9 cells infec­
ted with recombinant opsin virus (AcNPVDZl/l-ops) 
in the presence of labeled ¡14CJpalmitic acid. Opsin 
was immunoprecipitated with antiserum CERNJ-
S858. Lanes: 1, total cell extract; 2, DoM-pellet; 3, 
unbound fraction; 4, bound fraction. Opsin was 
identified (panel A) by incubation with antiserum 
CERNJS858. Per lane an amount of material was 
loaded corresponding to «5.104 cells (lane 1,2 and 
3) or "2.10s cells (lane 4). Position of glycosylated 
(arrow) and non-glycosylated (arrowhead) opsin is 
indicated. 
Figure 5.7 Palmitoylation of mutant opsins. Auto-
radiographic analysis of immunoprecipitated wildty-
pe and mutant opsins. Sf9 cells were infected with 
recombinant virus in the presence of labeled 
[14C]palmitic acid. Lanes: 1, v-ops; 2, v-ops with 
addition of tunicamycin (10 ßg/ml) during infection; 
3, K248L; 4, E134D; 5, E134R; 6, E134R/R135E; 
7, E113C; 8, E113D; 9, E113Q; 10. E113Y; 11. 
D83N; 12, W265F. All lanes contain the im-
munoprecipitated fraction of "8x10s cells. R, positi-
on ofrhodopsinfrom bovine ROS membranes as 
detected by Coomassie R-250 and subsequent 
silverstaining of the SDS-PÂGE gel. Position of 
glycosylated (arrow) and non-glycosylated (arrow-
head) opsin is indicated. 
Membrane translocation and targeting 
As we have shown before by immunocytochemical analysis [10,15] bovine opsin produced 
in Sf9 cells is targeted to the plasma mambrane (Fig. 5.8, panel A). Since the opsin does to 
a large extent recombine with added ll-cis retinal into rhodopsin it was assumed that the 
complex opsin protein had been correctly translocated and folded in the E.R. membrane of 
the Sf9 cell. However this cannot be a priori assumed for mutant proteins, since the 
mutation may impair translocation and/or folding without affecting targeting. A dual assay 
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Table 5.3 Membrane insertion of wildtype and mutant opsin analysed by double-label 
indirect immunofluorescence assay and immunoblot analysis of thermolysin treated cells. 
Immunohistochemical reactivity of rhodopsin monoclonal antibodies against the N-terminus 
(R2-12N) and C-terminus (1D4) on intact Sf9 cells infected with recombinant opsin or 
mutant virus was detected by reaction with fluorescein conjugated goat anti-mouse IgG (see 
Fig. 5.9). Total reactivity after fixation was determined with the polyclonal antiserum 
CERNJS858 and rhodamin conjugated swine anti-rabbit IgG. 
Immunoblot analysis of intact Sf9 cells after infection with recombinant virus and incubati-
on with thermolysin was performed as shown in Fig 5.10. 
species 
opsin 
R69H 
D83N 
E113Q 
E113D 
E113Y 
E113C 
E122L 
E134D 
E134R 
E134R/R135E 
K248L 
W265F 
Y268S 
P291A 
Y301F 
A299C,V300A,P303G 
IFA1 
R2-12N 
+ + + + 
+ + + + 
+ + + + 
+ + + + 
+ + + 
+ + + + 
+ + + + 
+ + + + 
+ + + 
+ + + 
+ + 
+ + 
+ + + 
+ + + + 
+ + + 
+ 
+ + + + 
1D4 
„ 
_ 
» 
+ + 
+ + 
+ + + + 
+ + + + 
+ + + + 
+ 
+ + 
+ + 
+ + 
+ 
_ 
+ 
_ 
thermolysin 
digestion2 
_ 
. 
» 
+ 
+ 
+ + 
+ + 
+ + 
+ 
+ + 
+ + + 
+ + 
-
-
-
-
1
 Immunoreactivity was rated as - <10%, + *25%, ++ *50%, + + + *75%, 
+ + + + >90%, referring to the number of reactive celL· compared to 
total reactivity with the polyclonal antiserum CERNJS858 after fixation. 
2
- <25%, + ^25-50%, ++ ^50-75%, + + + > 75% digestion. 
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to probe for correct translocation was developed, using limited proteolysis of intact cells as 
well as immunofluorescence assay of both intact and permeabilized cells with monoclonal 
antibodies directed against epitopes distributed over the opsin sequence [17,18]: antibodies 
against the N-terminal domain (R2-12N) and loop e2 (T13-34L) recognize extracellular 
located sequences in correctly folded opsin. Antibodies against the C-terminal domain 
(1D4, loop І2 (K16-193L) or loop i3 (K42-41L), recognize sequences which should be 
located intracellularly. Only after permeabilization of the cells by mild fixation the latter 
epitopes should become accessible to antibodies. Since cells dissociate from the surface 
after * 3 dpi, immunohistochemical analysis was performed at 1 or 2 dpi, and the polyclo­
nal antiserum CERNJS858 [16] was used to estimate the relative number of positive cells 
and their average reactivity. This approach was tested on Sf9 cells producing wild-type 
opsin and the expected results were obtained (Table 5.2): Epitopes which should be located 
intracellularly only become accessible after permeabilization of the cells. 
Table 5.2 Immunohistochemical reactivity of rhodopsin monoclonal antibodies with intact and fixed Sf9 cells, 
infected with recombinant opsin virus. Immunoreactivity was detected by reaction with fluorescein conjugated 
second antibodies. 
antibody 
R2-12N (N-termimis) 
K16-193L (loop i2) 
T13-34 L (loop e2) 
K42-41L (loop ІЗ) 
1D4 (C-terminus) 
858 (polyclonal) 
intact cells 
+ + 
_ 
+ 
. 
_ 
+ + 
fixed cells 
+ + + 
4* 
-p 
+ + 
+ + + 
+ + + 
Immunoreactivity was rated from - (= negative: signal not above background) up to +++ {- very strong 
positive reaction). 
From these results we conclude that Sf9 cells accomplish correct membrane insertion and 
'targeting of the opsin sequence. Interestingly, the same results were obtained when wild-
type was overexpressed to also produce the non-glycosylated species. This suggests, that 
under these conditions the latter form also folds correctly and that the glycosyl-transfer has 
become rate-limiting during biosynthesis. 
Subsequently, this approach has been used to analyze the effect of mutations on membrane 
translocation and targeting. Again, Sf9 cells were infected with recombinant mutant opsin 
virus and the immunofluorescent reactivity of intact cells with monoclonal antibodies 
against the N-terminal domain (R2-12N) and the C-terminal domain (1D4) was estimated, 
relative to the total immunofluorescent reactivity with CERNJS858 observed after 
permeabilization of the cells by fixation. The results are given in Table 5.3. This type of 
analysis shows that all mutants are targeted to plasma membrane (e.g. Fig 5.8), but that 
quite a number of mutations impaired correct membrane translocation. For example, 
mutations at position Glul34 resulted in a slight decrease of reactivity with R2-12N 
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Figure 5.8 Mutant opsins with patched plasma membrane distribution. Single-label indirect immunof-
luorescence assay ofSf9 cells infected with corresponding recombinant wild-type (AcNPVDZl/ops) and mutant 
opsin virus. After fixation at 2 dpi, opsin was localized with the polyclonal antiserum CERNJS858. Immunore-
activity was detected by reaction with fluorescein conjugated goat anti-rabbit IgG. Bar, Ipm. Panels: A, wild-
type opsin; B, W265F; C, E113Q; D, EU3D; E, E113Y; F, E113C. 
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(E134D > E134R = E134R/R135E), and an increase of reactivity with 1D4 (E134D < 
E134R - E134R/R135E) (Fig. 5.9; Table 5.3). These results suggest that a part of the 
produced proteins became incorrectly inserted into the plasma membrane. 
It seems logical to assume that the non-glycosylated mutant form is responsible for this 
phenomenon. However, in contradiction with this assumption is the fact that a number of 
mutant proteins do not produce detectable amounts of a non-glycosylated form but do react 
with 1D4 in intact cells (EU3Q, E113D, W265F and P291A). In order to distinguish 
between these two species the following experiment was performed. Sf9 cells were infected 
with recombinant virus, and after 3 dpi exposed to thermolysin digestion (Fig. 5.10; 
thermolysin cleavage sites in bovine rhodopsin are indicated in Fig. 5.1). In permeabilized 
cells these sites are accessible and proteolysis results in a shift to a lower molecular weight 
(Fig 5.10, panel A, lanes 3) and loss of reactivity with 1D4 (Fig 5.10, panel B, lanes 3). 
Proteolysis is allowed to proceed until 1D4 reactivity is no longer detectable in permeabili­
zed cells by immunoblot. During this incubation, intact cells slowly permeabilize but the 
large majority of wild-type opsin remains protected against proteolysis since it retains 
immunoreactivity with 1D4 (Fig 5.10, panel B, cf. v-ops lane 1 and 2). When applied to 
mutant opsins, the results generally support the immunofluorescent analysis. Mutations 
which result in a positive reaction with 1D4 on intact cells, generally show a parallel 
increase in susceptibility for proteolysis in intact cells (Table 5.3). For mutations, which 
produce glycosylated and non-glycosylated species (E134D/R, E134RR135E, K248L) both 
forms seem to be equally susceptible to proteolysis (Table 5.3; Fig 5.10). Our results 
indicate that the described mutations at position E113, E122, E134 (third membrane 
domain) and K248 (loop ІЗ) enhance the chance of incorrect translocation of the opsin 
sequence, which in the first group, is accompanied by a partial inhibition of glycosylation. 
The most severe effects are observed with the mutations E134R and E134RR135E which, 
according to our estimation, produce only 25 % correctly folded glycosylated protein. This 
might explain the low yields of regenerated pigment obtained with these mutants (5-10% of 
total protein produced). 
Another remarkable observation was done for some mutants (El 13 mutants, W265F and 
Y268S) upon immunohistochemical analysis. These mutants presented a different pattern 
from that observed for wild-type. Several cells showed a normal diffuse plasma membrane 
reaction, but other cells also showed a kind of spot-like pattern, possibly representing 
aggregated protein (Fig. 5.8, B-F). These spots are located in the plasma membrane, since 
intact Sf9 cells, infected with recombinant virus, showed the same pattern with CERNJS-
858, and subsequent fixation and incubation with 1D4 or R2-12N revealed no additional 
large intracellular storage sites of opsin. 
5.4 Discussion 
Apparently, biosynthesis, membrane translocation and glycosylation of opsin can be 
severely affected by point mutations. Only palmitoylation seems to occur properly in all 
mutants described here, and appears not to be coupled to glycosylation. Hence the 
palmitoylation sites are apparently recognized and modified, whether located at the 
intracellular or the intraluminal side of the endoplasmatic reticulum. 
From the overall results we can distinguish four types of mutants. 
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Figure 5.9 Incorrect translocation induced by several E134 mutants. Double-label indirect immunoflu­
orescence assay of Sf9 cells infected with recombinant mutant opsin virus and incubated with rhodopsin 
monoclonal antibodies R2-12N (A) and 1D4 (B). After fixation at 2 dpi, total opsin was localized with the 
polyclonal antiserum CERNJS858 (not shown). Immunoreactivity was detected by reaction with fluorescein 
conjugated goat ami-mouse IgG and rhodamin conjugated swine anti-rabbit IgG. V-ops in panel В was 
overexposed to establish background signals from non-reactive ceils. Bar, 10 μm. 
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Figure 5.10 Analysis of incorrect translocation by short thermolysin digestion of intact or permeabilized cells. 
Immunoblot analysis of intact and lysed Sf9 cells infected with recombinant wildtype and mutant opsin virus. 
R, bovine ROS membranes. Lanes 1, total cell extracts; Lanes 2, intact cells incubated with thermolysin (10% 
w/w, 5 min.); Lanes 3, lysed cells incubated with thermolysin. Opsin was identified with polyclonal antiserum 
CERNJS858 (panel A) or monoclonal antiserum 1D4 (panel B). Position of glycosylated (arrow) and non-
glycosylated (arrowhead) opsin is indicated. Note relative strong reaction of 1D4 with the non-glycosylated 
species (arrowhead). 
Type I: Amino acid substitutions that do not significantly affect opsin biosynthesis and 
folding of opsin. To this category belong D83N, A299C/V300A/P303G, and P291A. 
The P291A mutant did show reaction with 1D4 in intact cells, which would indicate a slip 
in the translocation stop of the last transmembrane domain, leading to extracellular location 
of the C-terminal in part of the protein. On the other hand our studies with limited 
thermolysin digestion indicate that in intact cells the P291A mutant is largely refractory 
towards this treatment. From the immunofluorescent approach, which is much more 
sensitive, we estimate that only a small part (<20%) of the P291A mutant is misfolded. 
This also agrees with our observation, that this mutant shows normal regeneration capaci-
ties and spectral properties (chapter 6). Hence, we think it is justified to classify P291A as 
a type I. 
РгоЗОЗ is fully conserved in the G-protein family, but its replacement by Gly does not 
affect biosynthesis or spectral properties (chapter 6) of (rhod)opsin. However, photocasca­
de and transducin activation still need to be examined. Substitution of this residue in the 
m3 -receptor to Ala increased the affinity for agonists but severely impaired stimulation of 
PI hydrolysis. Therefore, it may represent a key residue involved in mediating the agonist-
induced conformational changes required for g-protein activation [21]. On the other hand, 
substitution to Ser in the ß2-adrenergic receptor appeared to effect receptor processing 
(non-glycosylated and partially glycosylated forms) [22]. This again demonstrates that 
critical residues may have a complex contribution to structure/function relationships in this 
protein family. 
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Although Asp83 is highly conserved among the entire family of G-protein coupled 
receptors, substitution for Asn does neither significantly influence opsin biosynthesis or 
folding, nor regeneration, photocascade (cf. chapter 6) or transducin activation [23-27]. 
This is in contrast to adrenergic receptors, where substitution for Ala/Arg affected affinity 
for agonists and activation of the G-protein [28]. 
Type II: Amino acid substitutions that result in the production of a truncated protein (R69H 
and Y301F). The resulting incomplete protein was glycosylated, however, transferred to 
the plasma membrane and the amino-terminus was correctly located extracellularly. Hence, 
as expected, the first translocation start-signal was properly recognized. However, the 
cause of the eventual truncation is probably very different. The Y301F mutant produces a 
protein of ca 30 kD, which lacks the C-terminal. Hence, translation and translocation 
probably proceed normally until the point mutation is reached. Then either translocation 
and/or translation are aborted. Correct translocation of the intact protein followed by 
removal of the C-terminal part, due to increased susceptibility of the mutant to proteolysis 
is less likely since: 1, no trace of the intact protein is detectable; 2, the point-mutation 
resides within transmembrane domain VII, and is not expected to strongly change proteoly-
tic sensitivity outside that domain; 3, loss of the C-terminal need not abolish regeneration 
into a photopigment [29] and no evidence for regeneration was detected. Since Y301 is 
highly conserved in the G-protein coupled receptor family, we propose that it is essential 
for proper translocation and folding of the protein. 
The situation for R69H is quite different. This mutant produces a ca 22 kD truncated 
protein, which is glycosylated and still contains the "e2-loop". It is fully unclear presently, 
why translation and/or translocation are aborted shortly after the e2-loop by a mutation in 
the il-loop. Probably some spurious interaction with cytosolic components or the translati-
on/translocation machinery is involved. This position has been reported in relation with 
autosomal dominant retinitis pigmentosa (deletion mutant 68-71). This deletion mutant was 
not able to regenerate with 11-cis retinal in to a photopigment [30]. 
We propose that type II positions are quite essential for correct protein synthesis and 
translocation. 
Type III: Amino acid substitutions that affect membrane translocation and glycosylation. 
Substitutions at the positions El 13, E122, E134, R135 and K248 belong to this category. 
We already suggested before that the charge-pair E134,R135 could be part of an stop-
transfer site [19]. A possible mechanism, how these positions could affect membrane 
translocation and glycosylation and thereby folding of the protein [19,31; DeCaluwé, unpu-
blished], which explains our observations so far is depicted in Fig 5.11. The mutations in 
transmembrane domain (TM) III (positions 113, 122, 134 and 135) pertain to highly polar 
residues localized within the membrane or at the membrane interface. Protein translocation-
signals consist of a combination of polar and hydrophobic residues and probably require a 
specific three-dimensional arrangement, clear insight in which is still lacking [32]. We 
propose that these four positions are important elements for a translocation-signal which in 
wild-type opsin functions as a transfer-stop, thereby positioning TM III in the membrane 
(Fig 5.11 A). When point-mutations lower the affinity of the signal-site for the transloca-
tor, there is a chance that it is not recognized as such and the signal "slips" through. Then 
TM III will be fully translocated and translocation only stops at the next signal in TM IV, 
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Figure 5.11 Topographie models of-wild-type and mutant opsins. A, wild-type; B, TM Ш mutants (positions 
113, 122, 134 and 135); C, mutant K24SL (loop ІЗ). 
which in wild-type functions as a start-transfer signal (transfer-signals can both function as 
stop- or start-transfer sites, depending on the ongoing activity of the translocase [32]). 
Hence, if a slip in this TM-signal occurs, TM III and loop І2 will be translocated and the 
rest of the topography of opsin reverses, the C-terminal finally being located extracellularly 
(Fig 5.11 B). This model would explain the partial accessibility of these mutant to 1D4 and 
thermolysin in intact cells and the strong tendency of the misfolded protein to aggregate 
and its low solubility in detergent solution. Further it offers an explanation why misfolded 
non-glycosylated protein is produced: the severe misfolding of the protein near the N-
terminal glycosylation sites may interfere with glycosyl-transfer. In addition the disulfide 
bridge between TM HI and TM IV cannot be formed and these posttranslational modificati­
ons may be partially coupled [33]. Interestingly, the chance of such a slip to occur clearly 
depends on the type of substitution (E134R,R135E>E134R>E134D; E113Y>E1-
13D>E113Q). This suggests, that in wild-type the signal is very delicately tuned. A 
similar model can be put forward for the K248L mutant (Fig 5.11 С). K248 is located in 
the interface region of TM VI. Again, we propose, that substitution of the polar Lys248 for 
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the apolar Leu interferes with the proper functioning of the start-transfer signal in TM VI. 
If this signal "slips through" TM VI and loop e3 will not be translocated and the signal in 
TM П will induce translocation-start, again with extracellular location of the C-terminal 
as a result (Fig 5.11 C). The mutant K248L also produces a large amount of non-glycosyla-
ted product. Hence, although the disulfide bridge between TM III and TM IV in principle 
can be formed in the misfolded protein as well, the severe misfolding, possibly coupled to 
aggregation, apparently strongly impairs glycosyl-transfer. Hence, our results can be 
explained assuming that the type III mutations interfere with the function of a transfer-
signal, resulting in a significant "slip" of the signal. 
In this context it is interesting to note, that the natural mutation E122L also belongs to this 
category. While E122 is fully conserved in rod visual pigments, in cone visual pigments 
usually Leu or He is present in this position. Since cone and rod pigments show little 
conservation in TM Ш (except for E113, G114, G121, W126, G127, L128, E134 and 
R135), we assume that during evolutionary development of the rod pigments the necessary 
functional changes in TM ΠΙ had to be compensated by an essential Glu at position 122, to 
retain reliable translocation-signal activity in this domain. Exchange of larger parts of rod 
pigment TM III for cone pigment TM III might answer this question. 
Although the effect of mutations on folding and targeting has not been described in much 
detail in the literature, scattered results generally support our model. First of all, the 
extracellular domain is very sensitive to point-mutations and deletions. These usually lead 
to incorrect folding and loss of glycosylation [4,34-39], indicating that the structural 
organization of this domain is quite easily perturbed and that glycosylation is quite sensitive 
to the structure of this entire domain. Furthermore, the mutation R135L/W is found in 
patients with ADRP [30,35] and seems to be associated with glycosylation and targeting 
[35]. Mutation of El 13 to К also resulted in misfolding, impaired glycosylation and loss of 
regeneration [40,41]. This is also described for the mutant E122K [41]. 
A very interesting phenomenon is that all mutants of this type also affect signal trans­
duction. The effects however vary from a complete loss of transducin activation (R135 
[23,30,35,36]) to a variable decrease (E122Q/D/A, E134D, K248L [24,41-43]. Several 
mutants in these positions show constitutive activity (E113Q [40,44]; E134A [26]). In most 
other G-protein coupled receptors an Asp at the position corresponding to E134 is fully 
conserved and appears to be required for efficient signal transduction [21,28]. Residue 
K248 also seems to be of such a general importance [45,46]. Glull3 is considered to be 
the Schiffs base counterion in visual pigments [23,27,41] and a ligand counterion in G-
protein coupled receptors [21,28]. Substitution of this residue for one without a negative 
charge leads to constitutive activity in visual pigments, suggesting that it helps to constrain 
opsin into an inactive conformation via a charge-pair interaction [40,44]. 
Hence, it is striking that the same residues which are quite important for correct protein 
translocation during biosynthesis of opsin also are deeply involved in the mechanism of 
ligand binding and/or signal transduction. Possibly, the structural principles developed to 
govern membrane protein-docking protein/translocase-complex interaction have also been 
applied in the G-protein coupled receptor family for ligand recognition and G-protein 
interaction. 
Type IV: Amino acid substitutions that do produce an intact protein without detectable non-
glycosylated product, but lead to non-homogeneous distribution in the plasma membrane 
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and reduced regeneration. The mutations E113Q/D, W265F and Y268S belong to this 
category. Immunohistochemical analysis of these mutants produces a patched distribution in 
the plasma membrane, which could indicate an aggregation phenomenon (although this is 
not evident from immunoblot analysis), and they all have a strongly reduced regeneration 
capacity. These residues reportedly all interact with the retinal chromophore in bovine 
rhodopsin [24]. The effect of the E113Q or E113D mutation might represent a mitigated 
effect of the other El 13 mutations, which belong to type Ш. That is, Q or D can still 
substitute for E in this position without strong reduction of the efficacy of the start-transfer 
signal. However, the structural effects of the mutation, which for Q a.o. result in constitu­
tive activity, might lead to lower stability with enhanced tendency to aggregate and reducti­
on in regeneration capacity. Mutation of W265 into Y/F/A also may induce structural 
changes, as evident from lower regeneration capacities, a blueshift of 20-30 nm, very slow 
bleaching (F/A) and a decrease in transducin activation [24]. Also in the m3-receptor 
reduced affinities for both agonists and antagonists is observed upon mutation of this 
residue, which probably contributes in stabilizing the ligand/receptor complex [Wess, 
1993]. Evidence is also available for structural deformations in Y268 mutants. The 
mutation Y268F in rhodopsin reduced transducin activation [24] and in the m3-receptor 
leads to reduced ligand binding affinities. This residue may play a key role in mediating 
ligand-induced conformational changes in TM V and VI which are then transmitted to the 
connecting ІЗ loop, resulting in the activation of specific G-proteins [21]. 
Hence, type Г mutants also represent residues, which strongly contribute to ligand binding 
and signal transduction, but are less critical for correct translocation. The mutations 
however induce structural changes in the protein, which enhance its tendency to form non-
covalent aggregates, possibly by exposing interaction, which are normally buried. 
5.5 Conclusion 
Summarizing, we can state that single substitution of amino acids in the opsin sequence 
generally affects several structural or functional properties. This again emphasize that 
structure and function of such a G-protein coupled receptor are very closely connected and 
very delicately tuned. In view of these mosaic effects of single mutations, it should be 
emphasized never to rely on single functional assays when assessing the effect of a 
mutation. For instance, a decrease in effector activation maybe due to less effective 
receptor-G-protein coupling, but also to lower ligand-affinity, impaired signal development 
due to structural changes in the receptor, receptor-aggregation, misfolding of part of the 
receptor-molecules, or any combination of these effects. 
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CHAPTER 6 
EFFECT OF SELECTED MUTATIONS ON 
FUNCTIONAL PROPERTIES OF BOVINE RHODOPSIN* 
* adapted from: 
P. Rath, G.L.J. DeCaluwé, P.H.M. Bovee-Geurts, W.J. DeGrip and K.J. 
Rothschild (1993) Fourier Transform Infrared difference spectroscopy of rhodopsin 
mutants: Light activation of rhodopsin causes hydrogen-bonding change in residue Aspartic 
acid-83 during Meta II formation. Biochemistry 32, 10277. 
G.L.J. DeCaluwé, P.H.M. Bovee-Geurts, P. Rath, K.J. Rothschild and W.J. 
DeGrip (1995) Effect of carboxyl mutations on functional properties of bovine rhodopsin, 
Biophysical Chemistry, in the press. 
G.L.J. DeCaluwé, P.H.M. Bovee-Geurts and W.J. DeGrip. Contribution of highly 
conserved membrane located carboxyl residues to the Metarhodopsin I- Metarhodopsin II 
equilibrium of light activated bovine rhodopsin, in preparation. 

6.1 Introduction 
Rhodopsin, the visual pigment of the rod photoreceptor cell, is a complex integral 
membrane protein containing seven transmembrane helices, which harbor the chromopho-
re, П-ш-retinal, covalently linked to Lys296 via a protonated Schiff base [1]. The 
biosynthesis of opsin, the apoprotein, requires intermittent membrane translocation and 
several posttranslational modifications like glycosylation [2], palmitoylation [3] and 
disulfide bridge formation [4,5], in order to fulfill all its structural and functional proper­
ties. Absorbance of visible light near 500 run triggers isomerization of the chromophore to 
all-trans. The resulting fast conformational changes (Rho - Battio - Lumi - Meta I - Meta 
II) lead to signal site exposure, G protein (transducin) binding, and subsequent desensitiza-
tion by the specific rhodopsin kinase and a 45-kDa protein (S-antigen or arrestin). 
Metarhodopsin II then slowly decays indirectly via metarhodopsin III or directly into the 
apoprotein opsin and the chromophore is released (for reviews see [6,7]). 
The functional and structural properties of rhodopsin can be explored by in vitro 
expression and (site directed) mutagenesis combined with FTIR difference spectroscopy 
(e.g. [8]). For this purpose we have chosen the recombinant baculovirus expression system 
for the expression of wild-type and mutant bovine rhodopsin in insect cells [9,10,11,12]. 
The high sensitivity of FTIR difference spectroscopy provides detailed structural informa­
tion on changes occurring in each step of the photoactivation cascade (for review see [13]). 
Rhodopsin contains several highly conserved membrane-located carboxyl group bearing 
residues (Asp83, Glull3, Glu 122 and Glu 134). The presence of such polar acidic amino 
acid side chains in the membrane environment in combination with their strong conservati­
on suggests a specific contribution to folding and/or function of rhodopsin. We have 
addressed several highly conserved residues (Fig 5.1, chapter 5) using site-directed 
mutagenesis to investigate their role in rhodopsin structure and/or function. It appears that 
mutations at the different positions affect biosynthesis (cf. chapter 5) and functional 
properties in a complex way. 
6.2 Materials and methods 
Production and purification of wild-type and mutant bovine rhodopsin. All manipulations 
involving rhodopsin were performed in dim red light (Schott-Jena, RG 645 cut-off filter). 
Site-directed mutagenesis, cloning, isolation and propagation of recombinant baculovirus, 
and insect cell culture were performed as described [9-12,14]. The Spodoptera frugiperda 
cell line IPLB-Sf9 was maintained at 27 °C in TNM-FH medium plus 10% fetal calf serum 
(FCS), 50 /¿g/mL streptomycin and 50 units/mL penicillin. Large-scale production was 
achieved in suspension culture (100-1000 ml), stirred at 200 rpm with overlay aeration and 
with addition of Pluronic-F68 (Sigma) to a final concentration of 0.3%. Viral infections 
(МОЫ0) were performed in one third of the final volume during 1-2 h and then supple­
mented with medium without FCS to a final density of 2.106 cells/mL. Cells were harve­
sted at 3 days postinfection (dpi). Regeneration with 11-ris-retinal in total cellular 
membrane preparations, purification over ConA-Sepharose and reconstitution into retina 
lipids were performed as described (chapter 2;[8,12]). 
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Table 6.1 Absorbance maximum of native bovine rhodopsin 
and recombinant (mutant) pigments. 
1 species 
native 
v-rho 
D83N 
E113D 
E113Q 
E113Y 
E122L 
E134D 
E134R 
E134R/R135E 
K248L 
W265F 
Y268S 
P291A 
A299C/V300A/P303G 
»•max ( n m ) 
498 
498 
492 
505 
n.d. 
n.d. 
495 
498 
498 
498 
498 
n.d. 
n.d. 
499 
496 
n.d. no detectable absorbance band 
wavelength (nm) 
Figure 6.1 Difference spectra of wild-type and mutant rhodopsins (spectrum before illumination is subtracted 
from that after illumination in the presence of 50 mM hydroxylamine). X,^: wild-type v-rho, 498 nm; D83N, 
492 nm; E122L, 495 nm; E134D, 498 nm; E134R, 498 nm. 
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Photolysis: Rhodopsin proteoliposomes were resuspended in 20 mM buffer with appropiate 
pH (MES for pH 5.5-6; PIPES for pH 6.5; MOPS for pH 7-7.5; HEPPS for pH 8-9.5, 
with addition of 130 mM NaCl, 5 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 0.1 mM EDTA). 
Samples of 0.5-1 nmol pigment/ml were scanned from 250-700 nm on a Perkin Elmer X15 
UV/Vis spectrophotometer (spectrum 1). The suspension was then illuminated for 10 sec 
(150 W light bulb, Schott Jena YG 430 cut-off filter) and subsequently spectra were taken 
at 3-min intervals (spectrum 2-8). Then hydroxylamine was added to a final concentration 
of 50 mM (spectrum 9) followed by a final bleach (spectrum 10). The amount of metarho-
dopsin I remaining after illumination (spectrum 2) was calculated from (А480(2)-Аб50(2))-
(A48O(9)"A65O(9))/(A50O(l)"A65O(l))-(A50O(9)_A65O(9)) x 100%. 
FUR difference spectroscopy: Fourier transform infrared spectra of the Rho - Batho and 
Rho - Meta II transition were recorded as described [8]. In brief, samples were prepared 
by isopotential spin drying [19] of 0.3-0.9 nmol pigment in proteoliposomes on AgCl 
windows and then rehydrating prior to insertion into a sealed transmittance cell which was 
mounted in a Helitran cryostat (Air Products, Allentown, PA). The water content of the 
sample was checked by monitoring the ratio of the 3400 cm"1 OH streching mode of water 
to the CH streching bands of the protein and lipid near 2900 cm"1. The Rho - Batho 
difference spectra were recorded at 82 К at both 2- and 8-cm"1 resolution using a Nicolet 
Analytical Instruments (Madison, WI) 740 spectrometer. The sample was illuminated with 
light from a narrow-band 500-nm interference filter for approximately 5-min and photore-
versed back to a mixture of rhodopsin and isorhodopsin by illumination for the same period 
of time with a 600-nm narrow-band interference filter. Difference spectra from at least 25 
of these cycles were then averaged. The Rho - Meta II difference spectra were recorded at 
10 °C. The sample was illuminated for 3-min using a 500-nm long-pass filter, and spectra 
were recorded at 8 cm"1 resolution for 10-min intervals before and after illumination (3000 
scans for each spectrum) on a Bio-Rad FTS-60 spectrometer. Difference spectra were com­
puted by subtracting a block of spectra taken before illumination from a block of spectra 
after illumination [8]. 
6.3 Results 
Photochemical properties. 
To study the functional and structural properties of the in vitro expressed opsins, regenera­
tion with the chromophore 11-a'j-retinal, purification and reconstitution into proper lipids 
is essential [12]. Regeneration should produce a photosensitive pigment, as illustrated for 
wild-type (v-rho) and several mutant opsins in Fig 6.1 and Table 6.1. The mutations D83N 
(492 nm) and E122L (495 nm) caused a slight blue shift of the wild-type A
max
 (498 nm), 
while the mutants E134D/R (Fig 6.1), E134R,R135E and K248L have wild-type λ ^ . 
However, only the glycosylated form of the mutants E122L, E134D/R, E134RR135E and 
K248L (see chapter 5) gave significant regeneration, while the non-glycosylated species did 
not and was only poorly solubilized in the detergent dodecylmaltoside either (not shown). 
Our final purification procedure (ConA-Sepharose affinity chromatography) selects for the 
glycosylated species [12]. 
For functional analysis it is important to create a native-like environment; e.g. in detergent 
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waveíength (nm) »aveienath (nm) 
wavelength (nm) wavelength (nm) 
Figure 6.2 Late photointermediate formation in proteoliposomes of wild-type and mutant rhodopstns at pH 
65 A wild-type v-rho (1 nmol rhodopsin). The absórbame bands ofrhodopsin (Rh, 498nm), metarhodopsin 
I (M I, 480 nm), metarhodopsin 11 (MII, 380 nm) and metarhodopsin HI (M III, 455 nm) are indicated in the 
wild-type v-rho photolysis. (Inset) Photolysis of reconstituted native bovine rhodopsin under similar conditions 
(3 nmol rhodopsin). B, D83N. C, E122L. D, E134D. 
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wavelength (rm) wavelength (rm) 
2 Ι ι 1 1 1 'ι Ι 
»ο «ο s» eso 
wavelength (rm) 
Figure 6.3 PH-dependence of the late rhodopsin photocycle. Photolysis of native bovine rhodopsin in ROS 
membrane suspension at 10°C. A, pH 6. B, pH 8.5. C, difference spectra of rhodopsin photolysis (spectrum 2-
1) from pH 5.5~9, showing pH dependent shift of the absorbance minimum (k^ due to the pH-dependence of 
the Mela I ~ Meta II equilibrium. 
the pKa of the Meta I - Meta II equilibrium shows dramatic shifts from 7.3 in membrane 
suspension (Fig 6.4) upwards to > 8.5 (dodecylmaltoside [15]) or down to 6.4 (digitonin 
[16]). Such a native-like environment was achieved by reconstitution in retina lipids [12]. 
After purification and reconstitution into retina lipids the late photointermediates of the in 
vitro synthesized pigments were analyzed at pH 6.5 by UV/Vis spectroscopy (Fig 6.2). 
These photolytic transitions of wild-type v-rho are identical to native rhodopsin (inset Fig 
6.2, panel A). The mutant D83N (Fig 6.2, panel B) showes almost normal formation and 
kinetics of late photointermediates (Meta I: 480 nm; Meta II 380 nm; Meta III: 455 nm), 
with a slight decrease in Meta I, However, the mutant E122L (Fig 6.2, panel C) produces 
little Meta I and a relatively large amount of Meta III. The opposite is apparent for the 
mutants E134D (Fig 6.2, panel D) and E134R (not shown), which produce more Meta I. 
These results indicate that the latter substitutions affect the Meta I - Meta II equilibrium. 
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The Meta I - Meta II equilibrium is pH dependent, favoring Meta II at low pH (Fig 6.3, 
panel A) or Meta I at high pH (Fig 6.3, panel B). As a consequence the absorbance 
minimum (*
min) in the photolytic difference spectrum shows a pH dependent red-shift 
(spectrum 2-1; Fig 6.3, panel C). Therefore, the effect of the mutations on the pK of the 
Meta I - Meta Π equilibrium was estimated by performing the photolysis at different pH 
values (range 5.5spHs9.5). The pH-dependency of the percentage of Meta I present after 
illumination is shown in Fig 6.4, panel A. Wild-type v-rho and native bovine rhodopsin, 
purified and reconstituted just as the recombinant species (Rho ree), show a curve nearly 
identical to native bovine rhodopsin in ROS membrane suspension and the pKa is not 
significantly different. However, in the mutant D83N and even more obvious in E122L the 
Meta I - Meta II equilibrium is shifted towards Meta II at higher pH. Both the E134 
mutants seem to shift the Meta I - Meta II equilibrium towards Meta I but due to the 
restricted amount of pigment this was still only measured at one pH. The same trend is 
evident from the X
min shift in the first photolytic difference spectrum (range 5.5spHs9.5; 
Fig 6.4, panel B). 
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- o - fiOS DKa 7.3 
• Rho (ree) 
• E122L 
Figure 6.4 PH-dependency of the Meta I - Meta II equilibrium of native bovine rhodopsin and recombinant 
wild-type and mutant pigments. A, percentage Meta I remaining after 15 sec illumination at pH range 
5<pH<10. B, X
min shift of the photolytic difference spectrum (spectrum 2-1; cf. Fig 6.3) relative to the real 
absorbance maximum of the pigment i^mn^max) a t PH range 5<pH< 10. 
Substitution of the highly conserved residues Pro291 and РгоЗОЗ (P291A and 
A299C/V300A/P303G) does not significantly seem to affect the functional properties of 
bovine rhodopsin significantly (Table 6.1). Only minor changes in X
max
 are observed (wt v-
rho, 498 nm; P291A, 499 nm; A299C/V300A/P303G, 496 nm). Preliminary analysis of 
the late photocycle at pH 6.5 also indicates no major shift in the Meta I ~ Meta II equilibri­
um, with normal formation and kinetics of the late photointermediates Meta II and Meta III 
(not shown). 
The mutants EU3Q/Y, W265F and Y268S did not generate a detectable absorbance 
band after regeneration and purification (Table 6.1). This probably was due to a combinati­
on of low expression level and impaired regeneration. Although the mutant Ell 3D also 
suffered from the same problem, here a small amount of pigment with X
max
 at 505 nm 
could be detected. 
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1800 1700 1600 1500 1400 
Wavenumbers (cm ) 
Figure 6.5 Infrared absorbance spectra ofhydrated 
films of ROS and recombinant wild-type (WT) and 
mutant rhodopsins. Only that part of the spectrum is 
shown, which contains most relevant information on 
protein secondary structure (Amide I band around 
1650 cm"1 and Amide II band around 1550 cm"1). 
The band around 1740 cm"1 mainly derives from 
phospholipid and its relative size depends upon the 
lipid to protein ratio in the proteoliposomes. Resolu­
tion is 2 cm1. 
1800 
WAVntUMBEKS(CM ) 
Figure 6.6 Rho - Batho FTIR difference spectra of 
ROS, wild-type v-rho (2 cm"1 resolution) and the 
mutants E134D and D83N (8 cm1 resolution). The 
spectra were obtained at 82 К from photostationary 
mixtures created by successive illumination through 
500- and 600-nm narrow-band interference filters. 
The scale bar shown (0.0002 ODU) is for the D83N 
spectrum. For better comparison the other spectra 
were scaled using the bands in the 1500-1600 cm"1 
region. 
FTIR spectroscopy. 
Information about the structure of rhodopsin and its conformational changes during the 
photocascade were obtained by FTIR spectroscopy. The absolute vibrational spectra of 
bovine rod outer segment (ROS), and recombinant wild-type or mutant rhodopsin proteoli­
posomes are shown in Figure 6.5. The two most intense bands at 1657 and 1543 cm"1 are 
due to the amide I and amide II modes, respectively, which are sensitive to protein 
secondary structure [17,18]. The band around 1739 cm"1 arises mainly from the carbonyl 
stretch of lipid ester carbonyl groups [17] and its ratio relative to the amide I band depends 
on the amount of lipid incorporated during reconstitution. The bandshapes of the amide 
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bands in the spectra of ROS, wild-type, D83N and E122L is very similar, indicating that 
the secondary structure of these mutants is very similar to that of native rhodopsin. 
However, the spectra of E134D and E134R display a prominent shoulder near 1634 cm"1 
indicating the presence of some, at least partially misfolded, protein [8]. 
The Rho - Batho FTIR difference spectra of wild-type v-rho (WT) and the mutants D83N 
and E134D are shown in Figure 6.6. These spectra are very similar to the corresponding 
ROS difference spectrum (Fig 6.6, top). The retinal fingerprint region (1150-1250 cm"1) 
and the HOOP-region (800-950 cm"1) are nearly identical, indicating that the mutations 
have little effect on the normal 11-di - all-trans isomerization pathway of the retinylidene 
chromophore. 
The Rho - Meta II difference spectra of several mutants are shown in Figure 6.7. While 
E134D is quite similar to wild-type, all the other mutants exhibit clear changes. Most 
dramatic is the disappearance of two bands at 1767 cm"1 (negative) and 1748 cm"1 
(positive) in the D83N mutant [8,19]. A similar effect is observed for D83N exposed to 
D 2 0, where the two bands which downshift due to
 lH-2H exchange to 1755 and 1740 cm"1 
in ROS are absent in D83N (Fig 6.8). These bands have been previously assigned to a 
protonation and/or hydrogen-bonding change of protein carboxyl residues during the Meta 
I - Meta II transition [20]. The E122L mutant shows changes in the carboxyl region, with 
the disappearance of the negative band at 1728 cm"1. This is also evident in the difference 
of the ROS and E122L difference spectra (Fig 6.9). A similar effect is also observed in 
detergent micelles [18], although a positive band located at 1735 cm"1 was reported by 
these authors to disappear concomittantly, which we do not observe. E122L also displays a 
marked change in the amide I region (Fig 6.9) with the disappearance of prominent bands 
at 1663 cm"1 (negative) and 1641 cm"1 (positive). This most likely reflects altered structural 
changes during Meta Π formation. Finally, the mutant E134R has a relatively normal 
carboxyl region but shows reduced band intensities in the amide I region as well as changes 
in the amide II region (1547 cm"1 band). (Fig 6.8) 
6.4 Discussion 
In vitro expression of bovine rhodopsin using the recombinant baculovirus expression 
system results in a protein with correct posttranslational processing (translocation, 
glycosylation, palmitoylation and targeting, cf. chapter 5). After regeneration with the 
chromophore ll-m-retinal, purification over ConA-Sepharose and reconstitution in retina 
lipids a pigment with identical spectral and photolytical properties identical to native bovine 
rod rhodopsin is generated. 
Although a proline at position 291 is highly conserved in visual pigments (except for insect 
pigments) and the proline at position 303 is conserved throughout the entire family of G-
protein coupled receptors, substitution of these residues (mutants P291A and 
A299C/V300A/P303G, respectively) does not seem to affect posttranslational processing 
(cf. chapter 5) or photochemical properties of bovine rhodopsin. However, structural 
transitions and transducin activation still need to be examined since substitution of P303 in 
the m3-receptor impaired stimulation of PI hydrolysis [21]. It is unlikely that in the mutant 
A299C/V300A/P303G the other two mutations can neutralize a possible effect of the 
P303G substitution, because a Cys at position 299 occurs naturally in blue/violet cone 
pigments and Val300 is not conserved (Ile, Leu, Cys). However, analysis of the single 
mutation P303G will be necessary to obtain a definite answer. 
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(SUB: ROS-E122L). The subtracted spectrum shows 
the major changes at 1728, 1663 and 1641 cm'1 
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The K248L mutation affects glycosylation and folding of rhodopsin (cf. chapter 5), but it 
does not affect the spectral properties in agreement with earlier suggestions [22,23]. 
However, functionality is reportedly affected in a decrease in transducin activation [22,23]. 
The mutations W265F and Y268S affect translocation and/or folding (cf. chapter 5) and 
strongly reduce regeneration capacities. These residues reportedly interact with the retinal 
chromophore [24], but in contrast to our findings substitution of W265 into Y/F/A was 
reported to reduce regeneration only upto 68/58/22% respectively, whereas the mutation 
Y268F only slightly reduced regeneration (84%) [24]. This discrepancy may be due to the 
difference in expression system. The effect of the mutations W265F and Y268S on opsin 
biosynthesis and structure has already been discussed in detail (chapter 5) and probably is 
the cause for the strong reduction in regeneration capacities. 
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Since high conservation of polar side chains in membrane domain suggests their 
involvement in essential structural or functional properties, we investigated the effect of 
mutation of residues D83, El 13, E122 and E134 on posttranslational processing, and 
spectral and photolytic properties of (rhod)opsin. Our results so far indicate mosaic effects 
of the various mutations on (rhod)opsin properties, i.e. each mutation affects more than one 
of the properties investigated but in different combinations. Hence we will discuss the 
various mutations separately. 
D83N: Substitution of Asp83 for Asn has no detectable effect on posttranslational proces­
sing of opsin (cf. chapter 5). This actually is not surprising since the mutation D83N 
occurs "naturally" in frog rod rhodopsins [25] and hence is not expected to perturb the 
delicate balance of signals in the opsin sequence which regulate translation, translocation, 
folding and further posttranslational processing. However, the mutation does affect spectral 
and functional properties. A small but significant blue shift of the absorbance band (*
max
: 
498 - 492 nm) is observed, in agreement with earlier suggestions [26]. Although the 
kinetics of the slow photointermediates (Meta Π - Meta III) are not affected by this 
mutation, the Meta I - Meta Π equilibrium is slightly shifted towards Meta II, in agreement 
with results reported by Weitz et al [27] obtained in digitonin solution. Quite interesting is 
the disappearance of the two bands at 1767 cm'1 (negative) and 1748 cm"1 (positive) in the 
Rho - Meta II FTIR difference spectrum of D83N. As previously discussed [8,19], this 
indicates that Asp83 is structurally active in this transition, e.g., it undergoes an increase in 
hydrogen bonding or it directly affects the structural activity of a different Asp/Glu 
residue(s) upon Meta II formation. We can exclude the possibility that these missing bands 
are due to a defect in the mutant D83N which blocks Meta II formation, since an intense 
positive band charateristic for Meta II is found at 1686 cm"1 and the 952 cm"1 band charac­
teristic for Meta I is almost absent. In fact, as mentioned above, analysis by UV/Vis spec­
troscopy shows that D83N generates at least as much Meta II as wild-type under the same 
conditions (Fig 6.2). The disappearance of the 1767/1748 cm"1 bands could be caused by a 
simultaneous deprotonation/protonation of two different Asp/Glu residues. However, this is 
unlikely because the then expected appearance of a positive and negative band in the 
carboxylate region around 1400 cm"1 is not detected. Since the 1767 and 1748 cm"1 bands 
are not perturbed in Meta Π by mutation of the other membrane-located Glu residues (see 
below), we conclude that these bands represent Asp83 in the rhodopsin and Meta II state, 
respectively. The most direct explanation is, that Asp83 is structurally involved in Meta II 
formation, thereby increasing its Η-bond interaction. 
Apparently, substitution of Asp for Asn does not significantly perturb the normal hydrogen 
bonding pattern and does not significantly influence the Meta I - Meta Π transition. 
El 13 mutants: It is well documented that Glull3 is indispensable for correct protonation of 
the Schiff base linkage between Lys296 and ll-от retinal [26,28,29]. Only carboxyl 
residues at this position [28,30] or at the positions 90 [31] or 117 [32] can sustain a 
pigment with normal spectral properties. Other El 13 mutants can generate photosensitive 
pigments, but their absorbance bands are pH- and anion-dependent, lower pH and higher 
anion concentration stabilizing the protonated rhodopsin-like state [26,28,30]. However the 
mutants, generated with our expression system, even after regeneration and purification at 
low pH (pHs6) do not present a detectable absorbance band. This apparent discrepancy 
may lie in the difference of the used expression systems. We demonstrated that the El 13 
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mutants in our expression sytem show a non-homogeneous distribution in the plasma 
membrane and at least part of the protein is incorrectly translocated and/or folded (cf. 
chapter 5). It seems that the structure in the El 13 mutants is affected in such a way that 
regeneration is strongly impaired, e.g by aggregation. The "unnatural" insect cell membra­
ne matrix composition and the unphysiological temperature during biosynthesis may result 
in further destabilizition and/or aggregation of the protein. 
E122L: While E122 is absolutely conserved in rod visual pigments, cone pigments have an 
apolar residue at this position (L,I,M). Indeed, substitution of Glul22 for Leu much less 
affects the spectral properties of bovine rhodopsin (X
max
 498 - 495 run), than that reported 
for Gin, Asp or Ala (X
max
 475-480 run) [24,26,28,29,33]. The mutation E122I also 
induces only a small X
max
 shift [26]. This suggests that replacing E122 by similar polar 
groups like Q or D perturbs the tertiary structure to such an extent that an appreciable blue 
shift in absorbance results. Direct interaction of E122 with the chromophore is unlikely 
since then much larger effects of the mutations E122L and E122I should be expected. 
Hence apolar residues like Leu and He are good substitutions for E122 with regard to a 
correct structure for spectral tuning. However, they strongly affect other properties of 
opsin. During biosynthesis a large amount of non-glycosylated product is produced which 
has not been properly translocated and/or folded (cf. chapter 5). The "normal" .glycosyla­
ted, product, which has been purified, shows no aberrant folding as far as can be judged 
from the bandshape of the Amide I band in the FTIR spectrum (Fig 6.5). Apparently the 
mutation E122L interferes with the translocation process during opsin biosynthesis. 
Furthermore it strongly shifts the Meta I - Meta Π equilibrium towards Meta II (Fig 6.4). 
This is opposite to what Weitz et al [27] found by difference spectroscopy in digitonin 
solution for the mutation E122I. Although we tentatively attribute this discrepancy to the 
fact that our data are obtained in a native-like membrane-environment, this requires further 
investigation. The structural importance of a Glu at position 122 is also evident from 
changes induced by the Leu substitution in the Rho - Meta II difference spectrum. In the 
first, bands in the amide I region which most likely reflect structural changes involving the 
rhodopsin backbone are absent. Secondly, a negative band in the carboxyl region at 1728 
cm'
1
 disappears. This band has been previously tentatively identified as a buried carboxyl 
group [20], and assigned to Glul22 due to its disappearance in E122Q [19]. However, in 
view of the fact that a corresponding positive carboxyl band is not observed in our spectra 
(Fig 6.9), it appears that this group does not undergo hydrogen bonding changes as it 
occurs for Asp83. In addition, we also do not observe a significant change in the carboxy-
late region near 1400 cm"1 due to the E122L mutation which would be expected if Glul22 
undergoes deprotonation. Hence, we disagree with the assigment of the 1728 cm"1 band to 
Glu 122. An alternative possibility is that this band arises from a protein backbone vibration 
such as a Pro residue as suggested previously [34]. 
EÌ34 mutants: Both E134 mutations (D/R) and the E134R,R135E double mutant do not 
interfere with spectral tuning, but severely affect glycosylation and translocation (cf. 
chapter 5). We already postulated that these residues could be part of an important internal 
translocation signal [11,12]. Now also the FTIR spectrum of the purified glycosylated 
species shows the presence of some misfolded protein (Fig 6.5). Furthermore, both 
mutations shift the Meta I - Meta II equilibrium towards Meta I (Fig 6.4). This again is in 
contrast with results obtained in digitonin solution for the mutants E134Q and E134L, and 
the double mutants E134L,R135L and E134R.R135E [27]. FTIR analysis also shows that 
107 
secondary structural changes, as reflected in the amide I region upon Meta II formation, 
are altered in these mutants, in particular the E134R mutant. In contrast, the structural 
changes of carboxyl groups as reflected in the carboxyl region are unaffected. This further 
supports our earlier conclusion that E134 is not structurally active in the Meta I - Meta II 
transition [8]. 
Meta I - Meta II equilibrium: We earlier proposed that a Η-bonded network exists in 
rhodopsin which surrounds the chromophore and both modulates its electronic properties 
(wavelength regulation or spectral tuning) and is involved in the photoinduced conformati­
onal changes accompanying signal transduction and binding of transducin [34]. The 
essential role of El 13 in stabilizing the protonated Schiff-base can be explained in this 
concept, by assuming that it holds a key position controlling the integrity of the network. It 
may also explain that this function can be partly taken over by an Asp residue at this 
position or at the positions 90 [31] and 117 [32], and that in El 13 mutants even anions of 
varying size can increase the stability of the protonated Schiff-base by restoring some basic 
properties of the Η-bonded network. Analysis by FTIR-spectroscopy already indicated that 
Asp or Glu and Tyr residues change their protonation state upon entering the Meta I ~ 
Meta II equilibrium [20]. This led us to propose that a Η-bonded network is involved in 
this equilibrium and would reversibly change its structure upon (de)protonation, favoring 
Meta II in the protonated state [20,35]. Our present analysis of mutants supports this 
proposal. Asp83 changes from a weakly to a more strongly Η-bonded state upon Meta II 
formation, and the E122L mutation perturbs conformational changes during the Meta I -
Meta II transition. The effect of the D83N and E122L mutations on the Meta I - Meta II 
equilibrium is therefore explained by a subtle change in the charge distribution of the H-
bonded network, enhancing its proton-acceptor potential. This would shift the apparent pK 
of the equilibrium to higher pH. The perturbation of the Meta I •» Meta II equilibrium in 
E134 mutants can also be attributed to such a perturbation of the protonation-dependent 
network changes. Similarly the reported effects of substitution of conserved His residues on 
the Meta I - Meta II equilibrium would suggest, that the presence of His211 strongly 
favoring formation of Meta II, while the presence of His65 and 152 slightly favoring 
formation of Meta I [36], can also be accomodated in this framework. His211 is located in 
membrane domain IV and could easily participate in an interior Η-bonded network. The 
results with the His-mutants are, however, obtained in detergent solution, and need to be 
confirmed in the membrane-bound state. In retrospect, our earlier proposal that the Meta I 
- Meta II transition is regulated by a complex Η-bonded interaction of polar residues with 
one another and with the retinylidene moiety needs further experimental support, but so far 
is in line with the present evidence. 
6.5 Conclusion 
We have demonstrated that in vitro expression and mutagenesis of bovine rhodopsin in 
combination with FTIR difference spectroscopy is a very sensitive method to identify 
structural changes which occur during photoactivation. One of the striking observations is 
that a single amino acid substitution can have mosaic effects, i.e. cause changes in very 
different functional properties like glycosylation, translocation, folding, Meta I - Meta II 
equilibrium, and primary or secondary structural changes during photoactivation. Hence, 
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when analyzing effects of mutations on specific functional properties one should always 
consider the potential concomittant effects on folding and structural stability. 
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CHAPTER 7 
SUMMARY 

As described in Chapter 1 rhodopsin, the visual pigment of the rod photoreceptor 
cell in the vertebrate eye, is a complex integral membrane protein containing seven 
transmembrane helices, which harbor the chromophore 11-cw-retinal covalently linked to 
Lys296 via a protonated Schiff base. Absorbance of visible light near 500 run triggers 
isomerization of the chromophore to all-trans. The resulting fast conformational changes 
(Rh - Batho - Lumi - Meta I - Meta Π) lead to signal site exposure, G-protein (transducin) 
binding, and subsequent desensitization by the specific rhodopsin kinase and a 45-kDa 
protein (S-antigen or arrestin). Metarhodopsin II then slowly decays indirectly via 
metarhodopsin HI or directly into the apoprotein opsin and the chromophore is released. 
The biosynthesis of opsin, the apoprotein, requires intermittent membrane translocation and 
several posttranslational modifications like glycosylation, palmitoylation and disulfide 
bridge formation, in order to fulfill all its structural and functional properties. The N-
terminal region is glycosylated and is of structural importance, together with the three 
intradiscal loops and the disulfide bridge between CysllO and Cysl87. Two cytoplasmic 
loops are supposed to play a role in signal transduction together with an additional surface 
loop generated by palmitoylation and membrane-anchoring at Cys322 and Cys323. 
The functional and structural properties of rhodopsin can be explored by in vitro expression 
and (site directed) mutagenesis combined with FTIR difference spectroscopy. For this 
purpose the recombinant baculovirus expression system was chosen for the expression of 
wild-type and mutant bovine rhodopsin in insect cells, as this is an eukaryotic expression 
system, which performs all common eukaryotic posttranslational modifications and has 
successfully been employed for the high level expression of foreign genes. 
In chapter 2 materials and methods are described which were used throughout this 
thesis. Several of these methods were a result of the search for optimal conditions of 
expression, regeneration, purification, and reconstitution of bovine rhodopsin, as described 
in chapter 3. 
Under the various conditions described in chapter 3, the functionality of the opsin 
produced (glycosylation, targeting, capacity to regenerate into rhodopsin upon addition of 
11-cis-retinal) did not vary significantly. The highest expression level of functional opsin 
was achieved upon using recombinant virus with 5' truncated opsin c-DNA, a high 
infection density (MOI=10), addition of 0.3% Pluronic F-68 to stabilize the cells and a 
production time of 3 days. Under these conditions levels of 50 picomoles opsin/106 cells 
(ca 4 ftg opsin/mg protein; ca 4 mg opsin/liter culture) are reproducibly achieved. 
Although several factors which can be of influence on the regeneration capacity were 
examined, the relatively low overall functionality (regeneration capacity: 40-60%) remains 
presently unexplained, but may be related to "structural stress" due to a relative high 
packing density of this heterologous membrane protein in an unusual lipid environment. 
Regeneration in total membranes, purification over ConA-Sepharose and subsequent 
reconstition in retina lipids yielded in a 60-80% overall purification of v-rho, suitable for 
most functional analysis. The overall yield still compares favorably with those obtained in 
mammalian expression systems. In addition, a pilot experiment with regard to insect cell 
culture and recombinant viral infection in a 15 liter stirred vessel bioreactor gave promi­
sing results for scaling-up. In that case sufficient material can be produced to permit studies 
by powerful but rather insensitive biophysical techniques like solid-state NMR. NMR-
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analysis requires isotope-labeling of the protein and also for FTIR difference spectroscopy 
isotope- labeling of protein residues is generally required to identify their vibrational bands 
and investigate their role in the structural changes during phototransduction. Because 
labeled amino acids are very expensive minimal concentrations in the medium were 
determined. A four fold reduction in the concentration of quite a few amino acids could 
easily be tolerated without a change in opsin production, while (except for cysteine) a two 
fold reduction was generally tolerable. For labeling purposes the best strategy would be to 
examine and adapt the concentration of each amino acid individually. 
In chapter 4 a novel approach towards crystallization of rhodopsin is described: 
expression rhodopsin fusion proteins. In a first attempt, glutathione-S-transferase (GST) of 
Schistosoma japonicum was fused onto the N-terminus of opsin. Expression of this GST-
opsin fusion protein followed a normal biosynfhetic pattern as evident from its apparent 
molecular weight, the reactivity with a variety of antibodies, its glycosylation and correct 
translocation and targeting. However, the GST-opsin fusion protein did not recombine with 
11-cis retinal into a photosensitive pigment. It has been demonstrated, that small perturbati­
ons in the extracellular domains of rhodopsin easily lead to incorrect folding and loss of 
regeneration capacity. Although N-terminal addition of small peptides do not seem to affect 
the opsin structure, fusion with a large, soluble domain apparently impairs correct folding 
of opsin to such an extent, that the capacity to recombine with 11-си-retinal was comple­
tely lost. Nevertheless the very simple purification scheme for this fusion-protein demon­
strated the powerful potential of GST-fusion proteins for purification purposes. 
Since modifications at the C-termina! of rhodopsin do not seem to have such a detrimental 
effect on opsin regeneration, the strategy was changed towards C-terminally connected 
fusion partners. The first target, an opsin-T4 lysozyme fusion protein, could be correctly 
expressed using recombinant baculovirus and, most importantly, this fusion protein did 
recombine with 11-cis retinal into a photosensitive pigment. At this stage, it could not yet 
be definitely established whether the spectral properties of this fusion protein are identical 
to wild-type rhodopsin. Expression of the C-terminally connected fusion proteins opsin-
GST and opsin-polyhedrin is in progress. An advantage of polyhedrin (a baculovirus 
structural protein) as fusion partner may be that it already under physiological conditions 
forms crystalline arrays and might therefore strongly enhance rhodopsin crystallization. 
Chapter 5 reports on effect of mutations on biosynthesis and posttranslational 
processing of opsin. In vitro expression using the recombinant baculovirus expression 
system showed correct biosynthesis and posttranslational processing of "wild-type" bovine 
opsin (translocation, glycosylation, palmitoylation and targeting). However, several of 
these processes were severely affected by point mutations. Only palmitoylation seemed to 
occur properly in all mutants described here, and appeared not to be coupled to glycosylati­
on. From the overall results four types of mutants could be distinguished. 
Type I: Amino acid substitutions that did neither significantly affect opsin biosynthesis nor 
folding of opsin. To this category belong D83N, A299C/V300A/P303G, and P291A. 
Type II: amino acid substitutions that resulted in the production of a truncated protein 
(R69H and Y301F). The resulting incomplete protein was, however, glycosylated, 
transferred to the plasma membrane and the amino-terminus was correctly located 
extracellularly. It is fully unclear presently, why translation and/or translocation are 
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aborted but the cause is probably very different for either mutation. For the mutant Y301F 
translation and translocation probably proceeded normally until the point mutation was 
reached. The situation for R69H was quite different: translation and/or translocation 
proceeded beyond this mutation (il-loop) and only was aborted shortly after the e2-loop. 
Position R69 has been reported in relation to autosomal dominant retinitis pigmentosa 
(deletion mutant 68-71), and this deletion mutant was not able to regenerate with ll-cis 
retinal to a photopigment. It seemes that type II positions are quite essential for correct 
protein synthesis and translocation. 
Type HI: Amino acid substitutions that affect membrane translocation and glycosylation. 
Substitutions at the positions El 13, E122, E134, R135 and K248 belong to this category. 
As already suggested before, the charge-pair E134.R135 could be part of a stop-transfer -
site. The mutations in transmembrane domain (TM) III (positions 113, 122, 134 and 135) 
pertain to highly polar residues localized within the membrane or at the membrane 
interface. Protein transfer-signals consist of a combination of polar and hydrophobic 
residues and probably require a specific three-dimensional arrangement, clear insight in 
which is still lacking. We propose that these four positions are important elements for a 
transfer-signal which in wild-type opsin functions as a transfer-stop, thereby positioning 
TM III in the membrane. When the point-mutations lower the affinity of the signal-site for 
the translocation, there is a chance that it is not recognized as such and the signal "slips" 
through. Then TM III will be fully translocated and translocation only stops at the next 
signal in TM IV, which in wild-type functions as a start-transfer signal (transfer-signals can 
both function as stop- or start-transfer sites, depending on the ongoing activity of the 
translocase). Hence, if a slip in the TM-signal occurs, TM III and loop i2 will be transloca­
ted and the rest of the topography of opsin reverses, the C-terminal finally being located 
extracellularly. This would explain the partial accessibility of these mutants to 1D4 (a 
monoclonal antibody reactive with the C-terminal) and thermolysin in intact cells and the 
strong tendency of the misfolded protein to aggregate and its low solubility in detergent 
solution. In addition the disulfide bridge between TM III and TM IV cannot be formed and 
this posttranslational modification may be partially coupled to glycosylation. A similar 
explanation can be put forward for the K248L mutant. K248 is located in the interface 
region of TM VI. Again, substitution of the polar Lys248 for the apolar Leu could 
interfere with the proper functioning of the start-transfer signal in TM VI. If this signal 
"slips through" TM VI and loop e3 will not be translocated and the signal in TM VII will 
induce transfer-start, again with extracellular location of the C-terminal as a result. The 
mutant K248L also produces a large amount of non-glycosylated product. Hence, although 
the disulfide bridge between TM III an TM IV in principal can be formed in the misfolded 
protein as well, the severe misfolding, possibly coupled to aggregation, apparently strongly 
impairs glycosyl-transfer. Hence, it seems that type III mutations interfere with the function 
of a transfer-signal, resulting in a significant "slip" of the signal. 
Type Г : Amino acid substitutions that do produce an intact protein without detectable non-
glycosylated product, but lead to non-homogeneous distribution in the plasma membrane 
and a reduction in regeneration capacity. The mutations E113Q/D, W265F and Y268S 
belong to this category. Immunohistochemical analysis of these mutants produced a patched 
distribution in the plasma membrane, which could indicate an aggregation phenomenon 
(although this is not clearly evident from immunoblot analysis), and they all have a 
strongly reduced regeneration capacity. These residues reportedly all interact with the 
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retinal chromophore in bovine rhodopsin. The effect of the E113Q mutation might 
represent a mitigated effect of the other El 13 mutations, which belong to type III. That is, 
Q can still substitute for E in this position without strong reduction of the efficacy of the 
start-transfer signal. However, the structural effects of the mutation, which a.o. result in 
constitutive activity, might lead to lower stability with enhanced tendency to aggregate and 
reduction in regeneration capacity. Mutation of W265 also may induce structural changes, 
as evident from the reported lower regeneration capacities, a blueshift of 20-30 nm, very 
slow bleaching and a decrease in transducin activation. The mutation Y268F in rhodopsin 
also reportedly reduced transducin activation and the corresponding mutation affected 
ligand binding affinities in the m3-receptor, suggesting a key role of this position in 
mediating ligand-induced conformational changes in TM V and VI. The latter are to be 
transmitted to the connecting i3 loop, resulting in the activation of specific G-proteins. 
Hence, type IV mutants represent residues, which strongly contribute to ligand binding and 
signal transduction, but are less critical for correct translocation. The mutations however 
induce structural changes in the protein, which enhance its tendency to form non-covalent 
aggregates, possibly by exposing potential interaction sites, which are normally buried. 
In chapter 6 some structure-function relationships of recombinant wild-type and 
mutant bovine rhodopsins are investigated. After regeneration of wild-type bovine opsin 
with the chromophore 11-di-retinal, purification over ConA-Sepharose and reconstitution 
in retina lipids a pigment with spectral and photolytical properties identical to native bovine 
rod rhodopsin could be generated. The mutations P291A and A299C/V300A/P303G did 
not seem to affect the photochemical properties of bovine rhodopsin, despite the strong 
conservation of a proline at position 291 and 303. Also the K248L mutation did not affect 
the spectral properties, in agreement with earlier suggestions. The mutations W265F and 
Y268S strongly reduced regeneration capacities. These residues reportedly interact with the 
retinal chromophore, but in contrast to our findings substitution of W265 into Y/F/A was 
reported to reduce regeneration only upto 68/58/22% respectively, whereas the mutation 
Y268F only slightly reduced regeneration (84%). The effect of the mutations W265F and 
Y268S on opsin biosynthesis and structure in our expression system has already been 
discussed in detail (chapter 5) and probably is the cause for the strong reduction in 
regeneration capacity. 
Since high conservation of polar side chains in membrane domains suggests their involve­
ment in essential structural or functional properties, we investigated the effect of mutation 
of residues D83, El 13, E122 and E134 on spectral and photolytic properties of rhodopsin. 
The mutation D83N did affect spectral and functional properties only to a small extent. A 
small but significant blue shift of the absorbance band (X
max
: 498 - 492 nm) was observed, 
in agreement with earlier suggestions. Although the kinetics of the slow photointermediates 
(Meta II - Meta ΠΙ) were not significantly affected by this mutation, the Meta I - Meta II 
equilibrium is slightly shifted towards Meta II. Quite interesting is the disappearance of the 
two bands at 1767 cm"1 (negative) and 1748 cm"1 (positive) in the Rho - Meta II FTIR 
difference spectrum of D83N. The most direct explanation consequently is, that Asp83 is 
structurally involved in Meta II formation, thereby increasing its Η-bond interaction. 
Apparently, substitution of Asp for Asn does not significantly perturb the normal hydrogen 
bonding pattern and does not significantly influence the Meta I - Meta II transition. 
It is well documented that Glull3 is indispensable for correct protonation of the Schiff base 
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linkage between Lys296 and 11-см retinal. Only carboxyl residues at this position or at the 
positions 90 or 117 can sustain a pigment with normal spectral properties. Other El 13 
mutants can generate photosensitive pigments, but their absorbance bands are pH- and 
anion-dependent, lower pH and higher anion concentration stabilizing the protonated 
rhodopsin-like state. However the mutants, generated with our expression system, even 
after regeneration and purification at low pH (pHs6) did not present a detectable absorban­
ce band. We demonstrated that the El 13 mutants showed a non-homogeneous distribution 
in the plasma membrane and at least part of the protein is incorrectly translocated and/or 
folded. It seems that the structure in the El 13 mutants is affected in such a way that 
regeneration is strongly impaired, e.g by aggregation. The "unnatural" insect cell membra­
ne matrix composition and the unphysiological temperature during biosynthesis may result 
in further destabilizition and/or aggregation of the protein. 
While E122 is absolutely conserved in rod visual pigments, cone pigments have an apolar 
residue at this position (L,I,M). Indeed, substitution of Glul22 for Leu (or He) much less 
affects the spectral properties of bovine rhodopsin (Л
т а х
 498 - 495 nm), than that reported 
for Gin, Asp or Ala (Я
т а х
 475-480 nm). This suggests that replacing E122 by similar 
polar groups like Q or D perturbs the tertiary structure to such an extent that an apprecia­
ble blue shift in absorbance results. Direct interaction of E122 with the chromophore is 
unlikely since then much larger effects of the mutations E122L and E122I should be 
expected. Hence apolar residues like Leu and He seem good substitutions for E122 with 
regard to a correct structure for spectral tuning. However, the mutation E122L interferes 
with the translocation process during opsin biosynthesis. Furthermore it strongly shifts the 
Meta I - Meta II equilibrium towards Meta II. The structural importance of a Glu at 
position 122 is also evident from changes induced by the Leu substitution in the Rho -
Meta II FTIR-difference spectrum. Vibrational bands in the amide I region, which most 
likely reflect structural changes involving the rhodopsin backbone, are absent in E122L and 
a negative band in the carboxyl region at 1728 cm"' disappears. This band has previously 
tentatively been identified as a buried carboxyl group, and recently assigned to Glul22 due 
to its disappearance in the mutation E122Q. However, in view of the fact that a corres­
ponding positive carboxyl band was not observed in our spectra and also no significant 
change was seen in the carboxylate region near 1400 cm"1 due to the E122L mutation, we 
conclude that Glul22 undergoes neither hydrogen bonding changes nor deprotonation. A 
more likely possibility is that the 1728 cm"! band arises from a protein backbone vibration. 
Both E134 mutations (D/R) and the E134R,R135E double mutant did not interfere with 
spectral tuning, but severely affected glycosylation and translocation. Also the FTIR 
spectrum of the purified glycosylated species showed the presence of some misfolded 
protein. Furthermore, both mutations shifted the Meta I » Meta II equilibrium towards 
Meta I. FTIR analysis also showed that secondary structural changes upon Meta II 
formation, as reflected in the amide I region, were altered in these mutants, in particular 
E134R. In contrast, the structural changes of carboxyl groups as reflected in the carboxyl 
region are unaffected. This further supports our earlier conclusion that E134 is not 
structurally active in the Meta I - Meta II transition. 
We earlier proposed that a Η-bonded network exists in rhodopsin which surrounds the 
chromophore and both modulates its electronic properties (wavelength regulation or 
spectral tuning) and is involved in the photoinduced conformational changes accompanying 
signal transduction and binding of transducin. The essential role of El 13 in stabilizing the 
117 
protonated Schiff-base can be explained in this concept, by assuming that it holds a key 
position controlling the integrity of the network. It may also explain that this function can 
be partly taken over by an Asp residue at this position or at the positions 90 and 117, and 
that in El 13 mutants even anions of varying size can increase the stability of the protonated 
Schiff-base by restoring some basic properties of the Η-bonded network. Analysis by 
FTIR-spectroscopy already indicated that Asp or Glu and Tyr residues change their 
protonation state upon entering the Meta I » Meta II equilibrium. This led us to propose 
that a Η-bonded network is involved in this equilibrium and would reversibly change its 
structure upon (de)protonation, favoring Meta II in the protonated state. Our present 
analysis of mutants supports this proposal. Asp83 changes from a weakly to a more 
strongly Η-bonded state upon Meta II formation, and the E122L mutation perturbs 
conformational changes during the Meta I - Meta II transition. The effect of the D83N and 
E122L mutation on the Meta I - Meta II equilibrium is therefore explained by a subtle 
change in the charge distribution of the Η-bonded network, enhancing its proton-acceptor 
potential. This would shift the apparent pK of the equilibrium to higher pH. The perturbati­
on of the Meta I - Meta II equilibrium in E134 mutants can also be attributed to such a 
perturbation of the protonation-dependent network changes. 
It has been demonstrated in this thesis that in vitro expression and mutagenesis of 
bovine rhodopsin in combination with FTIR difference spectroscopy is a very sensitive 
method to study structure-function relationships. One of the striking observations is that a 
single amino acid substitution can have mosaic effects, i.e. cause changes in very different 
functional properties like glycosylation, translocation, folding, Meta I - Meta II equilibri­
um, and primary or secondary structural changes during photoactivation. This again 
emphasizes that structure and function of this G-protein coupled receptor are very closely 
connected and very delicately tuned. 
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SAMENVATTING 
Zoals beschreven is in hoofdstuk 1 is rhodopsine, het visuele pigment van de 
staafjesfotoreceptorcel in het oog van vertebraten, een complex integraal membraaneiwit 
dat zeven transmembraan helixen bevat, die de chromofore groep 11-cw retinal herbergen. 
Deze is via een geprotoneerde Schiffse base covalent gebonden aan Lys296. Bij absorptie 
van zichtbaar licht rond 500 nm isomeriseert de chromofoor naar de all-trans vorm. 
Hierdoor treden er conformationele veranderingen in het eiwit op: rhodopsine gaat over in 
bathorhodopsine en vervalt zo verder via lumirhodopsine, metarhodopsine I (Meta I) tot 
metarhodopsine Π (Meta II). Meta II is het actieve intermediair dat het G-eiwit (transduci­
ne) bindt waardoor de signaaltransductie in werking wordt gezet. Transducine activeert op 
zijn beurt het fosfodiesterase wat het cGMP hydrolyseert. Hierdoor wordt de cGMP 
concentratie in de cel verlaagd, wat tot gevolg heeft dat de Na+, К + en Ca 2 + ionkanalen in 
de plasmamembraan sluiten. De resulterende hyperpolarisatie wordt via transmitters in de 
synapse van de staafjesfotoreceptorcel doorgegeven via een aantal neuronen en via de 
oogzenuw naar de hersenen. 
Deactivering vindt plaats door binding van het specifieke rhodopsine kinase en een 45 kD 
eiwit, S-antigen of arrestine genaamd, aan Meta II. Meta Π vervalt dan langzaam, indirect 
via metarhodopsine III of direct tot het apo-eiwit en de chromofoor komt vrij. De biosyn-
these van opsine, het apo-eiwit, vereist intermitterende membraan translocatie en ver­
schillende posttranslationele modificaties zoals glycosylering, palmitoylering en vorming 
van disulfide bruggen, om al zijn structurele en functionele eigenschappen te kunnen uit­
voeren. De N-terminus is geglycosyleerd en van structureel belang, samen met de 
intradiscale lussen en de disulfide brug tussen CysllO en Cysl87. Van twee cytoplas-
matische lussen wordt gedacht dat ze een rol spelen in de signaaloverdracht, samen met een 
additionele lus die ontstaat door de palmitoylering en membraanverankering van Cys322 en 
Cys323. 
De functionele en structurele eigenschappen van rhodopsine kunnen worden 
onderzocht d.m.v. in vitro expressie en (plaatsgerichte) mutagenese, in combinatie met 
Fourier Transform Infrarood (FTIR) verschilspectroscopie. Voor dit doel werd gekozen 
voor het recombinant baculovirus expressiesysteem voor de expressie van wild-type en 
gemuteerd runderrhodopsine in insektencellen, omdat dit een eukaryotisch expressiesys­
teem is, dat alle normale eukaryotische posttranslationele modificaties kan uitvoeren en 
omdat het succesvol gebruikt is voor de hoge expressie van heterologe eiwitten. 
In hoofdstuk 2 zijn materialen en methoden beschreven die in dit proefschrift zijn 
gebruikt. Verschillende van deze methoden zijn een gevolg van de zoektocht naar de 
optimale condities voor expressie, regeneratie, zuivering and reconstitutie van runderrho­
dopsine, welke beschreven zijn in hoofdstuk 3. 
Onder de verschillende omstandigheden beschreven in hoofdstuk 3 varieerde de 
functionaliteit van het geproduceerde opsine (glycosylering, targeting, capaciteit om te 
regenereren tot rhodopsine bij toevoeging van 11-rii retinal) niet significant. De hoogste 
expressieniveaus van functioneel opsine werden bereikt wanneer het recombinant virus 
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werd gebruikt waarbij de leadersequentie was ingekort tot 5 baseparen, wanneer een hoge 
infectiedichtheid werd gebruikt, wanneer 0,3% Pluronic-F68 werd toegevoegd om de 
cellen in suspensie te stabiliseren en wanneer een productietijd van drie dagen werd 
aangehouden. Onder deze omstandigheden konden expressieniveaus van 50 picomolen 
opsine per miljoen cellen (ca. 4 ^g opsine per mg eiwit; 4 mg opsine per liter cultuur) 
worden bereikt. Hoewel verscheidene factoren die van invloed konden zijn op de regenera­
tiecapaciteit werden onderzocht, kan de relatief lage totale functionaliteit 
(regeneratiecapaciteit van 40-60%) op dit moment niet worden verklaard. Deze zou 
gerelateerd kunnen zijn aan de "structurele stress" als gevolg van relatief hoge pakkings­
dichtheid van dit heterologe membraaneiwit in een ongewone lipide-omgeving. Regeneratie 
in totale membranen, zuivering over ConA-Sepharose, gevolgd door reconstitutie in 
retinalipiden, resulteerde in een 60-80% opzuivering van het in vitro gemaakte rhodopsine 
(v-rho), wat geschikt is voor de meeste functionele onderzoekingen. Uiteindelijk is de 
totale opbrengst nog altijd beduidend meer dan verkregen wordt in andere op zoogdiercel­
len gebaseerde expressiesystemen. Bovendien leverde het testexperiment in een bioreactor 
veelbelovende resultaten op wat betreft celgroei en infectie met recombinant virus met het 
oog op opschaling. Op die manier kan voldoende materiaal geproduceerd worden om er 
studies zoals NMR mee te verrichten. Deze techniek vereist echter isotoop-labeling van het 
eiwit en ook voor FΉR verschilspectroscopie is labeling van eiwitresiduen doorgaans 
noodzakelijk om hun vibratiebanden te identificeren en hun rol in de structurele verande­
ringen tijdens het fototransductieproces te onderzoeken. Omdat gelabelde aminozuren erg 
duur zijn, werden de minimale aminozuurconcentraties in het kweekmedium bepaald. Het 
bleek dat een viervoudige reductie van een behoorlijk aantal aminozuren getolereerd werd 
zonder verandering in de opsine produktie, terwijl een tweevoudige reductie (behalve voor 
cysteine) algemeen getolereerd werd. Voor labelings-doeleinden zal de aminozuurconcen­
tratie individueel moeten worden bepaald. 
In hoofdstuk 4 wordt een nieuwe aanpak voor de kristallisatie van rhodopsine 
beschreven: de expressie van rhodopsine- fusie-eiwitten. In eerste instantie werd glutathio-
ne-S-transferase (GST) van Schistosoma japonicum gefuseerd met de N-terminus van 
opsine. De expressie van dit GST-opsine fusie-eiwit verliep volgens een normaal biosyn­
thetisch patroon, wat duidelijk bleek uit de grootte, de reactiviteit met diverse antilicha­
men, de glycosylering en de correcte translocatie en targeting. Maar helaas kon geen 
lichtgevoelig pigment gegenereerd worden uit het GST-opsine fusie-eiwit en U-cis retinal. 
Eerder al werd aangetoond, dat kleine veranderingen in het extracellulaire domein van 
rhodopsine snel leiden tot incorrecte vouwing en verlies van regeneratiecapaciteit. 
Niettemin toonde de zeer gemakkelijke zuivering van het GST-opsine fusie-eiwit aan dat 
GST een uitstekende fusiepartner is voor zuiveringsdoeleinden. 
Omdat modificaties aan de C-terminus van rhodopsine niet zo een nadelig effect op de 
regeneratie van opsine lijken te hebben, werd de aanpak verlegd naar fusie met de C-
terminus van opsine. Expressie van een opsine-T4 lysozyme fusie-eiwit verliep correct, en 
wat belangrijker was: dit fusie-eiwit regenereerde met 11 -cis retinal tot een lichtgevoelig 
pigment. In deze fase kon echter nog niet worden vastgesteld of de spectrale eigenschappen 
van dit rhodopsine-T4 lysozyme fusie-eiwit identiek waren aan die van het wild-type 
rhodopsine. 
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Hoofdstuk 5 beschrijft het effect van mutaties op de biosynthese en posttransla-
tionele modificatie van opsine. In vitro expressie, gebruikmakend van het baculovirus 
expressiesysteem, resulteerde in een correcte biosynthese en posttranslationele modificatie 
van "wild-type" runderopsine (translocatie, glycosylering, palmitoylering en targeting). 
Maar verschillende van deze processen werden verstoord door puntmutaties. Alleen 
palmitoylering leek normaal te verlopen in alle hier beschreven mutanten, en bleek niet 
gekoppeld te zijn aan glycosy lering. Uit het totaalbeeld van de resultaten blijkt, dat er vier 
typen van mutanten onderscheiden kunnen worden. 
Type I: aminozuursubstituties die de biosynthese en vouwing van het opsine niet significant 
beïnvloedden (D83N, P219A en A299C/V300A/P303G). 
Type II: aminozuursubstituties die resulteerden in de productie van een verkort eiwit 
(R69H en Y301F). Echter, het incomplete eiwit werd wel geglycosyleerd en getranspor-
teerd naar de plasmamembraan. Hoewel het tot nu toe nog niet duidelijk is, waarom de 
translatie en/of translocatie worden afgebroken, lijkt het voor de beide mutaties om 
verschillende mechanismen te gaan. Bij de mutant Y301F gaat het mis op de plaats van de 
mutatie, terwijl bij de mutant R69H de translatie en/of translocatie ongeveer 130 aminozu-
ren na de mutatie pas stopt. De positie R69 is ook beschreven in relatie tot autosomale 
dominante retinitis pigmentosa in de deletiemutant 68-71. 
Type III: aminozuursubstituties die de translocatie en glycosylering verstoren (El 13, E122, 
E134, R135 en K248). Zoals al eerder werd gesuggereerd, zou het ion-paar E134 en R135 
deel uit kunnen maken van een stop-transfersignaal. Ook de andere geladen residuen El 13 
en E122 in transmembraandomein (TM) III zouden deel uit kunnen maken van dit 
transfersignaal. Als dit niet herkend wordt, kan TM III geheel over de membraan worden 
getranslokeerd en zal de rest van de opsine-topografie tegenovergesteld komen te liggen 
waarbij de C-terminus extracellulair ligt. Dit zou de gedeeltelijke bereikbaarheid voor het 
monoclonaal 1D4 (dit reageert met de C-terminus) en de protease thermolysine (knipt in de 
C-terminus) bij intakte cellen kunnen verklaren. Een overeenkomstige verklaring kan ook 
voor residu K248 gelden dat, gelegen op de overgang van lus ІЗ en TM VI, deel uit kan 
maken van een start-transfersignaal. Als dit niet herkend wordt, blijft TM VI intracellulair 
en komt de C-terminus extracellulair te liggen. 
Type IV: aminozuursubstituties die leiden tot een niet-homogene verdeling in de plasma­
membraan en een gereduceerde regeneratiecapaciteit (El 13, W265F en Y268S). Immuno-
histochemische analyse van deze mutanten lieten een vlekkige verdeling in de plasmamem­
braan zien, wat duidt op aggregatie (hoewel dit niet te zien was op immunoblot). Ook 
vertoonden ze allemaal een sterk gereduceerde regeneratiecapaciteit. Eerder is in de 
literatuur beschreven dat deze residuen een interactie aangaan met de chromofoor in 
runderrhodopsine. 
In hoofdstuk 6 zijn enkele structuur-functie relaties van recombinant "wild-type" en 
mutant runderrhodopsine onderzocht. Na regeneratie van wild-type runderopsine met de 
chromofoor 11-си retinal, zuivering over ConA-Sepharose en reconstitute in retinalipiden, 
kon een pigment worden gegenereerd met spectrale en fotolytische eigenschappen identiek 
aan natief runderrhodopsine. De mutaties P291A en A299C/V300A/P303G bleken de 
fotochemische eigenschappen niet te beïnvloeden, ondanks de sterke conservering van een 
proline op positie 291 en 303. Ook de mutatie K248L verstoorde de spectrale eigen-
schappen niet. De mutaties W265F en Y268S leidden tot een sterk gereduceerde regenera-
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tiecapaciteit, wat waarschijnlijk veroorzaakt wordt door hun verstoorde biosynthese (zie 
hoofdstuk 5). 
Omdat sterke conservering van polaire groepen in membraandomeinen een 
essentiële rol in structurele en functionele eigenschappen suggereert, hebben we het effect 
van de mutatie van de residuen D83, El 13, E122 en E134 op de spectrale en fotolytische 
eigenschappen van rhodopsine bestudeerd. 
De mutatie D83N veroorzaakte een lichte blauw-verschuiving van de absorptieband 
(Xmax: 498-492). En hoewel de kinitiek van de vorming van de late fotointermediairen 
(Meta II - Meta ΠΙ) niet significant was veranderd, werd het Meta I - Meta II evenwicht 
verschoven naar Meta П. FTIR analyse van deze mutant leidde tot de verdwijning van twee 
pieken (1767 (negatief) en 1748 (positief) cm"1) in het Rho - Meta II verschilspectrum. De 
meest directe verklaring hiervoor zou zijn, dat Asp83 structureel actief is in de Meta II-
vorming, en daarbij een sterkere waterstofbrug-interactie aangaat. 
Zoals uitvoerig beschreven, is Glull3 noodzakelijk voor de correcte protonatie van 
de Schiffse base verbinding russen Lys296 en 11-cw retinal. Alleen een carboxylresidu op 
deze positie of de posities 90 of 117 kan een pigment in stand houden met normale 
spectrale eigenschappen. Andere El 13 mutanten genereren lichtgevoelige pigmenten 
waarvan de absorptieband pH- en anion-afhankelijk is; lage pH en hoge anionsterkte 
stabiliseren de geprotoneerde rhodopsine-achtige vorm. Echter bij de El 13 mutant 
pigmenten gegenereerd met ons expressiesysteem konden we zelfs bij lage pH (pHs6) geen 
absorptieband detecteren. Deze mutanten vertoonden een afwijkende biosynthese (zie 
hoofdstuk 5), waarbij de structuur zodanig is verstoord dat de regeneratiecapaciteit sterk 
gereduceerd wordt. Ook kan de "onnatuurlijke" membraansamenstelling van de insectencel 
en de niet fysiologische temperatuur tijdens de biosynthese resulteren in verdere destabili­
satie en/of aggregatie van het eiwit. 
Terwijl E122 totaal geconserveerd is in staafjespigmenten, hebben kegel­
tjespigmenten een apolair residu op deze positie (L,I,M). Inderdaad verschoof de absorptie­
band bij mutatie van Glul22 naar Leu (of Ile) minder (Я
т а х
 498-495) dan naar Gin, Asp of 
Ala ^
m a x
 475-480), zoals eerder gerapporteerd is. Echter, de E122L mutatie verschoof 
het Meta I - Meta II evenwicht sterk naar Meta II. Het structureel belang van Glu 122 bleek 
ook uit de veranderingen die ontstonden in het Rho-Meta II FTIR verschilspectrum van de 
E122L mutant. Vibratiebanden in het amide I gebied, die de structurele veranderingen van 
de rhodopsine "backbone" weergeven, waren afwezig in de E122L mutant en ook de 
negatieve piek bij 1728 cm"1 verdween. De laatste was voorheen geïdentificeerd als 
afkomstig van een carboxylgroep en recentelijk toegewezen aan Glul22 door zijn verdwij-
ning in de E122Q mutant. Omdat wij echter geen andere veranderingen zien in zowel het 
carboxyl- als carboxylaatgebied, concluderen wij dat Glu 122 geen veranderingen ondergaat 
in zowel de waterstofbrug-interactir als in de protoneringstoestand. Een meer voor de hand 
liggende verklaring zou zijn dat de 1728 cm"1 afkomstig is van eiwit "backbone"- vibraties. 
Beide E134 mutaties (D/R) en de dubbelmutant E134R,R135E verstoorden de 
spectrale afstemming niet, maar wel in sterke mate de glycosylering en translocatie. Ook 
uit FTIR-analyse van de gezuiverde, geglycosyleerde vorm van de E134 mutanten bleek de 
aanwezigheid van een zekere hoeveelheid niet goed gevouwen eiwit. Bovendien was het 
Meta I - Meta II evenwicht bij beide El 34 mutanten verschoven naar Meta I. Verdere 
FTIR-analyse van deze mutanten liet alleen enige secondaire structurele veranderingen zien 
in het Rho-Meta II verschilspectrum, wat erop duidt dat E134 niet structureel actief is in 
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de Meta I - Meta II overgang. 
Het bestaan van een waterstofbrugnetwerk in rhodopsine die de chromofoor omgeeft 
en daardoor de spectrale eigenschappen moduleert en de door licht geïnduceerde structurele 
veranderingen gevolgd door signaaltransductie beïnvloed, werd door ons al eerder 
geponeerd. De hier beschreven analyse van mutanten ondersteunt dit voorstel. Asp83 
ondergaat een verandering in waterstofbrug-interactie van een zwakke tot een sterkere 
binding in Meta II, en ook de E122L mutatie verstoort de conformationele veranderingen 
tijdens Meta II vorming. Het effect van de D83N en de E122L mutatie op het Meta I -
Meta II evenwicht zou verklaard kunnen worden door subtiele veranderingen in de 
ladingsdistributie van het waterstofbrugnetwerk. Ook de verstoring van het Meta I - Meta 
II evenwicht in de E134 mutanten kan worden toegeschreven aan de protonatie-afhankelijke 
netwerkveranderingen. 
In dit proefschrift is aangetoond dat in vitro expressie en mutagenese van run-
derrhodopsine, in combinatie met FTIR-verschilspectroscopie, een zeer gevoelige methode 
is om structuur-functie relaties te bestuderen. Een van de meest opvallende observaties 
was, dat één enkele aminozuursubstitutie een "mozaïek" effect kan hebben, dat is verande-
ringen in verschillende functionele eigenschappen kan veroorzaken, zoals glycosylering, 
translokatie, vouwing, het Meta I - Meta Π evenwicht, en primaire en secundaire structure­
le verandering tijdens de activatie door licht. Dit benadrukt weer, dat de structuur en 
functie van deze G-eiwit-gekoppelde receptor sterk verbonden en zeer subtiel op elkaar 
afgestemd zijn. 
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